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SUMMARY 
Thrombus formation at sites of vascular lesions is a dynamic process that requires a defined 
series of molecular events including the action of platelet adhesion/activation receptors, 
intracellular signal transduction, cytoskeletal rearrangements and activation of plasma 
coagulation factors. This process is essential to limit post-traumatic blood loss but may also 
contribute to acute thrombotic diseases such as myocardial infarction and stroke. With the 
help of genetically modified mice and the use of specific protein inhibitors and receptor-
depleting antibodies, the work presented in this thesis identified novel mechanisms 
underlying thrombus formation in hemostasis and thrombosis.  
In the first part of the study, it was shown that von Willebrand Factor (vWF) binding to 
glycoprotein (GP)Ibα is critical for the formation of stable pathological thrombi at high shear 
rates, suggesting GPIbα as an attractive pharmacological target for antithrombotic therapy. 
The subsequent analysis of recently generated phospholipase (PL)D1-deficient mice 
identified this enzyme, whose role in platelet function had been largely unknown, as a 
potential target protein downstream of GPIbα. This was based on the finding that PLD1-
deficient mice displayed severely defective GPIbα-dependent thrombus stabilization under 
high shear conditions in vitro and in vivo without affecting normal hemostasis.  
The second part of the thesis characterizes the functional relevance of the immunoreceptor 
tyrosine-based activation motif (ITAM)-bearing collagen receptor GPVI and the recently 
identified hemITAM-coupled C-type lectin-like receptor 2 (CLEC-2) for in vivo thrombus 
formation. Genetic- and antibody-induced GPVI deficiency was found to similarly protect 
mice from arterial vessel occlusion in three different thrombosis models. These results 
confirmed GPVI as a promising antithrombotic target and revealed that antibody-treatment 
had no obvious off-target effects on platelet function. Similarly, immunodepletion of CLEC-2 
by treating mice with the specific antibody INU1 resulted in markedly impaired thrombus 
growth and stabilization under flow in vitro and in vivo. Furthermore, it could be demonstrated 
that double-immunodepletion of GPVI and CLEC-2 resulted in severely decreased arterial 
thrombus formation accompanied by dramatically prolonged bleeding times. These data 
revealed an unexpected redundant function of the two receptors for in vivo thrombus 
formation and might have important implications for the potential development of anti-GPVI 
and anti-CLEC-2 antithrombotic agents. 
The third part of the thesis provides the first functional analysis of megakaryocyte- and 
platelet-specific RhoA knockout mice. RhoA-deficient mice displayed a defined signaling 
defect in platelet activation, leading to a profound protection from arterial thrombosis and 
ischemic brain infarction, but at the same time also strongly increased bleeding times. These 
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findings identified the GTPase as an important player for thrombus formation in hemostasis 
and thrombosis. 
Based on the previous proposal that the coagulation factor (F)XII might represent an ideal 
target for safe antithrombotic therapy without causing bleeding side effects, the last part of 
this thesis assesses the antithrombotic potential of the newly generated FXIIa inhibitor rHA-
Infestin-4. It was found that rHA-Infestin-4 injection into mice resulted in virtually abolished 
arterial thrombus formation but no change in bleeding times. Moreover, rHA-Infestin-4 was 
similarly efficient in a murine model of ischemic stroke, suggesting that the inhibitor might be 
a promising agent for effective and safe therapy of cardio- and cerebrovascular diseases. 
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ZUSAMMENFASSUNG 
Thrombusbildung an einer verletzten Gefäßstelle ist ein dynamischer Prozess, der ein 
definiertes Zusammenspiel von Thrombozytenadhäsions-/aktivierungsrezeptoren, 
intrazellulären Signalen, Zytoskelettumstrukturierungen sowie die Aktivierung von Plasma 
Koagulationsfaktoren benötigt. Dieser Prozess ist essenziell um Blutungen nach einer 
Gefäßverletzung zu stoppen, kann aber auch zu akuten thrombotischen Erkrankungen wie 
Herzinfarkt und Schlaganfall führen. Mit Hilfe von genetisch veränderten Mäusen und der 
Verwendung von spezifischen Proteininhibitoren und Rezeptor-depletierenden Antikörpern 
wurden in der hier vorliegenden Dissertation neue Mechanismen der Thrombusbildung in 
Hämostase und Thrombose identifiziert. 
In dem ersten Teil der Studie konnte gezeigt werden, dass die Interaktion zwischen von 
Willebrand Faktor (vWF) und Glykoprotein (GP)Ibα entscheidend für die Bildung von 
pathologischen Thromben bei hohen Scherraten ist, was auf die Eignung von GPIbα als eine 
attraktive pharmakologische Zielstruktur (Target) für eine antithrombotische Therapie 
hindeutet. Die anschließende Analyse von vor kurzem generierten Phospholipase (PL)D1-
defizienten Mäusen identifizierte dieses Enzym, dessen Rolle in der Thrombozytenfunktion 
bislang unbekannt war, als eine mögliches Targetprotein im Signalweg von GPIbα. Dies 
basierte vor allem auf der Erkenntnis, dass PLD1-defiziente Mäuse eine stark gestörte 
GPIbα-abhängige Thrombusstabilisierung unter hohen Scherbedingungen aufwiesen, ohne 
jedoch dabei die normale Hämostase zu beeinflussen. 
Im zweiten Teil der Arbeit wurde die funktionelle Relevanz des immunoreceptor tyrosine-
based activation motif (ITAM)-gekoppelten Kollagenrezeptors GPVI und des vor kurzem 
entdeckten hemITAM-gekoppelten C-type lectin-like receptor 2 (CLEC-2) für die in vivo 
Thrombusbildung charakterisiert. Es wurde gezeigt, dass genetisch- und durch Antikörper- 
induzierte GPVI-Defizienz Mäuse gleichermaßen vor arteriellem Gefäßverschluss in drei 
verschiedenen Thrombosemodellen schützt. Diese Ergebnisse bestätigten GPVI als ein viel 
versprechendes antithrombotisches Target und zeigten, dass eine Antikörperbehandlung in 
Mäusen keine offensichtlichen unspezifischen Effekte auf die Thrombozytenfunktion hatte. 
Eine gleichermaßen induzierte Immunodepletion von CLEC-2 durch die Behandlung von 
Mäusen mit dem spezifischen Antikörper INU1 führte zu deutlich vermindertem 
Thrombuswachstum und reduzierter Thrombusstabilisierung unter Flussbedingungen in vitro 
und in vivo. Darüber hinaus konnte gezeigt werden, dass eine Doppel-Immunodepletion von 
GPVI und CLEC-2 zu einer stark reduzierten arteriellen Thrombusbildung führte, die mit 
dramatisch verlängerten Blutungszeiten einherging. Diese Ergebnisse machten eine 
unerwartete funktionelle Redundanz der beiden Rezeptoren deutlich und könnten 
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möglicherweise einen wichtigen Einfluss auf eine eventuelle Entwicklung von anti-GPVI und 
anti-CLEC-2 antithrombotischen Wirkstoffen haben.  
Der dritte Teil der Arbeit liefert die erste funktionelle Analyse von Megakaryozyten- und 
Thrombozyten-spezifischen RhoA-Knockout Mäusen. RhoA-defiziente Mäuse zeigten einen 
definierten Signaldefekt in der Thrombozytenaktivierung, der zu einem deutlichen Schutz vor 
arterieller Thrombose und ischämischen Hirninfarkt aber gleichzeitig auch zu stark erhöhten 
Blutungszeiten führte. Dieses Ergebnis identifizierte die GTPase als einen wichtigen Spieler 
für die Thrombusbildung in Hämostase und Thrombose.  
Basierend auf dem vorausgegangenen Vorschlag, dass der Koagulationsfaktor XII (FXII) ein 
ideales Target für eine sichere antithrombotische Therapie darstellen könnte, ohne 
Blutungsnebenwirkungen zu verursachen, untersucht der letzte Teil der Arbeit das 
antithrombotische Potential des neu generierten FXIIa Inhibitors rHA-Infestin-4. Es konnte 
gezeigt werden, dass eine Injektion von rHA-Infestin-4 in Mäuse die arterielle 
Thrombusbildung nahezu aufhob aber Blutungszeiten nicht veränderte. Außerdem war rHA-
Infestin-4 gleichermaßen effizient in einem Mausmodell des ischämischen Schlaganfalls, 
was darauf schließen lässt, dass der Inhibitor ein vielversprechender Wirkstoff für eine 
effektive und sichere Therapie von kardio- und zerebrovaskulären Erkrankungen sein 
könnte. 
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1 INTRODUCTION 
1.1 Platelets 
Platelets are discoid-shaped anucleate cell fragments that originate from megakaryocytes 
residing in the bone marrow. The exact mechanism how platelet production occurs in vivo is 
still controversially discussed. According to a recently emerged hypothesis, mature 
megakaryocytes expand pseudopodial protrusions, so-called proplatelets, into sinusoids in 
the bone marrow where the tip of these structures become continuously shed and further 
fragmented into platelets by shear forces present in the blood stream1,2. Platelets are only 
found in mammals and represent the smallest cells of the blood system with a diameter of 
2-4 µm in humans and 1-2 µm in mice. They normally circulate in an inactive or resting state 
for 7-10 days in humans and approximately 5 days in mice at a relatively high concentration 
of ~250,000/µl and 1,000,000/µl, respectively. Most of the platelets never undergo activation 
during their life time and are then constantly removed from the circulation by the reticulo-
endothelial system in the spleen and liver. However, platelets have the capacity to rapidly 
respond at any time to disruption in the endothelial layers of the vessel wall. Under these 
conditions, exposed components of the extracellular matrix (ECM) trigger initial platelet 
adhesion and activation. Soluble mediators which are released from activated platelets 
further amplify this event and lead, together with locally produced thrombin, to the activation 
and recruitment of further platelets from the circulation resulting in aggregate and finally 
thrombus formation. This process is essential for normal hemostasis by preserving the 
vascular integrity after tissue trauma and limiting excessive blood loss. Under pathological 
conditions, however, such as after rupture of an atherosclerotic plaque in stenosed vessels, 
thrombus formation may cause complete vessel occlusion leading to ischemia in the distal 
tissue3. This results, if occurring in coronary arteries or in the brain, in myocardial infarction 
or stroke, respectively, which are among the most common causes of death in the developed 
world4. Therefore, antithrombotic treatment is the prime therapeutic option in the prophylaxis 
and treatment of ischemic cardio- and cerebrovascular diseases. 
The dual function of platelets indicates that their activation requires a very defined and tight 
regulation to guarantee on the one hand efficient sealing of a wound site while at the same 
time uncontrolled platelet adhesion and excessive platelet activation has to be limited to 
avoid undesired vessel occlusion. To achieve this tightrope walk under physiological 
conditions, platelets exhibit various adhesion/activation and inhibition receptors combined 
with a complex signaling machinery. 
It should be noted that beyond their function in hemostasis and thrombosis, platelets also 
play important roles in wound healing, inflammatory processes, angiogenesis and tumor 
metastasis.  
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1.2 Platelet activation and thrombus formation 
Platelet activation and thrombus formation at sites of vascular injury require a series of well 
coordinated signaling events which can be divided into three major steps: (1) Platelet 
tethering, (2) activation and (3) firm adhesion/aggregation (Figure 1). The first step of initial 
platelet adhesion involves sequential interactions of platelet surface receptors with numerous 
macromolecules of the exposed subendothelial ECM such as collagens, laminin and 
fibronectin. In general, the adhesion mechanisms are largely dependent on the predominant 
rheological conditions present in the vasculature. Assuming blood flow as laminar, the 
velocity of the fluid is greater in the center than near the wall, thereby causing shear forces 
between adjacent layers. Consequently, platelets are exposed to the maximal hemodynamic 
forces at the vessel wall5. The distinct wall shear rates, however, which trigger certain 
platelet adhesion mechanisms depend on the vascular bed. Under high shear flow 
conditions, such as found in arterioles or stenosed arteries, the initial platelet contact, also 
called “tethering”, with the ECM is mediated by the platelet receptor glycoprotein (GP)Ib and 
von Willebrand Factor (vWF) immobilized on exposed collagen6. This interaction is not stable 
enough to mediate firm platelet adhesion to the wound site but rather induces a rapid 
deceleration and “rolling” of the cells thereby facilitating the binding of other platelet receptors 
to ECM components. Among them, the interaction of the immunoglobulin family receptor 
GPVI with collagen is the most important event leading to platelet activation.  
 
 
Figure 1. Multistep model of platelet adhesion/activation and thrombus formation at sites of 
vascular injury. The GPIbα-vWF interaction mediates platelet deceleration and tethering on the 
exposed ECM thereby allowing the interaction of GPVI with collagen. This in turn leads to platelet 
activation by triggering the release of secondary mediators such as ADP and TXA2 and inducing a 
shift of integrins (most notably α2β1 and αIIbβ3 integrins) from a low to a high affinity state. Together 
with locally tissue factor (TF)-induced thrombin formation, soluble mediators enhance platelet 
activation and contribute to the recruitment of platelets into a growing thrombus. Activated integrins 
mediate firm adhesion of platelets to the ECM and stabilize the platelet thrombus by connecting 
platelets via αIIbβ3-bound fibrinogen or vWF. (Taken from: Varga-Szabo et al., Arterioscler Thromb 
Vasc Biol, 2008)7. 
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Platelets have evolved multiple activation receptors that can be classified according to their 
signal transduction into two major receptor groups which converge into common activation 
processes7.  
GPVI belongs to one class of platelet-activating receptors and signals upon binding to 
collagen via the immunoreceptor tyrosine-based activation motif (ITAM)-bearing Fc receptor 
(FcR) γ chain8. The related C-type lecitin-like receptor CLEC-2 is a type II transmembrane 
receptor that initiates activation via a single YXXL-motif and shares many similarities to 
GPVI-induced signaling with both culminating in the stimulation of the key effector molecule 
phospholipase (PL) Cγ29,10 (Figure 2). PLCs cleave the membrane phospholipid 
phosphatidylinositol-4,5-bisphosphate (PIP2) to the second messengers inositol-1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG). While the latter activates protein kinase (PK)C, 
IP3 can liberate Ca2+ from intracellular stores which then opens calcium channels in the 
plasma membrane leading to a transient but massive influx of extracellular Ca2+ via a process 
termed store operated Ca2+ entry (SOCE)11. The increases in cytosolic Ca2+ concentration 
([Ca2+]i) is a central step for platelet activation and required for proper platelet adhesion, 
secretion and aggregation. 
The release and secretion of soluble mediators by activated platelets is a crucial step for the 
amplification of the initial signal and the activation and recruitment of further platelets from 
the circulation12. Platelets exhibit three different types of granules: α granules, dense 
granules and lysosomes. α granules contain adhesive molecules like vWF, fibrinogen and 
thrombospondin but also growth and coagulation factors whereas dense granules contain 
small molecules like adenosine diphosphate (ADP), adenosine triphosphate (ATP) and 
serotonin. Among the released molecules, ADP and ATP together with intracellularly 
produced and released thromboxane A2 (TXA2) are the most important secondary mediators 
for autocrine and paracrine platelet activation (Figure 2). 
Upon vascular injury, platelet activation is also locally coordinated with the induction of the 
coagulation system, leading to thrombin generation. This is partially initiated by the exposure 
of tissue factor (TF) to coagulation factor (F)VII circulating in the blood (see also section 1.8) 
but also by the exposure of negatively charged phosphatidylserine (PS) on the surface of 
activated platelets, that provides a platform for the assembly of the prothrombinase13 and 
tenase14 complexes. These two coagulation enzyme-cofactor complexes are essential for 
effective propagation of coagulation. 
The above mentioned secondary mediators as well as thrombin act via specific receptors 
coupled to heterotrimeric G proteins (GPCRs) which represent the second largest group of 
activating receptors15 and induce different signaling pathways (Figure 2). G12/13 stimulation 
results in a Rho/Rho kinase-mediated regulation of myosin light chain (MLC) phosphorylation 
and consequently induction of platelet shape change16. Gq-induced signaling, in contrast, 
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leads to the activation of PLCβ17, followed by Ca2+ mobilization as well as PKC stimulation 
(see above), Gi proteins trigger subunit-specific adenylyl cyclase (AC) inhibition and 
phosphatidylinositol 3-kinase (PI3K) activation18  
These platelet signaling events converge in the “final common pathway” of platelet activation, 
the functional up-regulation of heterodimeric transmembrane adhesion receptors of the 
integrin family leading to firm platelet adhesion and aggregation7. The shift from a low to a 
high affinity state enables platelet adhesion to collagen (via α2β1), fibronectin (via α5β1) and 
laminin (via α6β1) present in the ECM19. The main platelet integrin αIIbβ3 is predominantly 
involved in the adhesion process by binding to collagen-bound vWF as well as fibronectin 
and it is a critical mediator of platelet aggregation by linking platelets via fibrinogen and vWF.  
 
Figure 2. Scheme of platelet receptors and main signaling pathways. Receptor stimulation leads 
to activation of different intracellular signaling molecules. Soluble agonists such as ADP, TXA2, 
thrombin, serotonin and epinephrine act via specific G protein-coupled receptors (GPCRs) involving 
G12/13, Gq and Gi/z activation. G12/13 stimulation leads to Rho/Rho kinase-mediated cytoskeleton 
rearrangements, Gq activates phospholipase (PL)Cβ and Gi/z induces inhibition of the adenylyl cyclase 
(AC). Adhesion receptor signaling induced by GPVI and CLEC-2, but also GPIb and integrins results 
in PLCγ2 activation. PLCs generate inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from 
phosphatidylinositol-4,5-bisphosphate (PIP2). IP3 then mediates elevation of intracellular Ca2+ 
concentration [Ca2+]i, a process that is crucial for full platelet activation. Abbreviations: TXA2, 
thromboxane A2; PAR, protease activated receptor; Rho-GEF, Rho-specific guanine nucleotide 
exchange factor; PI-3-K, phosphatidylinositol 3-kinase; PIP3, phosphatidylinositol-3,4,5-trisphosphate; 
Fg, fibrinogen. (Taken from: Stegner et al., J Mol Med, 2011)20.  
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1.3 The GPIb-V-IX complex  
At high shear rates, the rapid interaction between GPIb of the GPIb-V-IX complex and vWF 
immobilized on collagen is essential for the initial recruitment of flowing platelets to the ECM 
at sites of vascular injury6. As described above, this contact has a high “off-rate” and only 
mediates deceleration of platelets to enable the interaction of other surface receptors with 
their respective ligands exposed at the wound site. Recent findings proposed an additional 
role for GPIb at extremely high shear rates (>10.000 sec-1), such as found in stenosed 
arteries. Under these conditions, shear-microgradients guide initial adhesion and aggregation 
of discoid platelets and thereby constitute the driving force of thrombus formation, most likely 
through a GPIb-dependent mechanism but independently of integrin αIIbβ3 activation21-23. 
The GPIb-V-IX complex is a highly abundant receptor complex exclusively expressed in 
platelets and megakaryocytes that functions independently of the activation state of the cell. 
It is encoded by four different genes, the α- and β-subunit of GPIb, GPV and GPIX which all 
belong to the leucine-rich repeat proteins superfamily24,25. Lack or dysfunction of the GPIb-V-
IX complex in humans causes the Bernard-Soulier syndrome (BSS), a congenital bleeding 
disorder associated with mild thrombocytopenia and giant platelets26. Gene deletion of 
Gp1ba27 or Gp1bb28 in mice leads to a deficiency of the entire complex and resembles the 
human BSS, as the mice suffer from a severe bleeding phenotype and 
macrothrombocytopenia. Whereas lack of GPIX similarly results in BSS, GPV deficiency in 
humans has not been described to date26 and mice lacking the receptor show unaltered 
platelet counts and rather normal hemostasis29,30. 
GPIbα represents the main functional subunit of the receptor complex and bears multiple 
binding domains in its N-terminal extracellular part for different interaction molecules most 
notably vWF, which is the major and best characterized binding partner, Mac-1, P-selectin, 
thrombospondin-I, thrombin, high molecular weight kininogen and coagulation factors XI 
and XII25,31. Besides the pivotal role of GPIb-V-IX as adhesion receptor there is growing 
evidence that ligand-binding to the receptor complex generates transmembrane signals 
leading to intracellular Ca2+ mobilization, cytoskeletal rearrangements, granule release and 
integrin αIIbβ3 activation32,33. However, GPIb-V-IX signaling is generally considered to induce 
only weak platelet activation compared to GPVI or GPCR-dependent signaling pathways. 
Several molecules have been proposed to mediate GPIb-V-IX signaling via association with 
GPIbα such as 14-3-3ζ, Src kinases, calmodulin and PI3K34-36. Some reports indicated a role 
for GPIb-V-IX in ITAM signaling of FcγRIIA37 or the FcRγ chain38 by binding to GPVI39, 
whereas other studies could not confirm these observations40. Recently, the adhesion and 
degranulation promoting adaptor protein (ADAP) was shown to be involved in integrin αIIbβ3 
activation downstream of GPIb-V-IX upon vWF binding41. 
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The essential role for GPIbα in the process of arterial thrombus formation has been 
demonstrated in mice where the vWF binding site of GPIbα was blocked by Fab fragments of 
the inhibitory antibody p0p/B42 and in mice expressing GPIbα with a mutated extracellular 
domain43,44. Platelet tethering to the injured vessel wall and subsequent thrombus formation 
was abrogated in both mice. In addition, GPIbα and its interaction with vWF appears to be a 
major pathophysiological mechanism underlying ischemic brain infarction as administration 
of anti-GPIb Fab fragments or vWF deficiency profoundly protected mice from lesion 
progression in an experimental stroke model45,46. This absolute requirement for GPIbα in 
thrombosis makes this receptor and possibly also its downstream signaling machinery an 
attractive pharmacological target for antithrombotic therapy. 
 
1.4 Phospholipase D1 
Phospholipase C isoforms have been well characterized as major effector molecules 
required for intracellular signal transduction during platelet activation7. In contrast, the role of 
PLDs in platelet function is less clear and all findings so far have been obtained from either 
indirect inhibition studies of PLD activity or correlation studies, which consign the knowledge 
about PLD from other cells to platelets. 
Two isoforms of PLD, PLD147 and PLD2, which share a 50% sequence identity48, have been 
described to be ubiquitously expressed in mammalian cells49. PLDs comprise a 
phosphodiesterase activity and hydrolyze phosphatidylcholine (PC) to phosphatidic acid (PA) 
and choline. PA in turn is the major effector downstream of PLD and probably acts as a 
second messenger for direct enzyme activation, most notably phosphatidylinositol-4-
phosphate 5-kinase (PI4P5 kinase), but can also be further metabolized into DAG and lyso-
PA50. The regulation of PLD activity is still not fully understood, however, multiple candidate 
molecules/mechanisms have already been proposed. Among them, phospholipids, such as 
PIP2 and phosphatidylinositol-3,4,5-triphosphate (PIP3), have been shown to directly interact 
with specific binding sites of PLD and thus stimulating its enzymatic activity51. Furthermore, 
PKC and small GTPases of the ARF and Rho families have been reported to directly activate 
PLD52.  
According to the large number of downstream targets which have been proposed for PLD 
and PA, the protein is also supposed to mediate diverse cellular processes such as signal 
transduction, cytoskeletal reorganizations, vesicle trafficking, as well as endo- and 
exocytosis49,53-56. 
As mentioned above, only a limited number of studies addressed the role for PLD in platelet 
activation. Thrombin, U46619 and collagen, but not ADP alone have been shown to induce 
PLD activation in human platelets and thereby its translocation to the plasma membrane57-60. 
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Fibrinogen binding to integrin αIIbβ3 has been suggested to mediate similar events61. Other 
reports indicated that PLD modulates dense granule release60,62 but is required for lysosomal 
secretion in response to protease activated receptors (PAR) signaling63. Moreover, PLD is 
supposed to be involved in PAR1-mediated platelet aggregation via Rap163,64. However, the 
specific function of PLD in platelet activation and aggregation has not been definitively 
determined and hence its role in thrombosis and hemostasis was unclear when this project 
was started.  
 
1.5 GPVI 
Subendothelial fibrillar collagens represent the most potent thrombogenic substrates at the 
wound site which trigger platelet adhesion, activation and ultimately aggregation. Besides 
GPIb and integrin αIIbβ3, which indirectly interact with collagen via vWF6, platelets express 
several direct collagen receptors65, most importantly integrin α2β1 and GPVI. Whereas 
integrin α2β1 contributes to platelet adhesion on collagen, but plays only a subordinated role 
in platelet activation, GPVI has meanwhile been established as the main activatory receptor 
for collagen8. 
GPVI is a 62 kDa type I transmembrane receptor that is exclusively expressed in platelets 
and megakaryocytes66. It belongs to the immunoglobulin superfamily and is constitutively 
associated with ITAM-containing FcRγ-chain dimers which act as the signal-transducing 
subunit of the receptor complex67,68. Upon crosslinking of GPVI by ligand-binding, the Src 
family tyrosine kinases Fyn and Lyn, bound to the cytoplasmatic tail of GPVI, come into 
contact with the FcRγ-chain and mediate tyrosine phosphorylation of the ITAM69,70. As a 
consequence, Syk kinase can bind and becomes autophosphorylated thereby initiating a 
complex downstream signaling cascade via the phosphorylation of the adaptors linker for 
activated T cells (LAT) and Src homology 2 domain-containing leukocyte phosphoprotein of 
76-kDa (SLP-76), which leads to the activation of the central effector molecule PLCγ271. This 
signaling process results in Ca2+ mobilization, granule release, integrin activation and PS 
exposure8 (see also section 1.2). Moreover, recently laminin, a major component of the basal 
lamina in the basement membrane has been identified as a new endogenous ligand for 
GPVI72, however, its relative significance for platelet activation remains elusive. Laminin has 
a ten-fold lower affinity for GPVI as compared to collagen, probably because it requires initial 
interaction with its main receptor integrin α6β1 before enabling GPVI binding73.  
For a detailed investigation of GPVI-induced platelet activation events in vitro, different 
experimental tools are available. Besides special forms of collagen, also synthetically 
generated collagen-related peptide (CRP) is used to induce GPVI signaling. CRP is a 
powerful platelet agonist consisting of repeated GPO (G=glycine, P=proline, 
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O=hydroxyproline) motifs, a typical amino acid sequence found in native collagen I and III, 
which are cross-linked to achieve a fibrillar structure74. Furthermore, numerous snake venom 
peptides have been demonstrated to act on GPVI, most notably the C-type lectin convulxin 
which induces platelet activation by clustering of the collagen receptor75,76. 
During the last years, major advances have been made in the understanding of GPVI-
dependent platelet activation and aggregation as well as its particular role in thrombus 
formation in vivo by the generation and analysis of mice lacking the receptor77-81. The first in 
vivo study showed that injection of the anti-GPVI antibody JAQ1 into mice induces an 
irreversible downregulation of the receptor from the surface of circulating platelets, resulting 
in a transient “GPVI knockout-like” phenotype for at least two weeks. These mice exhibit a 
long-term antithrombotic protection in experimental thrombosis models but display overall 
normal tail bleeding times42,77,82,83, an observation which could later be confirmed in FcRg−/− 
and Gp6-/-mice44,78,81,84. In addition, antibody-induced GPVI-depletion also effectively 
protected mice from ischemic brain infarction in a model of transient middle cerebral 
occlusion (tMCAO) without increasing bleeding complications45. Based on these results, 
GPVI has been proposed as an attractive antithrombotic target for the therapy of cardio- and 
cerebrovascular diseases. However, some studies with GPVI-deficient mice provided 
contradictory results on the relative importance of GPVI in different experimental thrombosis 
models78,79,85,86. 
So far, also two GPVI-deficient patients have been reported with high levels of anti-GPVI 
autoantibodies in their blood87,88. These patients showed a mild bleeding syndrome and their 
platelets were refractory to collagen stimulation. As mentioned above, this observation could 
later be explained by the phenomenon of antibody-induced GPVI-depletion in mouse 
platelets77. Furthermore, two patients have been described which bear a compound 
heterozygous mutation in GPVI89,90. One of the mutations prevents expression of GPVI and 
the other causes impaired receptor function, resulting in both cases in a mild bleeding 
disorder. 
 
1.6 CLEC-2 
The 32 kDa C-type lectin-like receptor 2 (CLEC-2) was initially identified on a transcript level 
in immune cells such as monocytes, dendritic cells and granulocytes91,92 and later found at a 
low level on peripheral blood mouse neutrophils93. Only recently, CLEC-2 has been 
discovered to be expressed primarily on the surface of platelets where it can mediate potent 
platelet activation and aggregation by the snake venom protein rhodocytin, isolated from the 
Malayan pit viper Calloselasma rhodostoma9. CLEC-2 is a type II transmembrane receptor 
and contains, in contrast to the GPVI/FcRγ-chain complex, only one single YxxL sequence 
which forms together with three upstream amino acid residues a novel signaling motif 
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referred to as hemITAM9,10. Ligand-binding to the extracellular domain of CLEC-2 induces 
Src kinase-dependent tyrosine phosphorylation of the YxxL sequence followed by Syk kinase 
binding that is suggested to trigger a successional activation pathway by linking two 
phosphorylated hemITAMs of dimerized CLEC-2 receptors9,94. This Syk-regulated signaling 
involves activation of similar effector molecules to those stimulated by signaling of the 
GPVI/FcRγ-chain complex such as LAT, SLP-76, Gads and PLCγ29,10. 
The physiological role of CLEC-2 is only partially known to date but represents a very 
dynamic and rapidly proceeding research field. First evidence for a specific function of 
CLEC-2 came from a study where platelets were identified to facilitate the transport of the 
human immunodeficiency virus type I (HIV-1). CLEC-2 is suggested to act as a binding 
partner for the virus on the platelet surface, whereby it probably enables virus-spread in 
infected humans95. Recent studies also reported important roles for CLEC-2 in phagocytic 
activity and release of proinflammatory cytokines of neutrophils93, and in hematogenous 
tumor metastasis by binding to podoplanin, a type I transmembrane sialomucin-like 
glycoprotein expressed on the tumor surface96. Podoplanin has been described as the only 
established endogenous ligand for CLEC-2 so far and displays a wide tissue distribution with 
high expression levels in lung type I alveolar cells, kidney podocytes, distinct tumor cells and 
lymphatic endothelial cells97. CLEC-2 induced platelet activation by endothelial podoplanin 
from the lymphatic sac has recently been shown to be essential for the separation of the 
lymphatic from the blood vascular system during embryonic development98-100. According to 
the remarkable platelet activatory potential of CLEC-2, it was early speculated that the 
receptor might become a valuable antithrombotic target; however, a direct proof for a role of 
CLEC-2 in hemostasis and in the setting of thrombotic events was lacking. 
 
1.7 Small GTPases of the Rho family 
Mammalian Rho GTPases comprise a subfamily of 20 small Ras-related proteins that are 
best known for their important roles in regulating the actin cytoskeleton101. Among them, the 
best documented family members are the highly conserved GTPases RhoA, Rac1 and 
Cdc42. A common feature of many Rho GTPases is the molecular switch between an 
inactive guanosine diphosphate (GDP)-bound form and an active guanosine triphosphate 
(GTP)-bound status which is catalyzed by upstream guanine nucleotide exchange factors 
(GEFs). Conversely, GTPase-activating proteins (GAPs) initiate the hydrolysis of GTP to 
GDP, thereby inactivating the Rho GTPase. Guanine nucleotide-dissociation inhibitors 
(GDIs) reduce the dissociation rate of GDP from the Rho protein and prevent its activation. 
The capacity of Rho GTPases to cycle between these two states enables a spatially and 
temporally controlled activation of effector molecules initiating a variety of processes, 
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including cell migration, adhesion and division. Moreover, Rho GTPases are implicated in 
vesicle trafficking, microtubule dynamics, cell-cycle progression and gene transcription102. 
The specific role of Rho GTPase-mediated signaling in platelet function has been intensively 
studied during the last years as cytoskeleton reorganizations are crucial to mediate proper 
platelet activation responses at sites of vascular injury. This involves change of the discoid to 
a spherical shape of the platelets (so-called: shape change), as well as adhesion and 
spreading on the exposed components of the ECM such as collagen, fibronectin and laminin. 
Stimulation of Cdc42 and Rac1 has been suggested to induce formation of filopodia and 
lamellipodia, respectively103,104, whereas RhoA has been proposed to mediate shape change 
and stress fiber formation upon platelet activation105,106. The major findings, however, about 
the functional role of Rho GTPase were yielded by overexpression studies in cell lines with 
dominant negative and constitutively active Rho proteins or in the case of platelet analysis 
mainly from pharmacological inhibition studies. These approaches often provide conflicting 
results probably caused by additional uncontrolled side effects or unspecific protein inhibition 
in the manipulated cells. The recent development of platelet and MK-specific knockout mice 
for several Rho GTPases could provide more reliable conclusions about their role in platelet 
function and moreover their contribution to thrombus formation under in vivo conditions. MK 
and platelet-specific Cdc42-deficent mice, for example, showed that the protein is not per se 
required for filopodia formation upon platelet activation107. Furthermore, these platelets 
displayed, in contrast to previous indications, increased granule release after activation that 
even translated into accelerated thrombus formation in vivo. Conditional Rac1 knockout mice 
could clearly confirm that this GTPase is essential for platelet lamellipodia formation and for 
PLCγ2 activation downstream of the platelet collagen receptor GPVI108. These signaling 
defects protected Rac1-deficient mice from arterial thrombosis.  
In this thesis, the relevance of RhoA for platelet function was addressed in detail using a 
conditional knockout approach. 
 
1.7.1 RhoA 
RhoA is ubiquitously expressed and implicated in many cellular functions most notably cell 
contraction, adhesion, migration and cytokinesis109. Activation of RhoA has been 
demonstrated to be crucial for the organization of cytoplasmatic stress fiber assembly and 
maturation of focal adhesions in multiple cell types110-112. Further studies indicated an 
important role of the GTPase in vascular smooth muscle cell contractility113,114 and 
destabilization of endothelial cell-cell junctions115, thereby regulating blood pressure116 and 
vascular membrane permeability, respectively. In the hematopoietic system, overexpression 
studies revealed that RhoA inhibition leads to increased hematopoietic stem and progenitor 
cell proliferation117 and enhanced T cell polarization and survival118,119. Other studies reported 
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a role for RhoA in neutrophil chemotaxis120 and phagocytic activity of macrophages121. The 
first cell type-specific conditional knockout mouse for RhoA was recently published by 
Jackson et al.. This study described mice with a keratinocyte-restricted loss of RhoA which 
displayed normal skin development but reduced keratinocyte contraction and migration122. 
The functional role of RhoA in platelet activation has also been assessed in numerous 
pharmacological inhibition studies using either botulinum C3 ADP ribosyltransferase to 
inactivate RhoA123 or inhibitors for specific RhoA downstream effectors. The GTPase was 
shown to be activated by GPCR-induced signaling most notably downstream of Gα12/13 by 
specific RhoGEFs (Figure 3)124. Some studies also indicated that RhoA can be stimulated via 
Gq-mediated activation processes, particularly at high agonist concentrations125,126. RhoA in 
turn mediates activation of RhoA-kinase (ROCK)127, which is the best characterized RhoA 
effector molecule, and mDia1 (first identified mammalian homologue of Drosophila 
diaphanous)128. Consequently, RhoA-kinase inhibits myosin light chain phosphatase (MLCP) 
which regulates together with the Ca2+/calmodulin-dependent myosin light chain kinase 
(MLCK) phosphorylation of the myosin light chain (MLC; Figure 3)129. The RhoA/RhoA-
kinase-mediated MLC phosphorylation results in actomyosin assembly and contraction which 
is thought to be crucial for shape change and stress fiber formation during platelet 
activation105,130-134. Furthermore, RhoA is suggested to be involved in dense granule release 
and integrin αIIbβ3 activation135-137 as well as in sustained αIIbβ3-dependent platelet 
adhesion on ECM proteins at high shear138. In a recent study, Gong et al. reported a defined 
regulation of RhoA activity during integrin αIIbβ3-induced intracellular signaling events139. 
They suggested that Gα13, bound to the cytoplasmatic tail of the activated β3 domain, 
triggers a transient inhibition of RhoA during the early phase of platelet spreading which is 
finally terminated by calpain leading to the reactivation of RhoA to mediate clot retraction139. 
This is in line with a previous report by Leng et al. showing that RhoA is dispensable for 
platelet spreading on fibrinogen but contradicts with the finding that the protein is also not 
required for clot retraction140. In contrast, Gao et al. implicated a role for RhoA in mDia1-
dependent spreading of thrombin-stimulated platelets141. Moreover, one study on cultured 
human MKs indicated that the RhoA/ROCK signaling pathway may negatively regulate 
proplatelet formation142. 
Although multiple studies have already investigated the function of RhoA in platelets, it has 
not been addressed in detail yet, particularly not in a knockout approach. Furthermore, the 
role of RhoA-mediated signaling in physiological and pathological thrombus formation is 
entirely unclear. 
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Figure 3. Scheme of RhoA-dependent 
signaling in platelets. RhoA becomes 
activated upon Gα12/13 protein-coupled 
receptor stimulation by RhoGEFs or 
downstream of Gαq protein-coupled 
receptors via so far unknown 
mechanisms. GTP-bound RhoA 
stabilizes MLC phosphorylation through 
inhibition of myosin phosphatase by 
ROCK. MLC phosphorylation is initially 
induced by a Ca2+/calmodulin-
dependent activation of MLC kinase. 
These platelet signaling pathways result 
in actomyosin contraction and shape 
change. 
 
 
1.8 Blood coagulation 
Vascular injury also triggers rapid activation of the plasma coagulation system that acts in 
concert with activated platelets to induce the formation of a fibrin- and platelet-rich clot. In the 
classical cascade or waterfall model, blood coagulation is described as a process which can 
be initiated by two distinct pathways, the extrinsic and the intrinsic pathway. These cascades 
involve a tightly regulated sequential activation of plasma serine proteases and cofactors 
culminating in the formation of thrombin. This in turn enhances platelet stimulation via 
cleavage of PARs (see section 1.2) and converts fibrinogen into fibrin143,144, thereby 
stabilizing the growing thrombus. Clot formation through the extrinsic pathway occurs when 
the transmembrane glycoprotein TF, expressed by cells within the vessel wall and adjacent 
tissue or on cell-derived microparticles, comes into contact with activated coagulation factor 
VII (FVIIa) leading to concomitant activation of FX and FIX145 (Figure 4). FXa and FIXa then 
amplify TF-bound FVII activation in a feedback signal and efficiently propagate coagulation 
by activating prothrombin and FX, respectively, when assembled in enzyme-cofactor 
complexes on the platelet surface13,14 (see also section 1.2). According to the original 
assumption, the intrinsic pathway is initiated when FXII (Hageman factor) becomes 
autoactivated on a negatively charged surface (contact activation) and forms the enzyme 
αFXIIa comprising a 50 kD heavy and a 30 kDa catalytic domain-bearing light chain linked by 
a disulfide bond146. Surface-bound αFXIIa is capable of activating FXI followed by successive 
activation of FIX and FX147 (Figure 4). Furthermore, it converts prekallikrein (PK) into plasma 
kallikrein and initiates the classical complement cascade by activation of C1 esterases. 
Kallikrein in turn reciprocally activates more FXII and liberates the vasoactive peptide 
bradikinin (BK) from high molecular weight kininogen (HK)148. Further αFXIIa cleavage by 
kallikrein leads to formation of a soluble 28 kDa catalytic domain fragment βFXIIa that can 
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activate PK and the complement system but lacks the catalytic activity for FXI149,150. FXII has 
also been shown to promote fibrinolysis directly by activation of plasminogen151 or the 
inhibition of the plasminogen activator inhibitor-I (PAI-1)152 and indirectly by kallikrein which 
can activate tissue plasminogen activator (tPA) and urokinase plasminogen activator 
(uPA)153, however the relevance of each function in vivo has yet to be determined. 
 
 
Figure 4. Scheme of the classical coagulation cascade. The extrinsic pathway is initiated by the 
tissue factor (TF): factor (F)VII complex at sites of vascular injury followed by the activation of FX and 
FIX. FXII, the starting point of the intrinsic pathway, is activated via contact activation and triggers 
sequential activation of FXI, FIX and X. Both pathways culminate in the prothrombinase (FX:FV 
complex)-induced activation of prothrombin. The resulting thrombin is the key protease of the 
coagulation system and activates multiple proteases and cofactors. Thrombin can also cleave 
fibrinogen into soluble fibrin monomers which are consequently cross-linked by the action of the 
activated FVIII, leading to clot-stabilizing fibrin polymers.  
 
Although negatively charged material, such as glass, kaolin, silicone rubber and various 
polymers are well known to initiate contact activation in vitro, the mechanisms and 
substances supporting FXII autoactivation under physiological conditions are still a matter of 
intensive debate. A number of biologic candidates have already been suggested to promote 
FXII activation, including fatty acids, sulfatides, glycosaminoglycans, cholesterol sulfate as 
well as phosphatidic acid154. Recent studies identified novel interesting procoagulant 
mediators such as extracellular RNA155, misfolded or aggregated proteins156, inorganic 
polyphosphates released from dense granules of activated platelets157 and exposed 
collagen158 and laminin159 at sites of vascular injury. However, the (patho-) physiological 
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relevance of these mediators as well as the relative contribution of each substance to FXII 
activation remains to be elucidated. 
In order to prevent uncontrolled protease activation and limit excessive blood clotting, the 
coagulation system is also tightly linked to endogenous anticoagulatory pathways. This is 
primarily done by the tissue factor pathway inhibitor (TFPI) limiting TF-FVIIa complex 
activity160, the protease inhibitor antithrombin and the FVa-FVIIIa specific Protein C inhibitor 
pathway161. Until recently, C1 esterase inhibitor (C1 inhibitor) was considered the best known 
physiological inhibitor of FXIIa162, however, new in vitro studies suggested that platelet-
induced FXII activation is dominantly regulated by antithrombin163 and that Histidine-rich 
glycoprotein (HRG) is involved in the inhibition of FXIIa-mediated coagulation164.  
The two classical pathways of coagulation also serve as the basis of the widely used 
standard methods to determine overall plasma coagulation in clinical practice: the 
prothrombin time (PT) by TF-FVIIa-initiated coagulation and the activated partial 
thromboplastin time (aPTT) by FXII-mediated clotting. The relevance of the intrinsic pathway 
for blood coagulation in vitro, as aforementioned, has been obvious for decades now, 
whereas its importance for physiological clot formation remained elusive. A long-standing 
model suggested that fibrin formation is mainly, if not exclusively, mediated by the TF-FVIIa 
pathway, whereas FXII-induced processes were considered not to be relevant for blood 
clotting in vivo. This hypothesis was mainly based on the observation that hereditary 
deficiency of FXII is not associated with hemorrhages165 contrary to deficiencies of 
components of the extrinsic cascade. TF-deficient humans have not been described and 
severe FVII deficiency was only found at a low frequency166 which could be reproduced in 
mice lacking either of the proteases and die during embryonic development or perinatally due 
to massive vascular and hemostatic defects167,168. 
This original view was recently challenged by studies showing that FXII-deficient mice are 
profoundly protected from pathological thrombus formation in different models of arterial 
thrombosis and ischemic stroke but do, like FXII-deficient humans, not display any 
detectable alteration of hemostasis169,170. These surprising observations not only changed the 
long-standing paradigm that hemostasis and thrombosis involve the same mechanisms but 
also led to the intriguing hypothesis that inhibitors of FXII-dependent coagulation might 
represent powerful antithrombotic agents that do not induce an increased bleeding risk, the 
major clinical complication associated with current anticoagulative therapies, most notably 
heparins and vitamin K antagonists.  
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1.9 Murine arterial thrombosis models 
Arterial thrombus formation is a complex process involving a well-coordinated action and a 
defined interplay of numerous platelet adhesion/activation receptors, intracellular signaling 
molecules, subcellular structures and plasma coagulation factors. The generation of 
genetically modified mouse strains during the last decade has provided a powerful tool to 
elaborate the functional significance of a certain protein or signaling pathway for platelet 
physiology. In this context, in vitro experiments are indispensable for a detailed analysis of 
the individual roles and the interactions of defined proteins during platelet adhesion, 
activation and aggregation processes. However, these findings are partially difficult to 
correlate with their true in vivo relevance for thrombosis and hemostasis, as in vitro 
conditions cannot resemble the innumerable hemodynamic changes and spatiotemporal 
cellular and molecular interactions that are present during the initiation and propagation of 
thrombi at sites of vascular lesions.  
Therefore, multiple mouse models of thrombotic disease have been developed during recent 
years to assess the molecular mechanisms underlying arterial thrombus formation in vivo. 
These models differ in the type of vessel injury, the severity of injury, the targeted vascular 
bed and consequently the signaling pathways that are predominantly triggered171. The 
combination of thrombosis models with in vivo fluorescence microscopy, e.g. of fluorescently 
labeled platelets, allows direct real-time visualization and quantification of dynamics during 
the thrombotic process. 
The most commonly used method to induce vascular injury is the topical application of 
Ferric(III)chloride (FeCl3) on a macro- or microvessel (carotid artery or mesenteric arterioles), 
which typically results in formation of platelet-rich occlusive thrombi172,173 that are 
morphologically similar to those found in humans174. The mechanisms underlying FeCl3-
induced thrombosis are still controversially discussed. While it was widely accepted until now 
that FeCl3 treatment leads to vascular endothelial denudation and exposure of the ECM 
through production of reactive oxygen species172,175, a recent study suggested alternative 
mechanisms86. In that study, Eckly et al. showed that FeCl3 diffuses through the vessel wall 
resulting on the one hand only in the exposure of endothelial basement membrane 
components and on the other hand in the development of FeCl3-filled spherical bodies on the 
endothelium which carry large amounts of TF on the surface86. Another, less commonly 
applied chemical injury model involves a systemic injection of the photoreactive reagent 
Rose Bengal followed by exposure of a vessel segment to epi-illumination at 540 nm176. The 
endothelial damage is caused by the generation of free radicals that leads to formation of 
occlusive thrombi. A laser-induced vascular injury in the microcirculation is another frequently 
used technique to trigger thrombus formation177. In this model, the intensity of the laser-beam 
and the exposure time can be tightly controlled to produce different types of lesions ranging 
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from mild endothelial injury or activation to denudation of the endothelium. It has been 
proposed that the consequently activated signaling events that drive thrombus formation 
depend on the severity of the laser-induced injury78,85,178. Whereas, a severe injury is 
suggested to trigger thrombus growth predominantly by TF-dependent thrombin generation, 
a superficial injury has been shown to also involve collagen-mediated platelet activation. A 
third principle to experimentally achieve a vascular damage is the mechanical injury of a 
macrovessel (abdominal aorta, carotid artery or femoral artery) either by compression or 
ligation of the vessel using a forceps169 or a filament42 or by direct injury of the luminal side of 
the artery with a flexible wire179. This model is characterized by occlusive thrombus formation 
within a few minutes after massive endothelial denudation. 
As the mentioned murine thrombosis models differ in their experimental procedures and may 
accordingly induce different signaling pathways that predominately drive thrombus formation, 
mutant mice should be ideally analyzed in different injury models. Thereby, more reliable 
conclusions can ultimately been drawn about the relevance of the particular targeted protein 
in arterial thrombosis.  
All thrombosis models have in common that the vascular damage is induced in healthy blood 
vessels instead of diseased, atherosclerotic vessels where atherothrombotic events normally 
occur in humans. To replicate the thrombogenic conditions of a ruptured atherosclerotic 
plaque in mice two groups have developed a special thrombosis model using Apoe-/- mice. 
Thrombus formation in this model was provoked by acute plaque rupture in the carotid artery 
using either an ultrasound treatment180 or a suture needle technique181. However, the results 
obtained in this model were largely variable, indicating that further studies are required to 
improve the reproducibility of thrombus formation upon plaque rupture. 
Although murine thrombosis models are artificial and have many limitations, they have 
already provided enormous insights into the molecular mechanisms of platelet function and 
thrombus formation in vivo during the last years and they will also be a promising tool in the 
future to improve the understanding of arterial thrombosis and as a consequence to propose 
new antithrombotic therapies in humans.  
In this thesis, different in vivo thrombosis models were utilized where arterial thrombus 
formation was initiated by either FeCl3-induced injury of small mesenteric arterioles or the 
carotid artery or mechanically induced vascular damage in the abdominal aorta. A severe 
laser-induced injury model was also established in our laboratory under supervision by the 
master student Marianne Frings. This technique was, however, not used for the analyses in 
the present study.  
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2 AIM OF THE STUDY 
Thrombus formation during hemostasis and thrombosis is a multistep process that involves 
the sequential interplay of platelet adhesion and activation receptors, intracellular signal 
transduction, cytoskeletal reorganizations, granule release, integrin activation and initiation of 
coagulation. However, the respective key proteins and signaling mechanisms underlying 
these processes are still not fully identified or understood.  
The aim of this thesis was (I) to analyze the function of different platelet signaling proteins 
and receptors during the distinct steps of platelet adhesion/activation, aggregation and 
consequently thrombus formation and thereby (II) to identify novel pharmacological target 
candidates or pathways for a possible antithrombotic therapy. The focus of this thesis was on 
the relevance of the GPIbα-vWF interaction for arterial thrombus formation, the functional 
significance of the collagen receptor GPVI in different murine thrombosis models, the role of 
the recently identified platelet activating receptor CLEC-2 for hemostasis and thrombosis as 
well as on the effect of GPVI/CLEC-2 double deficiency on in vivo thrombus formation. 
Furthermore, this study intended to assess the function of the intracellular signaling protein 
PLD1 particularly during platelet aggregation and thrombus formation and the role of the 
small GTPase RhoA in platelet function and signaling. For this purpose, different strategies 
of specific protein blockage or deficiency in mice were used. The vWF binding site of 
GPIbα was inhibited in mice by injecting Fab fragments of the GPIbα blocking antibody 
p0p/B. GPVI and CLEC-2 deficient mice were generated by immunodepletion of the 
respective receptors after antibody injection. Furthermore, constitutive Gp6 and Pld1 as well 
as conditional RhoA knockout mice were analyzed.  
The (III) aim of the study was to determine the suitability of a newly generated anti-FXIIa 
inhibitor as potential antithrombotic agent. 
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Chemicals and kits 
2-methyl-2-butanol     Sigma (Deisenhofen, Germany) 
6x Loading Dye Solution    Fermentas (St. Leon-Rot, Germany) 
acetic acid      Roth (Karlsruhe, Germany) 
ADP       Sigma (Deisenhofen, Germany) 
agarose      Roth (Karlsruhe, Germany) 
agarose, low melting     Euromedex (France) 
ammonium peroxodisulphat (APS)   Roth (Karlsruhe, Germany) 
apyrase (grade III)     Sigma (Deisenhofen, Germany) 
Avertin® (2,2,2-tribromoethanol)   Sigma (Deisenhofen, Germany)  
beta-mercaptoethanol    Roth (Karlsruhe, Germany) 
bovine serum albumin (BSA)    AppliChem (Darmstadt, Germany) 
calcium chloride     Roth (Karlsruhe, Germany) 
Chrono-Lume® (d-luciferase/luciferin reagent  
+ATP standard)     Probe & go (Osburg, Germany) 
convulxin      Axxora (Lörrach, Germany) 
D-Dimer ELISA kit, Asserachrom   Roche (Basel, Switzerland) 
dNTP mix      Fermentas (St. Leon-Rot, Germany) 
Dylight-488™      Pierce (Rockford, IL,USA) 
eosin       Roth (Karlsruhe, Germany) 
Epinephrine      Sigma (Deisenhofen, Germany) 
epon 812      Roth (Karlsruhe, Germany) 
ethanol      Roth (Karlsruhe, Germany) 
ethidium bromide     Roth (Karlsruhe, Germany) 
Eukitt mounting medium    Sigma (Deisenhofen, Germany) 
fat-free dry milk     AppliChem (Darmstadt, Germany) 
fentanyl      Janssen-Cilag GmbH,   
       (Neuss, Germany) 
fibrilar type I collagen (Horm)   Nycomed (Munich, Germany) 
flumazenil      Delta Select GmbH    
       (Dreieich, Germany) 
fluorescein-isothiocyanate (FITC)   Molecular Probes (Oregon, USA) 
Forene® (isoflurane)     Abott (Wiesbaden, Germany) 
Fura-2 acetoxymethyl ester    Molecular Probes (Oregon, USA) 
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Gelatine capsules     Agar scientific (Stansted, England) 
GeneRuler 1kb DNA Ladder    Fermentas (St. Leon-Rot, Germany) 
glucose      Roth (Karlsruhe, Germany) 
glutaraldehyde     Roth (Karlsruhe, Germany) 
hematoxylin      Sigma (Deisenhofen, Germany  
Hexomethyldizilasin (HMDS)    Merck (Darmstadt, Germany) 
high molecular weight heparin   Sigma (Deisenhofen, Germany) 
human fibrinogen     Sigma (Deisenhofen, Germany) 
iron-III-chloride hexahydrate (FeCl3 6H2O)  Roth (Karlsruhe, Germany) 
isopropanol      Roth (Karlsruhe, Germany) 
magnesium cloride     Roth (Karlsruhe, Germany) 
medetomidine      Pfizer (Karlsruhe, Germany)  
midazolam      Roche Pharma AG   
       (Grenzach- Wyhlen, Germany) 
naloxon      Delta Select GmbH    
       (Dreieich, Germany) 
NP40       Sigma (Deisenhofen, Germany) 
paraformaldehyde     Roth (Karlsruhe, Germany) 
phenol/chloroform/isoamylalcohol   AppliChem (Darmstadt, Germany) 
Pluronic F-127     Invitrogen (Karlsruhe, Germany) 
poly L-lysin      Sigma (Deisenhofen, Germany) 
propyleneoxide     Sigma (Deisenhofen, Germany) 
prostacyclin      Calbiochem (Bad Soden, Germany) 
R-phycoerythrin (PE)     EUROPA (Cambridge, UK) 
sodium cacodylate     Roth (Karlsruhe, Germany) 
sodium chloride     AppliChem (Darmstadt, Germany) 
Taq polymerase buffer (10x)    Fermentas (St. Leon-Rot, Germany) 
Taq polymerase     Fermentas (St. Leon-Rot, Germany) 
thrombin      Roche Diagnostics (Mannheim, Germany) 
Triton X-100      AppliChem (Darmstadt, Germany 
U46619      Alexis Biochemicals (San Diego, USA) 
uranylacetate  Electron Microscopical Sciences (Hatfield, 
USA)  
Vectashield hardset mounting medium  Vector Laboratories (Burlingame, USA) 
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Chromogenic substrates were purchased from Chromogenix (Lexington, USA) or Hyphen 
Biomed (Neuville sur Oise, France). All enzymes were obtained from Invitrogen (Karlsruhe, 
Germany). Collagen related peptide (CRP) was kindly provided by Paul Bray (Baylor 
College, USA). Rhodocytin was a generous gift from Johannes Eble (University Hospital 
Frankfurt, Germany). All other chemicals were obtained from Sigma (Deisenhofen, Germany) 
or Roth (Karlsruhe, Germany). 
 
3.1.2 Antibodies 
3.1.2.1 Purchased primary and secondary antibodies 
hvWF antibody     DAKO (Hamburg, Germany 
myosin light chain antibody  Cell Signaling Technologies (Danvers, 
USA) 
phalloidin-atto647N     Sigma (Deisenhofen, Germany) 
phalloidin-FITC     Sigma (Deisenhofen, Germany) 
phospho-myosin light chain antibody  Cell Signaling Technologies (Danvers, 
USA) 
rat anti-mouse IgG-HRP    DAKO (Hamburg, Germany) 
RhoA antibody     Cytoskeleton (Denver, USA) 
α-tubulin antibody-Alexa 488    Invitrogen (Karlsruhe, Germany) 
 
3.1.2.2 Monoclonal Antibodies (mAbs) 
mAbs generated and modified in our laboratory 
 
antibody isotype antigen described in 
JAQ1 IgG2a GPVI 77 
INU1 IgG1 CLEC-2 182 
p0p4 IgG2b GPIbα 183 
p0p/B IgG2b GPIbα 42 
DOM2 IgG2a GPV 183 
p0p6 IgG2b GPIX 183 
JON/A IgG2b GPIIbIIIa 184 
JON1 IgG2b GPIIbIIIa 183 
ULF1 IgG2a CD9 183 
12C6 IgG2b α2 integrin unpublished 
WUG1.9 IgG1 P-selectin unpublished 
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3.1.3 Human serine proteases 
coagulation factor XIIaα   Kordia (Leiden, Netherlands) 
coagulation factor XIIaβ   Kordia (Leiden, Netherlands) 
coagulation factor XIa   Kordia (Leiden, Netherlands) 
coagulation factor IXa   Kordia (Leiden, Netherlands) 
coagulation factor Xa    Kordia (Leiden, Netherlands) 
coagulation factor VIIa   Kordia (Leiden, Netherlands) 
thrombin     Kordia (Leiden, Netherlands) 
kallikrein     Kordia (Leiden, Netherlands) 
plasmin     Kordia (Leiden, Netherlands) 
tissue plasminogen activator   Kordia (Leiden, Netherlands) 
urokinase plasminogen activator  Kordia (Leiden, Netherlands) 
Thromborel S     Dade Behring (Marburg, Germany) 
 
3.1.4 Buffers 
All buffers were prepared and diluted in double distilled water (ddH2O). 
 
• Acid-citrate-dextrose buffer (ACD), pH 4.5 
Trisodium citrate dehydrate    85 mM 
Citric acid anhydrous     65 mM 
Glucose anhydrous     110 mM 
 
• Cacodylate buffer (electron microscopy) 
sodium cacodylate (pH 7.2)    50 mM 
 
• Citrate buffer, pH 7.0 
Sodium citrate     0.129 M 
add H2O 
 
• Fixation buffer I (electron microscopy) 
Sodium cacodylate, pH 7.2   0.1 M 
Glutaraldehyde     2.5% 
Formaldehyde     2% 
 
• Fixation buffer II (electron microscopy) 
Sodium cacodylate, pH 7.2   50 mM 
Osmium tretroxid    2% 
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• Lysis buffer (DNA isolation) 
TRIS base     100 mM 
EDTA      5 mM 
NaCl      200 mM 
SDS      0.2% 
add Proteinase K (20 mg/ ml)    100 µg/ml 
 
• Phosphate buffered saline (PBS), pH 7.14 
NaCl      137 mM (0.9%) 
KCl      2.7 mM  
KH2PO4     1.5 mM 
Na2HPO4     8 mM 
 
• 50x TAE buffer 
TRIS base     0.2 M 
Acetic acid     5.7 % 
EDTA (0.5 M, pH 8)    10 % 
 
• TE buffer 
TRIS base     10 mM 
EDTA      1 mM 
 
• Tris-buffered saline (TBS), pH 7.3 
NaCl      137 mM (0.9%) 
Tris/HCl      20 mM 
 
• Tris-HCl buffer, pH 7.8  
Tris-HCl      200 mM 
BSA      1% 
 
• Tyrode-HEPES buffer, pH 7.3 
NaCl      137 mM (0.9%) 
KCl      2.7 mM  
NaHCO3     12 mM 
NaH2PO4     0.43 mM 
CaCl2      2 mM 
MgCl2      1 mM 
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HEPES      5 mM 
BSA      0.35% 
Glucose      0.1% 
 
• Blocking solution for immunoblotting 
BSA or fat-free dry milk    5% 
in PBS or washing buffer 
 
• Blotting buffer A for immunoblotting 
TRIS, pH 10.4     0.3 M 
Methanol     20% 
 
• Blotting buffer B for immunoblotting 
TRIS, pH 10.4     25 mM 
Methanol      20 % 
 
• Blotting buffer C for immunoblotting 
ε-amino-n-caproic acid, pH 7.6  4 mM 
Methanol     20% 
 
• Coomassie staining solution 
Acetic acid      10% 
Methanol      40% 
Coomassie Brilliant blue    1 g 
 
• Coomassie destaining solution 
Acetic acid      10% 
Methanol      40% 
 
• IP buffer 
TRIS HCl, pH 8.0    15 mM 
NaCl      155 mM 
EDTA      1 mM  
NaN3      0.005% 
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• Laemmli buffer for SDS-PAGE 
TRIS      40 mM 
Glycine      0.95 M 
SDS      0.5% 
 
• PHEM buffer, pH 6.8 
PIPES      100 mM  
HEPES      5.25 mM  
EGTA      10 mM 
MgCl2      20 mM  
 
• SDS sample buffer, 2x 
β-mercaptoethanol (for reduced conditions) 10% 
TRIS buffer (1.25 M), pH 6.8   10% 
Glycerine     20% 
SDS      4% 
Bromophenolblue    0.02% 
 
• Separating gel buffer 
TRIS HCl, pH 8.8    1.5 M 
add H2O 
 
• Stacking gel buffer 
TRIS/ HCl, pH 6.8    0.5 M 
add H2O 
 
• Washing buffer (western blot) 
Tween 20      0.1 %  
in PBS 
 
3.1.5 Animals 
Specific pathogen free NMRI and C57Bl6/J mice were purchased from Harlan Winkelmann 
GmbH (Borchen, Germany). Mice with floxed genes of RhoA were kindly provided by Cord 
Brakebusch (University of Copenhagen, Denmark) and transgenic mice carrying the Cre 
recombinase under the PF4 promoter (PF4-cre+) were from Radek Skoda (Basel, 
Switzerland). For the PF4-Cre strategy, these two mice were crossed to receive RhoAfl/fl/PF4-
cre+ mice where gene deletion occurred intrinsically upon activation of the PF4 promoter 
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during megakaryopoiesis. Littermates (RhoAfl/fl/PF4-cre- mice) served as controls. The Gp6-/- 
and the Pld1-/- mice were generated in our laboratory by Markus Bender and Attila Braun, 
respectively. For GPVI and CLEC-2 receptor depletion in platelets, NMRI or C57Bl6/J mice 
were intravenously or intraperitoneally injected with 100 µg of JAQ1 and 200 µg of INU1, 
respectively. Mice were used for experiments 5 to 6 days after antibody injection.  
Animal studies were approved by the district government of Lower Frankonia 
(Bezirksgerierung Unterfranken). 
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3.2 Methods 
3.2.1 Mouse genotyping 
3.2.1.1 Isolation of genomic DNA from mouse ears 
An approximately 5 mm2 piece of the mouse ear was cut and dissolved in 500 µl lysis buffer 
by overnight incubation at 56°C under shaking condi tions (~900 rpm). 500 µl of a 
phenol/chloroform mixture were added to the samples which were then vortexed and 
centrifuged at 14,000 rpm for 10 min at room temperature (RT). 450 µl supernatant were 
transferred into a new tube containing 500 µl isopropanol. After vigorous shaking, samples 
were centrifuged at 14,000 rpm for 10 min at 4°C. T he resulting DNA pellet was washed 
twice with ice cold 70% ethanol and centrifuged at 14,000 rpm for 5 min at RT. Finally, the 
DNA pellet was left to dry and resuspended in 50 µl TE buffer. The genotyping PCR was 
performed using 1 µl DNA solution. 
 
3.2.1.2 Detection of the RhoA floxed allele by PCR 
• Composition of the sample 
1 µl  DNA 
2 µl  10x Taq polymerase buffer 
0.6 µl  MgCl2 (50 mM) 
0.4 µl  dNTPs (10 µM) 
0.2 µl  Primer 1 1:10 (stock: 1 µg/µl) 
0.2 µl  Primer 2 1:10 (stock: 1 µg/µl) 
0.2 µl  Taq polymerase (0.5 U/ml) 
14.4 µl  H2O 
 
• Primers 
RhoA_for  AGC CAG CCT CTT GAC CGA TTT A   
RhoA_rev  TGT GGG ATA CCG TTT GAG CAT 
 
• PCR program 
94°C  2:00 min 
94°C  0:30 min 
55°C  0:30 min 35x 
72°C  0:30 min  
72°C  10:00 min  
4°C  ∞ 
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• Band sizes 
wt:  297 bp 
floxed:  393 bp 
 
3.2.1.3 Detection of the PF4-Cre transgene by PCR 
• Composition of the sample 
1 µl  DNA 
2.5 µl  10x Taq polymerase buffer 
2.5 µl  MgCl2 (25 mM) 
1 µl  dNTPs (10 µM) 
1 µl  Primer 1 1:10 (stock: 1 µg/µl) 
1 µl  Primer 2 1:10 (stock: 1 µg/µl) 
0.5 µl  Taq-Polymerase (0.5 U/ml) 
15.5 µl  H2O 
 
• Primers 
PF4-Cre_for  CCC ATA CAG CAC ACC TTT TG 
PF4-Cre_rev  TGC ACA GTC AGC AGG TT 
 
• PCR program 
95°C  5:00 min 
95°C  0:30 min 
58°C  0:30 min 35x 
72°C  0:45 min 
72°C  5 min 
4°C  ∞ 
 
• Band sizes 
wt:  no PCR product 
PF4-cre+  450 bp 
 
3.2.2 In vitro analysis of platelet function 
3.2.2.1 Platelet isolation and washing 
Mice were bled under isofluran anesthesia from the retroorbital plexus. 700 µl blood were 
collected into a 1.5 ml tube containing either 300 µl heparin in TBS (20 U/ml, pH 7.3) or ACD 
buffer (pH 4.5). Blood was centrifuged at 1,800 rpm (Eppendorf 5415C) for 5 min at RT. 
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Supernatant and buffy coat were transferred into a new tube and centrifuged at 800 rpm for 6 
min at RT to obtain platelet rich plasma (prp). To prepare washed platelets, prp was 
centrifuged at 2,500 rpm for 5 min at RT in the presence of prostacyclin (PGI2) (0.1 µg/ml) 
and apyrase (0.02 U/ml). The resulting pellet was resuspended in 1 ml Ca2+-free Tyrode’s 
buffer, containing PGI2 (0.1 µg/ml) and apyrase (0.02 U/ml) and left to incubate at 37°C for 
10 min. After a second washing step, the platelet pellet was resuspended in Tyrode’s buffer 
containing apyrase (0.02 U/ml) and left to incubate for at least 30 min at 37°C before 
analysis.  
 
3.2.2.2 Platelet counting 
For determination of platelet counts and size, 50 µl blood were drawn from the retroorbital 
plexus of anesthetized mice using siliconized microcapillaries and collected in a 1.5 ml tube 
containing 300 µl heparin in TBS (20 U/ml, pH 7.3). Platelet counts and size were determined 
using a Sysmex KX-21N automated hematology analyzer (Sysmex Corp., Kobe, Japan). 
 
3.2.2.3 Western blotting 
For western blot analysis, prp was prepared as described in section 3.2.2.1. Prp was 
centrifuged at 1500 rpm for 5 min and platelets were washed twice in PBS + 5 mM EDTA. 
The final platelet pellet was resuspended in IP buffer containing protease inhibitors and 1% 
NP40 to a final concentration of at least 0.5x106 platelets/µl. After an incubation step of 
20 min at 4°C and centrifugation at 14,000 rpm for 5 min,  the supernatant was mixed with an 
equal amount of 2x SDS sample buffer and boiled at 95°C for 5 min. Samples were 
separated by 12 or 15% SDS-PAGE and transferred onto a polyvinylidene difluoride (PVDF) 
membrane. To prevent non-specific antibody binding, membranes were blocked in 5% fat-
free milk or 5% BSA dissolved in washing buffer for 2 h at RT or over night (o/n) at 4°C. 
Membranes were incubated with the required primary antibody (5 µg/ml) o/n at 4°C by gentle 
shaking. Afterwards membranes were washed three times with washing buffer for 15 min at 
RT under shaking conditions. Then, membranes were incubated with appropriate HRP-
labeled secondary antibodies for 1 h at RT. After three washing steps, proteins were 
visualized by ECL. 
 
3.2.2.4 Flow cytometric analysis  
To determine glycoprotein expression levels, platelets (1x106) were stained for 15 min at RT 
with saturating amounts of fluorophore-conjugated antibodies described in section 3.1.2.2, 
and analyzed directly after addition of 500 µl PBS. For activation measurements, platelets 
were stimulated with different agonists in the presence of saturating amounts of the 
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phycoerythrin (PE)-coupled JON/A and the fluorescein isothiocyanate (FITC)-coupled anti-P-
selectin antibody for 5 min at 37°C and additional 5 min at RT. The reaction was stopped by 
addition of 500 µl PBS and the samples were analyzed on a FACSCalibur (Becton Dickinson, 
Heidelberg, Germany). For a two-colour staining, the following settings were used: 
 
Detectors/Amps: 
Parameter Detector Voltage 
P1 FSC E01 
P2 SSC 380 
P3 Fl1 650 
P4 Fl2 580 
P5 Fl3 150 
 
Threshold: 
Value Parameter 
253 FSC-H 
52 SSC-H 
52 Fl1-H 
52 Fl2-H 
52 Fl3-H 
 
Compensation: 
Fl1 2.4% of Fl2 
Fl2 7.0% of Fl1 
Fl2 0% of Fl3 
Fl3 0% of Fl2 
 
3.2.2.5 Aggregation 
For aggregation studies, washed platelets were adjusted to a concentration of 
1.5 x 108 platelets/ml with Tyrode’s buffer. Alternatively, prp from heparinized blood was 
diluted 1:3 in Tyrode’s buffer. Agonists were added (100-fold concentrated) and light 
transmission was recorded over 10 min on an Apact 4-channel optical aggregation system 
(APACT, Hamburg, Germany). As calibration before each measurement, Tyrode’s buffer (for 
washed platelets) or 1:3 diluted plasma (for prp) was set as 100% aggregation and washed 
platelet suspension or prp was set as 0% aggregation. Measurements with washed platelets 
(except for thrombin-induced aggregation) were performed in the presence of Tyrode’s buffer 
containing 100 µg/ml fibrinogen. 
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3.2.2.6 Aggregation + ATP release 
Washed platelets were adjusted to a concentration of 5 x 108 platelets/ml with Tyrode’s buffer 
and further diluted 1:3 in Tyrode’s buffer containing 100 µg/ml fibrinogen (except for 
measurements with thrombin). For ATP release measurements, 25 µl Chrono-Lume reagent 
was added to the platelet suspension and incubated for 2 min at 37°C before addition of 
agonists (50-fold concentrated). Subsequent ATP release and increase in light transmission 
was recorded using a Chrono-Log 4-channel aggregation system (Probe & go, Osburg, 
Germany). Calibration for the aggregation measurement was performed as mentioned above 
(section 3.2.2.5). An ATP-standard solution was used as calibrator to determine the 
concentration of agonist-induced ATP release. 
 
3.2.2.7 Intracellular Calcium-measurements 
Washed platelets at a concentration of approximately 5x108 platelets/ml in Ca2+-free Tyrode’s 
buffer were loaded with fura-2 AM (5 µM) in the presence of Pluronic F-127 (0.2 µg/ml) for 
30 min at 37°C. After labeling, platelets were wash ed once and resuspended in Tyrode’s 
buffer without Ca2+ (for measurement of store release). Stirred platelets were activated with 
different agonists and fluorescence was measured with a PerkinElmer LS 55 fluorimeter 
(Massachusetts, USA). Excitation was alternated between 340 and 380 nm, and emission 
was measured at 509 nm. Each measurement was calibrated using 1% Triton X-100 and 
EGTA. 
 
3.2.2.8 Determination of platelet filamentous (F)-actin content 
Washed platelets were prepared and the platelet count was adjusted to approximately 2x105 
platelets/µl in Tyrode’s buffer without Ca2+. Platelets were diluted 1:10 in Tyrode’s buffer in a 
final volume of 50 µl per sample and incubated for 3 min at 37°C after addition of 5 µl 
Dylight 649-conjugated anti-GPIX Ig derivative. Then, platelets were stimulated with 1 U/ml 
thrombin (final concentration) for 2 min at 37°C (4 00 rpm) and fixed for 10 min by addition of 
0.55% volume 10% PFA in PBS. Samples were finally centrifuged for 5 min at 2500 rpm, the 
pellet was resuspended in 55 ml Tyrode´s buffer containing 0.1 volume % Triton-X 100 and 
50 µl were mixed with phalloidin-FITC at a final concentration of 10 µM. Samples were 
incubated 30 min at RT in the dark and the reaction was stopped by addition of 500 µl PBS. 
After centrifugation for 5 min at 2500 rpm and the pellet was resuspended again in 500 µl 
PBS. Samples were immediately analyzed on a FACSCalibur. 
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3.2.2.9 Clot retraction 
For Clot retraction studies, platelets were adjusted to a concentration of 3x108 platelets/ml in 
platelet poor plasma (ppp). 250 µl of the platelet suspension was mixed with 1.5 µl 
erythrocyte suspension (to contrast the clot), obtained during platelet isolation from whole 
blood, and 20 mM CaCl2. Clotting was induced by addition of high thrombin concentrations 
(3 U/ml). Subsequent clot retraction was monitored at 37°C under non-stirring conditions and 
recorded with a digital camera over time.  
 
3.2.2.10 Static adhesion on human fibrinogen 
Rectangular glass coverslips (Roth, Karlsruhe, Germany) were coated with 100 µg human 
fibrinogen (diluted in PBS) overnight at 4°C under humid conditions and blocked for 2 h at RT 
with 1% BSA in PBS. The coverslips were rinsed with Tyrode´s buffer and 100 µl thrombin-
stimulated (0.001 U/ml) washed platelets (0.03 x 106 platelets/µl) were immediately added 
and incubated at RT for the indicated time periods. The coverslips were rinsed again with 
Tyrode´s buffer and platelets were visualized with an Axiovert 200M inverted microscope 
(Zeiss, Göttingen, Germany) at 100x magnification using differential interference contrast 
(DIC) microscopy. Representative images were taken and evaluated according to different 
platelet spreading stages. 
 
3.2.2.11 Adhesion under flow conditions 
3.2.2.11.1 Flow adhesion assay on collagen 
Coverslips (24 x 60 mm) were coated with 200 µg/ml fibrilar type-I collagen (Horm) overnight 
at 37°C and blocked for 1 h with 1% BSA. Blood (700  µl) was collected into 300 µl heparin 
(20 U/ml in TBS, pH 7.3) and diluted 2:1 with Tyrode´s buffer. For flow adhesion studies 
under non-coagulated conditions, blood was taken 1:10 into citrate buffer (129 mM; pH 7.0). 
Platelets were labeled with a Dylight-488 conjugated anti-GPIX Ig derivative (0.2 µg/ml) for 
5 min at 37°C and blood was finally filled into a 1  ml syringe. Perfusion studies were 
performed as follows. Transparent flow chambers with a slit depth of 50 µm, equipped with 
the coated coverslips, were connected to the syringe filled with the diluted whole blood. 
Perfusion was performed using a pulse-free pump under high shear stress equivalent to a 
wall shear rate of 1000 sec-1, 1700 sec-1 or 7700 sec-1 (5 min, 4 min or 2 min, respectively). 
Thereafter, coverslips were washed by a 1 to 4 min perfusion with Tyrode’s buffer at the 
same shear stress and phase-contrast and fluorescent images were recorded from at least 
five different microscope fields (40x objective). Image analysis was performed off-line using 
MetaMorph® software (Visitron, Munich, Germany). Thrombus formation was expressed as 
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the mean percentage of total area covered by thrombi, and as the mean integrated 
fluorescence intensity per mm2. 
 
3.2.2.11.2 Flow adhesion assay on vWF 
Coverslips were coated with 200 µl rabbit anti-human vWF antibody (1:500, diluted) over 
night at 37°C and rinsed with Tyrode`s buffer. Afte r blocking with 1% BSA for 1 h at 37°C, 
coverslips were rinsed again and incubated with 200 µl mouse plasma for 2 h at 37°C. Blood 
preparation and subsequent perfusion studies were performed as described in section 
3.2.2.11.1. Platelet adhesion on vWF was determined by counting the platelet number per 
visual field. 
 
3.2.3 Coagulation and fibrinolysis assays 
3.2.3.1 Preparation of mouse plasma 
Anesthetized mice were bled and 720 µl blood were collected into a 1.5 ml tube containing 
80 µl citrate buffer. Blood was centrifuged at 2500 rpm for 5 min at RT and supernatant was 
transferred into a new tube. After a second centrifugation step at 10,000 rpm for 5 min at RT, 
supernatant containing pure plasma was used for experiments.  
 
3.2.3.2 Determination of aPTT and PT 
Activated partial thromboplastin time (aPTT) and prothrombin time (PT) of standard human 
plasma (SHP), mouse and rat plasma was determined using standard methods according to 
the manufacturer´s protocol. (Siemens Healthcare, Erlangen, Germany). These assays have 
been performed in the laboratory of Stefan Schmidbauer, CSL Behring Marburg, Germany). 
 
3.2.3.3 Chromogenic assays 
rHA-Infestin-4 was incubated at different concentrations with pure human serine proteases 
(FXIIaα, FXIIaβ, FXIa, FIXa, FVIIa, FXa, thrombin, kallikrein, plasmin, tPA and urokinase, 
respectively) for 10 min at 37°C in a 96-well plate  (total volume 160 µl). Tris-HCl buffer, pH 
7.8 was used for all required dilutions. A specific chromogenic substrate (40 µl, 2-4 mM) for 
the respective protease was added and incubated for a defined time period according to the 
protease activity. The reaction was stopped by acetic acid (20%) and absorption was 
measured at 405 nm on an ELISA reader a Multiskan EX (Thermo Scientific, Waltham, 
USA). Additionally, different concentrations of rHA-Infestin-4 were incubated with FXIIaα and 
FXIa, respectively, for 3 h at 37°C in the presence  of the macromolecular chromogenic 
substrate Casein-Resorufin. The reaction was stopped by trichloroacetic acid and absorption 
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was measured at 574 nm. The amount of active protease was calculated against a standard 
curve. 
 
3.2.3.4 D-Dimer concentration measurements 
Pooled mouse plasma (100 µl) was incubated with vehicle (PBS) or rHA-Infestin-4 
(0.1/1/10 mg/ml) for 2 min at 37°C. Clot formation was induced using Thromborel S (200 µl) 
according to the manufacturer’s instructions and samples were left for 1 h at 37°C. 
Fibrinolysis was stopped by addition of 4.5 µl HCl (1:1) and samples were neutralized by 
25 µl NaOH (1 M) and centrifuged at 14,000 rpm for 5 min at RT. D-Dimer concentration in 
the supernatant was finally determined with an ELISA kit (Asserachrom, Roche) according to 
the manufacturer’s instructions. 
 
3.2.4 In vivo murine models 
3.2.4.1 Determination of platelet life span 
Mice were injected intravenously with a Dylight-488 conjugated anti-GPIX Ig derivative 
(0.5 µg/g body weight). 1 h after injection (day 0), as well as at the other indicated time 
points, 50 µl blood were collected and the percentage of GPIX-positive platelets was 
determined by flow cytometry. 
 
3.2.4.2 FeCl3-induced thrombus formation in small mesenteric arterioles 
3- to 4-wk-old mice were anesthetized with 2,2,2-tribromoethanol (450 µg/g body weight). 
After a midline abdominal incision, 35-60-µm-diameter arterioles were gently exteriorized and 
visualized at 10x magnification with an inverted microscope (Axiovert 200; Zeiss, Göttingen, 
Germany) equipped with a 100-W mercury lamp (HBO) and a CoolSNAP-EZ camera 
(Visitron, Munich, Germany). Endothelial damage was induced by topical application of a 
3 mm2 filter paper saturated with 20% FeCl3. Digital images were recorded and analyzed 
offline using MetaMorph® software. Adhesion and thrombus formation of fluorescently 
labeled platelets (DyLight 488-conjugated anti-GPIX Ig derivate) were recorded for 40 min or 
until complete occlusion of the vessel (blood flow stopped for >1 min) occurred. 
 
3.2.4.3 Mechanical injury of the abdominal aorta 
The abdominal cavity of anesthetized mice was opened with a longitudinal incision to expose 
the abdominal aorta. An ultrasonic flowprobe (0.5PSB699, Transonic Systems, New York, 
USA) was placed around the vessel and thrombus formation was induced by a single firm 
compression with a forceps upstream of the flowprobe. Blood flow was monitored for 30 min. 
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3.2.4.4 Carotid artery thrombosis model 
Mice were anesthetized and the left carotid artery was exposed through a vertical midline 
incision in the neck. Thrombus formation was induced by a filter paper saturated with a FeCl3 
solution at the indicated concentration and placed on the carotid artery for a defined period. 
Blood flow was monitored using an ultrasonic flow probe (Transonic System, New York, 
USA) until complete vessel occlusion occurred or for 30/60 min. 
 
3.2.4.5 Bleeding time assays 
Mice were anesthetized with a triple anesthesia (medetomidine 0.5 µg/g, midazolam 5 µg/g 
and fentanyl 0.05 µg/g body weight) and a 2 mm segment of the tail tip was removed with a 
scalpel. Tail bleeding was monitored by gently absorbing blood with filter paper at 20 second 
intervals, without directly contacting the wound site. When no blood was observed on the 
paper, bleeding was determined to have ceased. Alternatively, the tail was immediately 
immersed in 0.9% isotonic saline at 37°C and the bl eeding time was defined as time until 
cessation of blood flow. Experiments were stopped in each case after 20 min. 
 
3.2.4.6 Transient occlusion model of the middle cerebral artery 
Analyses were conducted according to the published recommendations for research in 
mechanism-driven basic stroke studies185. Transient middle cerebral artery occlusion 
(tMCAO) was induced under inhalation anesthesia using the intraluminal filament 
(6021PK10; Doccol Company) technique186. After 60 min, the filament was withdrawn to 
allow reperfusion. For determination of ischemic brain volume, mice were sacrificed 24 h 
after induction of tMCAO and brain sections were stained with 2% 2,3,5-triphenyltetrazolium 
chloride (TTC; Sigma-Aldrich). Brain infarct volume was calculated and corrected for edema 
as described 24 h after tMCAO Neurological function was analyzed by two independent and 
blinded investigators. Global neurological status was scored according to Bederson et al.187. 
Motor function and coordination were graded using the grip test188. This model was 
performed by Christoph Kleinschnitz in the group of Prof. Guido Stoll, Department of 
Neurology, University Clinic, Würzburg, Germany.  
 
3.2.5 Statistics 
Statistical evaluation was performed using the Welch’s test. Results are indicated as mean ± 
SD of at least three individual experiments. If appropriate, the Fisher`s exact test was used. 
Data of Bederson score and grip test in the rHA-Infestin-4 study were analyzed with the 
Mann-Whitney U test. P-values <0.05 were considered statistically significant. 
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3.2.6 Electron microscopy 
3.2.6.1 Transmission electron microscopy (TEM) of platelets in suspension 
Washed platelets were adjusted to a concentration of 3x108 platelets/ml in Tyrode’s buffer. 
Platelets in a resting state or activated with 0.01 µM U46619 were fixed by addition of an 
equal amount of cacodylate buffer containing 5% glutaraldehyde for 10 min at 37°C without 
stirring. For complete fixation, samples were incubated for 1 h at RT and afterwards stored at 
4°C until further processing. A small amount of the  sample was further diluted to 1:10 in 
cacodylate buffer and washed three times by addition of 1 ml cacodylate buffer and 
subsequent centrifugation for 5 min at 1,000 x g (RT). Platelets were then left to adhere for 
1 h on poly-lysine-coated coverslips and processed for scanning electron microscopy (see 
3.2.6.2). The remaining samples were washed three times for 5 min by addition of 1 ml 
cacodylate buffer and subsequent centrifugation for 5 min at 1,500 x g (37°C). A 2% low 
melting agarose solution in cacodylate buffer was prepared and kept at 45°C. After the final 
washing step, platelets were resuspended carefully in 1 ml agarose solution and immediately 
centrifuged for 5 min at 14,000 rpm (37°C). The aga rose solution was discarded except 
100 µl and samples were incubated on ice for 10 min. The hardened agarose pellets were 
cut out of the tubes and the platelet pellets were cut into approximately 1 mm2 pieces and 
stored in cacodylate buffer. Samples were fixed in cacodylate buffer containing 1% OsO4 for 
45 min - 1 h at RT, washed twice with ddH2O and incubated for 1 h at 4°C in 2% 
uranylacetate in ddH2O. After three washing steps with ddH2O, samples were dehydrated in 
70% (4x5 min), 95% (3x15 min) and 100% (3x15 min) ethanol. Next, samples were 
incubated in 100% propylenoxyde (2x10 min) and then in a 1:1 mixture of propylenoxyde and 
epon for 1 h under rotating conditions. After 2 further incubations in epon at RT (first step: 
o/n¸ second step: 2-3 h) samples were embedded in gelatine capsules and left to dry for 48 h 
at 60%. 50 nm thin sections were cut using a Leica Ultracut microtom UCT (Leica 
Microsystems, Wetzlar, Germany), contrasted and analyzed on an FEI electron microscope 
(Phillips, Hillsboro, USA). This method was performed by Irina Pleines in the group of Prof. 
Bernhard Nieswandt. 
 
3.2.6.2 Scanning electron microscopy (SEM) of platelets 
For immobilization and visualization of platelets fixed in suspension, coverslips were coated 
with 0.01% poly-lysine for 15 min at RT and left to dry o/n at RT. Fixed platelets (see 3.2.6.1) 
were left to adhere for 20 min - 1h and further processed as described below.  
For static adhesion, roundish coverslips (12 mm diameter) were coated with 100 µg/ml 
human fibrinogen in PBS for 2 h at RT, blocked for 1 h with 1% BSA in PBS and shortly 
washed with PBS. Washed platelets were adjusted to a concentration of 3x104 platelets/µl 
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and activated with 0.01 U/ml thrombin. 100 µl of this suspension were immediately added to 
the coverslips and incubated at 37°C for the indica ted time points. Samples were fixed by 
addition of 300 µl cacodylate buffer containing 2.5% glutaraldehyde for 1 h at 37°C, 1 h at RT 
and kept at 4°C until further processing. Coverslip s were washed twice with 200 µl 
cacodylate buffer and dehydrated in 70% (4x5 min), 80% (1x5 min), 95% (1x5 min) and 
100% (2x30 min) ethanol. The coverslips were then incubated with increasing concentrations 
of hexomethyldizilasin (HMDS) in 100% ethanol (25%: 1x 5 min; 50%: 1x5 min; 75%: 1x5 
min and 100%: 2x5 min). Samples were left to dry, sputtered with gold using a Cressington 
Sputter Coater 108 Auto and a 0.2 µm thin gold foil (both from Cressington, Chalk Hill, 
England) and analyzed using a FEI electron microscope (Phillips, Hillsboro, USA). This 
method was performed by Irina Pleines in the group of Prof. Bernhard Nieswandt. 
 
3.2.7 Fluorescence microscopy of platelets 
3.2.7.1 Staining of spread platelets for confocal microscopy 
Washed platelets were activated with 0.01 U/ml and immediately put on a fibrinogen-coated 
coverslip as described in section 3.2.2.10. After 40 min, fully spread platelets were fixed in 
PHEM buffer containing 4% PFA and 10% NP40 for 20 min at 4°C and blocked with 5% BSA 
in PBS for 2 h at 37°C. Samples were washed with PB S and stained with mouse anti 
α-tubulin-Alexa 488 antibody (1:100) and phalloidin-atto647N (1:300) for 1 h in the dark at 
37°C. Then, samples were washed again with PBS, mou nted using Vectashield mounting 
medium and finally left to dry o/n at 4°C. Samples were visualized on a Leica SP5 confocal 
microscope with a 100x oil objective (Leica Microsystems, Mannheim, Germany). 
 
3.2.7.2  Stimulated Emmision Depletion (STED) microscopy of spread platelets 
Spread platelets were prepared and stained as described in sections 3.2.2.10 and 3.2.7.1. 
Samples were analyzed on a STED-Leica SP5 microscope (Leica Microsystems, Mannheim, 
Germany). This method was performed by Shuchi Gupta in the group of Prof. Bernhard 
Nieswandt. 
 
3.2.8 Histology 
3.2.8.1 Preparation of paraffin sections 
A piece of the abdominal aorta was cut around the injury site at the end of the perfomed 
thrombosis model (see 3.2.4.3) and immediately fixed in PBS 4% PFA o/n. Afterwards, 
organs were washed 3 times with PBS and directly dehydrated and embedded in paraffin. 
Organs were cut using a Microm Cool Cut microtom (Thermo Scientific, Braunschweig, 
Germany) to prepare 5 µm thin sections. 
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3.2.8.2 Hematoxylin/eosin staining of paraffin sections 
Sections were deparaffinated by two incubation steps in Xylol (3 min each). Rehydration was 
carried out using decreasing ethanol concentrations (100, 96, 90, 80 and 70%) with 2 
incubation steps in each solution and a final incubation of 2 min in ddH2O. Sections were 
then stained for 2 min with hematoxylin, followed by a 10 min washing step using running tab 
water and 2 min staining with 0.05% Eosin G. The sections were washed shortly and 
dehydration was carried out using the same ethanol concentrations and incubation times as 
described above in reversed order. Finally, sections were incubated twice in Xylol for 3 min 
each, dried and mounted onto an object plate with Eukitt mounting medium. Samples were 
analyzed using a Leica DHI 4000B inverse microscope equipped with a Leica digital camera 
(Leica Microsystems, Wetzlar, Germany). 
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4 RESULTS 
4.1 Relevance of the GPIbα-vWF interaction and downstream signaling in 
thrombus formation 
Initiation of thrombus formation at sites of vascular damage involves platelet recruitment to 
the exposed ECM, a process that is mediated by the platelet receptor GPIb-V-IX complex. Its 
essential role for arterial thrombus formation has been impressively demonstrated using 
FeCl3-induced injury models in mice lacking the functional extracellular domain of GPIbα or a 
binding site for the signaling molecule 14-3-3ξ in the C-terminus of the molecule43,44,189. In 
contrast, vWF, the main ligand of GPIbα, has been shown to be less but still significantly 
important for arterial thrombosis in the same injury model173,175, however essential for platelet 
tethering after mechanical injury of the carotid artery42. Interestingly, the use of vWF-/- mice 
and Fab fragments of the GPIbα blocking antibody p0p/B revealed that the interaction of 
GPIbα and vWF is a major pathophysiological mechanism underlying stroke 
development45,46. 
Since the role of GPIbα and vWF in thrombus formation has previously been analyzed, this 
part of the present study assessed the effect of p0p/B Fab fragments in commonly used 
FeCl3- and mechanically induced thrombosis models to initially characterize the reliability and 
comparability of these in vivo models when performed in our laboratory. 
 
4.1.1 Targeting of GPIbα protects mice from arterial thrombosis, but causes a 
hemostatic defect 
Wild-type mice were intravenously injected with 100 µg p0p/B Fab fragments 30 min prior to 
vascular injury to specifically block the vWF-binding site on GPIbα. These mice were first 
challenged in a model of FeCl3-induced endothelial damage in small mesenteric arterioles 
and intravital microscopy of fluorescently labeled platelets was used to visualize subsequent 
platelet adhesion and aggregation. In all wild-type mice, first thrombi >10 µm in diameter 
formed within 6.4 ± 1.6 min after injury and expanded to full vessel occlusion in 8 out of 9 
arterioles (mean time to occlusion 16.7 ± 4.4 min; Figure 5A,B). In line with data obtained in 
vWF-/- mice173, beginning of thrombus formation was significantly delayed in p0p/B Fab 
fragment-treated mice (10.6 ± 2.0 min; p<0.05) and further thrombus growth was clearly 
decelerated and finally arrested leaving a small open channel in 8 out of 9 vessels (Figure 
5A,B). This defect could be ascribed to the permanent release of single platelets from the 
thrombus surface which became maximal when the thrombus reached ~50 to 90% of the 
vessel diameter (mean vessel stenosis 77.6 ± 16.5% for p0p/B Fab fragment-treated mice 
and 97.3 ± 8.6% for wild-type mice; p<0.01; Figure 5C). These data clearly confirmed that in 
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this experimental setting the GPIbα-vWF interaction only partially contributes to the adhesion 
of platelets to the injury site but is essential for platelet incorporation into a growing 
thrombus, particularly under conditions of very high-shear.  
 
 
Figure 5. Defective FeCl3-induced thrombus formation in mice treated with Fab fragments of a 
GPIbα blocking antibody. Mesenteric arterioles were injured by application of FeCl3 and thrombus 
formation was monitored using intravital fluorescence microscopy. Mice were i.v. injected with vehicle 
or 100 µg p0p/B Fab fragments 30 min prior to injury. A, Time to beginning of thrombus formation (left) 
and to stable vessel occlusion (right) are shown. Horizontal lines indicate mean values. Each symbol 
represents one arteriole. B, Representative pictures acquired at the indicated time points/intervals. 
Bar, 50 µm. Asterisk indicates vessel occlusion. C, Percentage of maximal thrombus-caused vessel 
stenosis is illustrated. *, p<0.05; **, p<0.01. p0p/B Fab indicates p0p/B Fab fragments. 
 
Additionally, mice injected with 100 µg p0p/B Fab fragments were analyzed in an arterial 
thrombosis model where the abdominal aorta was injured by a single tight compression with 
a forceps. An ultrasonic perivascular Doppler flowprobe was used to monitor thrombus 
formation. Under these conditions, all wild-type vessels irreversibly occluded (7/7) after 280 ± 
107 sec. However, although blood flow initially declined in most of the p0p/B Fab fragment-
treated mice similar to wild-type, indicating beginning of thrombus formation, it remained 
rather constant at this level for the rest of the observation period (Figure 6A,B). 
Consequently, none of these vessels occluded, demonstrating that functional GPIbα is 
crucial for occlusive arterial thrombus formation also under these experimental conditions. 
To test whether GPIbα blockage also impairs hemostasis, a tail bleeding time assay was 
performed. The tail tip of anesthetized mice was removed 30 min after injection of 100 µg 
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p0p/B Fab fragments and time until cessation of blood loss was determined using the filter 
paper method. Whereas bleeding stopped in 11 out of 12 (92%) wild-type mice within 12 min 
(mean bleeding time 436 ± 178 sec; Figure 6C), only 5 out of 15 (33%) of the p0p/B Fab 
fragment-treated mice could arrest bleeding while the rest bled for >20 min (p<0.01; Figure 
6C). All together, these findings support previously published data and emphasize the 
importance of the GPIbα-vWF interaction in thrombosis and hemostasis. 
 
 
Figure 6. Blockage of GPIbα results in protection from mechanically induced thrombosis and 
in prolonged bleeding times. The abdominal aorta was injured by one firm compression with a 
forceps 30 min after injection of either vehicle or p0p/B Fab fragments (100 µg i.v.). Thrombus 
formation was monitored by blood flow measurements. A, Time to vessel occlusion and B. 
representative curves of the blood flow after injury are shown. C, Tail bleeding times of vehicle-treated 
and p0p/B Fab fragment-injected wt mice. Each symbol represents one individual. p0p/B Fab indicates 
p0p/B Fab fragments. 
 
4.1.2 Phospholipase D1 is a critical mediator of shear-dependent thrombus formation 
downstream of GPIb 
The role of PLC isoforms as essential intracellular signaling proteins during platelet activation 
is well established. In contrast, the specific function of PLD in platelets has been elusive. 
Platelets express two PLD isoforms, PLD1 and PLD2 which are known to produce PA and 
translocate to the plasma membrane upon platelet activation58. To elucidate the relevance of 
the PLD1 isoform for platelet physiology and thrombus formation, constitutive knockout mice 
for PLD1 were generated and analyzed in our laboratory. In vitro studies with these mice 
were mainly performed by Margitta Elvers and David Stegner in our group. 
Pld1-/- mice displayed normal platelet counts and only slightly increased platelet size which 
was accompanied with a small increase in the expression levels of some prominent surface 
receptors, indicating that PLD1 is dispensable for megakaryopoiesis and platelet 
production190. The ability of these platelets to become activated in response to agonists was 
determined by flow cytometric measurements of fibrinogen-binding to the activated 
integrin αIIbβ3 and α-degranulation-dependent P-selectin exposure. Binding of fibrinogen 
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after stimulation with low doses of CRP or PAR-4 activating peptide was significantly reduced 
in Pld1-/- platelets compared to wild-type but unaltered when high agonist concentrations 
were used. Moreover, this activation defect could be ascribed to the lack of PLD1-generated 
PA190. Interestingly, and contrary to a previous hypothesis191, agonist-induced dense-granule 
release, and also α granule release was not affected190. These findings suggested that PLD1 
acts as a signaling mediator contributing to integrin αIIbβ3 activation downstream of 
G protein and ITAM-coupled receptors after submaximal stimulation.  
 
4.1.2.1 Pld1-/- platelets fail to form stable aggregates on collagen under flow 
conditions  
Under physiological conditions, platelet adhesion and aggregation occur in the flowing blood 
where shear forces strongly influence platelet functions. To analyze the functional 
consequence of the aforementioned impaired integrin activation in this setting, the ability of 
Pld1-/- platelets to form thrombi on a collagen-coated surface at different shear rates was 
tested in a whole-blood perfusion system. At low (150 sec-1) and intermediate (1000 sec-1) 
shear rates, which resemble venous or arterial flow conditions, respectively, no alterations in 
initial platelet adhesion or in aggregate formation on collagen were detectable between Pld-/- 
and wild-type platelets (Figure 7A). Remarkably, however, Pld1-/- platelets displayed strongly 
reduced thrombus stability under high shear rates (1700 sec-1) which mimics flow conditions 
in small arterioles. Although, Pld1-/- platelets normally adhered to the collagen fibers and 
formed large thrombi covering a comparable surface area as wild-type platelets during the 
perfusion time (mean surface coverage 48.2 ± 15.8% for Pld1-/ mice and 56.8 ± 9.7% for 
wild-type mice, p=0.77; Figure 7A, bottom left), all thrombi of Pld1-/- platelets disintegrated 
during the following washing period. Consequently, virtually no aggregates remained on the 
surface and only a monolayer of adherent platelets was detectable at the end of the 
perfusion experiment (relative thrombus volume 0.9 ± 0.6 for Pld1-/ mice and 3.7 ± 1.3 for 
wild-type mice; p<0.01; Figure 7A, bottom right). These results demonstrated that PLD1 is 
required for thrombus stabilization at high, but not at intermediate and low shear rates, 
suggesting defective shear-dependent GPIb-mediated signaling in Pld1-/- platelets. 
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Figure 7. Pld1-/- platelets fail to form stable aggregates on collagen and to adhere on vWF under 
high shear conditions. Whole blood of wt and Pld1-/- mice was perfused over a collagen-coated (A) 
and a vWF-coated (B) surface at the indicated shear rates and then washed with Tyrode`s buffer for a 
period equal to the perfusion time. A, Representative phase contrast images at the end of the 
perfusion and washing period (top). Bar, 100 µm. Mean surface coverage (bottom, left) and relative 
thrombus volume expressed as integrated fluorescence intensity (IFI) per mm2 (bottom, right) ± SD of 
6 mice per group are shown. B, Representative phase contrast images at the end of the washing 
period (top). Number of platelets were counted 100 sec after beginning of blood perfusion (bottom, 
left) and at the end of the washing period (bottom, right). Values are mean ± SD of 6 mice per group. 
**, p<0.01; ***, p<0.001. (Elvers. et al., Sci.Signal.,2010)190. 
 
4.1.2.2 PLD1-deficient platelets display defective adhesion on vWF under flow 
conditions  
To directly investigate a possible role of PLD1 in GPIb-dependent interaction of platelets with 
vWF, adhesion of Pld1-/- platelets on immobilized vWF under high shear conditions was 
analyzed in a flow chamber system. In this experimental setting, thrombogenic collagen 
which drives platelet activation is absent and thus a shift from transient to stable platelet 
adhesion is exclusively dependent on integrin αIIbβ3 activation triggered by vWF-occupied 
GPIb192. At all tested shear rates, wild-type platelets rapidly attached to the immobilized 
murine vWF and in part firmly adhered to the surface (Figure 7B). In contrast, whereas the 
initial tethering of Pld1-/- platelets was unaltered compared to wild-type platelets, transition to 
firm adhesion was defective, resulting in strongly reduced numbers of Pld1-/- platelets 
detectable on the surface at the end of the experiment (Figure 7B). This defect could be 
observed at all tested shear rates but was most profound at very high shear rates (3400 and 
6800 sec-1), resembling flow conditions in small arterioles and stenosed arteries. These 
results indicated that PLD1 might be involved in GPIb-mediated integrin αIIbβ3 activation 
under flow. 
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4.1.2.3 PLD1-deficient mice are protected from occlusive arterial thrombus formation 
In a next step, the relevance of the so far described functional defects in Pld1-/- platelets for 
in vivo thrombus formation was assessed in two different arterial thrombosis models. In the 
first model, thrombosis was induced by mechanical injury of the abdominal aorta and blood 
flow was subsequently monitored using an ultrasonic flow probe. In all wild-type vessels 
blood flow progressively decreased to complete and irreversible vessel occlusion within 
12 min after injury (mean time to occlusion 444 ± 174 sec; Figure 8A,B). In contrast, blood 
flow irreversibly stopped in only 20% (2/10) of Pld1-/- mice during the observation period of 
30 min (p<0.001; Figure 8A,B). In 30% of Pld1-/- mice no vessel occlusion occurred, and 
although in 50% of Pld1-/- mice blood flow declined similar to wild-type, vessels were only 
occluded for <1 min and then completely recanalized (Figure 8A,B). 
To confirm these findings, mice were challenged in a second arterial thrombosis model in 
which the right carotid artery was injured by topically applied FeCl3 (15%). Blood flow was 
again monitored with an ultrasonic flow probe. Whereas in all wild-type vessels (8/8) full 
occlusion occurred within 14 min (mean time to occlusion 538.9 ± 255.6 sec) and persisted in 
all animals except one (87.5%) for the rest of the observation period, vessel occlusion 
occurred in only 2 out of 7 Pld1-/- mice (28.6%). However, this occlusion was only transient 
and consequently all vessels of Pld1-/- mice remained open until the end of the experiment 
(Figure 8C). These data show that PLD1 plays an important role for occlusive thrombus 
formation in vivo. 
To determine the effect of PLD1-deficiency on normal hemostasis, a tail bleeding time assay 
was performed. Interestingly, no differences in the bleeding times of Pld1-/- mice compared to 
wild-type mice were detectable (mean bleeding time 337 ± 242 sec for Pld1-/- mice and 
367 ± 282 sec for wild-type mice; p=0.76; Figure 8D), demonstrating that PLD1 is not 
required for hemostasis. 
Since ischemic stroke development has previously been described to be largely dependent 
on vWF/GPIbα interactions45,46, wild-type and Pld1-/- mice were analyzed in a stroke model of 
transient middle cerebral artery occlusion (tMCAO). Remarkably, also Pld1-/- mice displayed 
markedly reduced brain infarction areas and a better neurological outcome than wild-type 
mice in this model that was not associated with an increased risk of intracranial 
hemorrhage190. These data were also confirmed by bone marrow transplantation 
experiments where lethally irradiated wild-type mice were reconstituted with Pld1-/- bone 
marrow and vice versa190, indicating that the observed protection of Pld1-/- mice resulted from 
the lack of PLD1 in the hematopoietic system.  
 
Results 
 
44 
 
 
Figure 8. Pld1-/- mice show reduced thrombus stability in arterial thrombosis models but 
unaltered bleeding times. The abdominal aorta of wt and Pld1-/- mice was injured by a single firm 
compression with a forceps and thrombus formation was monitored using an ultrasonic flow probe. A, 
Time to stable vessel occlusion (left) and amount of (1) non-occluded, (2) recanalized and (3) stably 
occluded vessels after injury of wt and Pld1-/- mice (right) are shown. Each symbol represents one 
individual. B, Representative blood flow curves after injury (left) and cross sections of the aorta taken 
30 min after injury (right). Bar, 200 µm. C, The carotid artery of wt and Pld1-/- mice was injured by 15% 
FeCl3 and time to stable vessel occlusion was determined using blood flow measurements. Each 
symbol represents one individual. D, Tail bleeding times of wt and Pld1-/- mice are depicted. Each 
symbol represents one individual. (Elvers et al., Sci.Signal.,2010)190. 
Results 
 
45 
 
4.2 Genetic and antibody-induced GPVI deficiency similarly protects mice 
from FeCl3- and mechanically induced thrombosis 
GPVI is the major receptor for platelet adhesion and activation on exposed collagen at the 
wound site. Different mouse models of GPVI deficiency (GPVI-immunodepleted77, FcRg-/- 79 
and Gp6-/- mice80,81) have been used to determine the functional relevance of the receptor in 
arterial thrombus formation in diverse models of chemically, mechanically or laser-induced 
vascular injury. Although GPVI is generally considered as a critical mediator of pathological 
thrombus formation, the relative significance of GPVI-dependent platelet activation in some 
of these models, particularly FeCl3-induced injury models, is still controversially 
discussed42,44,78,86. To systematically assess the relevance of GPVI-mediated platelet 
adhesion/activation at sites of FeCl3- and mechanically injured vessel walls, Gp6-/- and GPVI-
immunodepleted mice were analyzed in three different thrombosis models. For 
immunodepletion of GPVI from the surface of circulating platelets, wild-type C57Bl/6 mice 
received 100 µg of the anti-GPVI antibody, JAQ1, i.p. 6 days before the experiment and loss 
of GPVI was confirmed by flow cytometric measurements at the day of the experiment. In the 
first model, endothelial damage was induced by topical application of a drop of 20% FeCl3 
solution on small mesenteric arterioles and subsequent thrombus formation of fluorescently 
labeled platelets was monitored using intravital microscopy for 40 min or until complete 
occlusion of the vessel had occurred. Kinetics of initial platelet adhesion (data not shown) 
and beginning of first thrombus formation were comparable between control and Gp6-/- mice 
and only slightly delayed in some of the GPVI-immunodepleted mice (7.5 ± 1.5 min for 
control, 7.5 ± 1.4 min for Gp6-/- mice; p=0.99; and 9.5 ± 2.7 min for GPVI-immunodepleted 
mice; p=0.08; Figure 9A). In all control mice, thrombi grew progressively finally resulting in 
stable vessel occlusion (mean time to occlusion 17.9 ± 3.2 min, Figure 9A,B), whereas both 
groups of GPVI-deficient mice displayed reduced thrombus stability evident by permanent 
embolization of differently sized thrombus fragments during the propagation phase. 
Consequently, most vessels of Gp6-/- (8/10) and GPVI-immunodepleted mice (6/11) 
remained open during the entire observation period or occlusion occured significantly 
delayed compared to control mice (mean time to occlusion 30.8 ± 8.1 for GPVI-
immunodepleted; p<0.05, Figure 9A,B).  
Similar results were obtained in the second model where the carotid artery of mice was 
injured by topical application of a filter paper saturated with 10% FeCl3 for 1.5 min and blood 
flow was monitored with an ultrasonic flow probe. Whereas 11 out of 12 vessels in control 
mice rapidly occluded within 589 ± 295 sec after injury, initial reduction of blood flow was 
observed in both Gp6-/- and GPVI-immunodepleted mice but permanent embolization in most 
vessels prevented or delayed stable vessel occlusion (7/9 Gp6-/- and 6/9 GPVI-
immunodepleted mice; Figure 9C). 
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These data demonstrated that GPVI plays a significant role for FeCl3-induced thrombus 
formation and that this is independent of the studied vascular bed. 
 
 
 
Figure 9. GPVI-deficient mice display defective thrombus formation in FeCl3-induced 
thrombosis models. Mesenteric arterioles of control, Gp6-/- and GPVI-immunodepleted mice were 
injured with 20% FeCl3 and adhesion and thrombus formation of fluorescently labeled platelets was 
monitored by in vivo microscopy. A, Beginning of first thrombus formation (left) and time to occlusion 
(right) are shown. Horizontal lines indicate mean values. Each symbol represents one arteriole. B, 
Representative images at the indicated time points after injury are depicted. Bar, 100 µm. Asterisk 
indicates vessel occlusion. C, Carotid arteries were topically injured with 10% FeCl3 and time to 
occlusion was determined. Each symbol represents one individual. Depl.=depleted. (Bender*, 
Hagedorn* et al. J Thromb Haemost. 2011)193. 
 
Furthermore, mice were subjected to a mechanical injury model in which the abdominal aorta 
was compressed for 15 sec with a forceps and thrombus formation was monitored by blood 
flow measurements. In line with findings from the previous two thrombosis models, GPVI 
deficiency resulted in profound protection from occlusive thrombosis. Remarkably, the 
thrombus formation defect in this model was even more pronounced than that observed in 
GPVI-deficient mice after FeCl3-induced vascular injuries. All Gp6-/- (6/6) and 6 out of 7 
GPVI-immunodepleted mice indeed displayed initial reduction of the blood flow and in some 
cases also minimal embolization was detected; however, the blood flow remained rather 
constant throughout the observation period of 30 min, (Figure 10A,B). In comparison, all 
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control mice exhibited irreversible vessel occlusion within 272 ± 98 sec. This demonstrated 
that GPVI deficiency results in severely reduced thrombus growth after mechanical vessel 
injury. Furthermore, the data suggested that genetic- and antibody-induced loss of GPVI lead 
to comparable defects in arterial thrombus formation. 
 
 
Figure 10. GPVI-deficient mice are protected from mechanically induced arterial thrombosis. 
The abdominal aorta was injured by tight compression with a forceps and blood flow was monitored for 
30 min. A, Time to stable vessel occlusion and B, representative blood flow curves are shown. Each 
symbol represents one individual. Depl.=depleted. (Bender*, Hagedorn* et al. J Thromb Haemost. 
2011)193. 
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4.3 The platelet activating receptor CLEC-2 is essentially involved in 
thrombosis and hemostasis 
The recently identified platelet activating receptor CLEC-2 has been shown to use a similar 
intracellular signaling pathway as GPVI73. However, the functional role of CLEC-2 for platelet 
activation during hemostasis or thrombosis has not been determined. The following study 
was conducted together with Frauke May, who mainly performed the in vitro analyses on the 
function of CLEC-2 in platelets. 
 
4.3.1 CLEC-2 can specifically be downregulated from circulating platelets by the 
monoclonal antibody INU1 
To analyze the effect of CLEC-2 deficiency in platelets, an approach of antibody-induced 
depletion of the receptor from the platelet surface, similar to the previously described GPVI-
immuodepletion (see77 and section 4.2), was used.  
A novel rat monoclonal antibody against murine CLEC-2, termed INU1 (rat IgG1), was 
generated by Frauke May in our laboratory182. Intravenous injection of INU1 (8 µg/g body 
weight) into NMRI mice resulted in a rapid but transient thrombocytopenia with a maximal 
reduction of platelet counts of more than 85% on day 1182. Platelet counts returned to normal 
or in some mice slightly increased levels on day 5 (Figure 11A, left) where they remained for 
at least 6 more days. Platelet size was also slightly increased in these animals, most 
probably due to increased production of new platelets to overcome the induced 
thrombocytopenia (Figure 11A, right). Interestingly, platelets of INU1-teated mice completely 
lacked CLEC-2 on the surface from day 1 to 5 and even for up to 7 days post injection as 
determined with INU1-FITC by flow cytometry, whereas expression levels of other prominent 
surface receptors such as GPIb-V-IX, GPVI, CD9 and integrins αIIbβ3 and α2β1 were 
unaltered (Figure 11B). Blockage of the CLEC-2 receptor in vivo by INU1 could be excluded 
as the injected antibody was not detectable by a FITC-conjugated anti-rat IgG antibody on 
the surface of the platelets182. To test the physiological relevance of CLEC-2 deficiency in 
more detail, flow cytometric analysis of integrin αIIbβ3 activation and α granule release-
dependent P-selectin exposure in response to different platelet agonists was performed. 
Platelets from mice on day 5 after INU1 injection were completely resistant to activation with 
rhodocytin but displayed normal activation responses to ADP, U46619 (a TxA2 analogue), 
thrombin and convulxin (Figure 11C,D). These findings were confirmed by aggregation 
studies182. These results demonstrated that INU1-treatment specifically abolished CLEC-2 
signaling in platelets while leaving other activation pathways fully intact.  
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Figure 11. INU1-treatment induces specific loss of the CLEC-2 receptor and abolishes CLEC-2 
signaling in circulating platelets. Mice were injected with either vehicle or 8 µg/g b.w. INU1 and 
platelets were analyzed on day 5 on a FACSCalibur. A, Mean platelet count expressed as mean 
events/sec (left) and mean platelet size (right) determined by FSC characteristics. B, Relative 
expression of glycoproteins and integrins on the platelet surface. Diluted whole blood of the indicated 
mice was incubated with the respective FITC-labeled antibodies and analyzed directly. Values are 
means ± SD of 5 mice per group. C, Flow cytometric analyses of αIIbβ3 integrin activation (binding of 
JON/A-PE) and D, degranulation-dependent P-selectin exposure in response to the indicated 
agonists. Values are mean fluorescence intensity (MFI) ± SD of 5 mice per group. U46=U46619, 
thr=thrombin, CVX=convulxin, RC=rhodocytin. ***, p<0.001. (May, Hagedorn et al., Blood, 2009)182. 
 
The following experiments were performed with mice 5 days after INU1-treatment to ensure 
normal platelet counts but complete CLEC-2 deficiency in these animals. 
 
4.3.2 CLEC-2 deficiency leads to the formation of unstable thrombi under flow 
Since platelet activation at sites of vascular injury involves a complex interplay of various 
receptors to enable thrombus formation under flow conditions, the importance of CLEC-2 in 
this process was assessed in a whole blood perfusion assay. Thus, anticoagulated blood 
from control and INU1-treated mice was perfused over a collagen-coated surface at an 
arterial shear rate of 1700 sec-1. Control platelets rapidly adhered to collagen within 2 min 
and formed small aggregates that constantly grew into big thrombi covering 51 ± 5.7% of the 
surface area at the end of the 4 min perfusion period. In sharp contrast, although CLEC-2 
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deficient platelets normally adhered to collagen (Figure 12A), they failed to subsequently 
build stable thrombi. During the entire perfusion time, adherent platelets recruited numerous 
platelets from the blood flow but many of these were unable to firmly attach and were 
released after a few seconds. Consequently, only small aggregates formed and the overall 
surface coverage was reduced by 36% (31 ± 12.1%; p<0.01, Figure 12B). The thrombus 
formation defect became even more evident by assessing the relative thrombus volume, 
determined as the integrated intensity of fluorescently labeled platelets per mm2, which was 
reduced by ~82% compared to control mice (0.3 ± 0.2 for CLEC-2 deficient mice, 1.4 ± 0.2 
for control mice; p<0.01; Figure 12B). Similar results were obtained in studies using a higher 
shear rate of 3400 sec-1 (data not shown). This indicates that CLEC-2 is dispensable for the 
initial adhesion of platelets on collagen but essential for stable aggregate formation. 
To test whether the observed aggregate instability was based on altered platelet activation, 
the same perfusion study was performed with non-anticoagulated blood to allow thrombin 
generation. To do so, blood was drawn from mice into citrate buffer instead of heparin, 
coinfused with a CaCl2/MgCl2 buffer and then perfused over a collagen surface in the flow 
chamber system. Under these conditions, both control and CLEC-2 deficient platelets formed 
stable thrombi covering equal surface areas (Figure 12C). This was also true when 
anticoagulated blood was coinfused with ADP (10 µM) and U46619 (1 µM) into the flow 
chamber system (data not shown). CLEC-2 deficient platelets displayed similarly sized 
thrombi as compared to control platelets, demonstrating that CLEC-2 is a platelet activating 
receptor that is critically involved in thrombus stabilization under conditions where other 
platelet agonists are limited and unable to provide full platelet activation.  
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Figure 12. CLEC-2-deficient platelets fail to form stable thrombi under flow conditions. Whole 
blood from the indicated mice was perfused over a collagen-coated surface at a shear rate of 
1,700 sec-1. A, Platelet adhesion on collagen after 30 sec, indicated as number of platelets per visual 
field. Values are mean ± SD. B, Aggregate formation on collagen after 4 min perfusion time under 
anticoagulated conditions. Top, representative phase contrast images. Bottom, mean surface 
coverage (left) and relative thrombus volume expressed as integrated fluorescence intensity (IFI) per 
mm2 (right) ± SD of 6 mice per group, **, p<0.01. C, Aggregate formation on collagen after 4 min 
perfusion time under non-anticoagulated conditions. Top, representative phase contrast images. 
Bottom, mean surface coverage ± SD of 6 mice per group. Bar, 100 µm. Ctrl=control. (May, Hagedorn 
et al., Blood, 2009)182. 
 
4.3.3 CLEC-2-deficient mice display defective thrombus formation in a FeCl3-injury 
model and prolonged bleeding times 
Based on the previous results, it was important to assess the relevance of CLEC-2-mediated 
platelet activation in thrombus formation in vivo after vascular injury. Thus, INU1-treated mice 
were analyzed in a thrombosis model where endothelial damage was induced by FeCl3 on 
mesenteric arterioles and subsequent thrombus formation was monitored by intravital 
fluorescence microscopy. In all control mice, appearance of first thrombi >10 µm in diameter 
was observed 5 to 8 min after injury with progression to complete and stable occlusion of the 
vessel within 20 min (mean time to occlusion 16.4 ± 2.2 min; Figure 13). Remarkably, 
whereas the initial adhesion and formation of small aggregates occurred with similar kinetics 
in CLEC-2 deficient mice compared to control (6.9 ± 1.5 min for CLEC-2 deficient mice and 
6.5 ± 1.5 min for control mice; p=0.7), progression to occlusive thrombi was virtually 
abrogated (Figure 13). This defect was mainly caused by the release of individual platelets 
from the thrombus surface, but also to a certain extent by embolization of small fragments 
during thrombus growth leading to maintenance of the blood flow during the entire 
observation period of 40 min. This observation revealed a crucial role for CLEC-2 for 
pathological thrombus formation. 
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Figure 13. Defective thrombus formation in CLEC-2-deficient mice. Thrombus formation in 
mesenteric arterioles was induced by FeCl3 and monitored using intravital fluorescence microscopy. A, 
Beginning of first thrombus formation and B, time to stable vessel occlusion are shown. Each symbol 
represents one arteriole. Data are representative of 2 individual stets of experiments. C, 
Representative fluorescence microscopical images at the indicated time points. Bar, 100 µm. Asterisk 
indicates occlusion of the vessel. Ctrl=control. (May, Hagedorn et al., Blood, 2009)182. 
 
To further assess whether CLEC-2 deficient mice are similarly protected from thrombus 
formation after mechanically induced vascular injury, these animals were challenged in a 
model where the abdominal aorta was injured by a single firm compression with a forceps 
and thrombus formation was monitored by blood flow measurements. Interestingly, and in 
contrast to the findings of the FeCl3-injury model, CLEC-2 deficient mice displayed largely 
unaltered thrombus formation as compared to control mice (Figure 14). Only 3 out of 7 
CLEC-2 deficient mice displayed slightly but not significantly delayed vessel occlusion (mean 
time to occlusion 425.9 ± 179.1 sec for CLEC-2 deficient and 275.9 ± 69.2 sec for control 
mice; p=0.07, Figure 14). To clarify whether this observed tendency has a considerable 
statistical relevance, the number of animals subjected to this injury model has to be further 
increased. So far, these findings indicated that CLEC-2 is of minor importance for arterial 
thrombus formation in the mechanically injured aorta in mice.  
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Figure 14. CLEC-2 deficient mice are not protected from mechanically induced thrombosis. 
Thrombus formation was induced in control and INU1-injected mice by a single firm compression of 
the abdominal aorta with a forceps. A, Time to vessel occlusion and B, representative blood flow 
curves are shown. Each symbol represents one individual.  
 
Next, a tail bleeding assay was performed to study the impact of CLEC-2 deficiency on 
physiological thrombus formation. To do so, 2 mm of the mouse tail tip were removed and 
time to cessation of bleeding was determined using the filter paper method. Whereas all 
tested control mice (22/22) were able to arrest bleeding during the 20 min observation time 
(mean bleeding time 6.1 ± 3.9 min), bleeding times of CLEC-2 deficient mice were highly 
variable. While 33.3% (8/24) of these mice stopped bleeding within the same time frame as 
control mice, 33.3% had a prolonged bleeding time (10.8 ± 6.0 min in total, p<0.05) and the 
remaining 33.3% of the mice bled for more than 20 min, indicating an important, but not 
essential role for CLEC-2 in hemostasis (Figure 15). 
 
 
Figure 15. Prolonged bleeding times in 
CLEC-2 deficient mice. Bleeding times after tail 
tip cut of control and CLEC-2 deficient mice. 
Each symbol represents one individual. (May, 
Hagedorn et al., Blood, 2009)182. 
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4.4 Severely defective arterial thrombus formation in mice lacking GPVI and 
CLEC-2 
As described in sections 4.2 and 4.3, the (hem)ITAM receptors GPVI and CLEC-2 can be 
specifically targeted and immunodepleted from the platelet surface which results in a clear 
protection from arterial thrombosis but only mildly77 prolonged or variably increased bleeding 
times, respectively. Since both receptors involve similar downstream effector proteins, most 
notably LAT, SLP76 and PLCγ273, the question raised whether both receptors have 
redundant functions in platelet activation in vivo. To address this issue, NMRI mice were 
intravenously injected with INU1 (200 µg) and JAQ1 (100 µg) to concomitantly deplete GPVI 
and CLEC-2. The in vitro characterization of these mice in comparison to the respective 
single deficient mice was performed by Markus Bender and Frauke May in our group. 
Mice subjected to the combined antibody treatment (JAQ1+INU1) displayed a transient 
thrombocytopenia with a recovery of platelet counts after 5 to 6 days, similar to the 
observations in INU1-treated mice182. Flow cytometric analyses of the platelets showed that 
JAQ1 + INU1 treatment induced the specific loss of the respective receptor without 
significantly influencing the expression levels of other platelet surface proteins. Accordingly, 
these platelets were unresponsive to collagen-related-peptide (CRP), convulxin and 
rhodocytin but activation with other classical platelet agonists was fully functional (Bender, 
May et al., in revision). Only P-selectin exposure upon thrombin stimulation was slightly 
reduced at early time points after antibody injection but completely restored on day 6, which 
is in line with observations made in JAQ1-injected mice82. These findings revealed that GPVI 
and CLEC-2 can be simultaneously downregulated from circulating platelets without 
interfering with other platelet activation pathways. 
Hence, the following experiments on single- and double-deficient mice were conducted on 
day 5 or 6 after antibody treatment and loss of the appropriate platelet receptor(s) was each 
time confirmed by flow cytometry. 
To study the functional effect of GPVI/CLEC-2 double deficiency on occlusive thrombus 
formation, JAQ1-, INU1- and JAQ1 + INU1-injected mice were subjected to the FeCl3-
induced thrombosis model in small mesenteric arterioles. In all control mice, small 
aggregates formed at 7.8 ± 1.2 min after injury (Figure 16A,C) and continuously grew to large 
thrombi which completely occluded the vessel within 20 min (mean time to occlusion 
16.4 ± 2.2 min; Figure 16B,C). In line with the previously described results (section 4.2 and 
4.3), GPVI and CLEC-2 single-deficient mice showed similar kinetics of small aggregate 
formation compared to control mice but exhibited, as expected, reduced thrombus stability 
preventing in most cases firm vessel occlusion during the observation period (8/12 of GPVI-
depleted and 7/10 of CLEC-2 depleted mice). Remarkably, already the onset of small 
aggregate formation was significantly delayed in GPVI/CLEC-2-depleted mice compared to 
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control and single-deficient mice (11.4 ± 3.0 min, p<0.01; Figure 16A,C) and following 
propagation of thrombi was dramatically reduced as indicated by the strongly decreased ratio 
of thrombi size to vessel diameter (44 ± 19% for GPVI/CLEC-2 double-deficient mice, 
p<0.001, 80 ± 18% for GPVI-deficient mice, 81 ± 20% for CLEC-2 deficient mice and 
100 ± 0% for control mice, Figure 16D). As a consequence, blood flow was maintained in all 
vessels (12/12; Figure 16B,C) of double-deficient mice.  
 
 
Figure 16. Arterial thrombus formation in mice lacking GPVI and CLEC-2 is virtually abrogated 
in contrast to the respective single-deficient mice. Small mesenteric arterioles of the indicated 
mice were injured by FeCl3 on day 5 after antibody injection and thrombus formation was analyzed 
using intravital fluorescence microscopy. A, Beginning of thrombus formation and B, time to stable 
vessel occlusion are shown. Horizontal lines indicate mean values. Each symbol represents one 
arteriole C, Representative pictures of thrombus formation at the indicated time points after injury. Bar, 
100 µm. Asterisk indicates stable vessel occlusion. D, Percentage of maximal thrombus-caused 
vessel stenosis is illustrated. **, p<0.01; ***, p<0.001. Ctrl=control.  
 
The consequence of GPVI/CLEC-2 double-depletion on hemostasis was assessed by 
Markus Bender and Frauke May in a tail bleeding assay. Whereas the phenotype of GPVI 
and CLEC-2 single-deficient mice could be reproduced in this model, mice lacking both 
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receptors displayed virtually abrogated hemostatic function, as bleeding did not stop and 
even the drop size remained constant during the 20 min observation period (Bender, May 
et al., in revision). Taken together, these data demonstrate that, in contrast to the respective 
single-deficient mice, the lack of both receptors, GPVI and CLEC-2, results in almost 
completely abolished thrombus formation and thereby suggest partially redundant functions 
of the two platelet receptors in vivo. 
To at least partially exclude that the profound defect in thrombus growth and stability 
observed in GPVI/CLEC-2 depleted mice was based on possible side effects of the antibody 
treatment, Gp6-/- mice were injected with INU1 (200 µg) and analyzed on day 6 post injection 
in the FeCl3-injury model. Gp6-/- and wild-type C57Bl6/J mice injected with INU1 were 
analyzed in parallel as controls. These single-deficient mice showed the expected 
phenotypes in this model as described before and are therefore not depicted again. 
However, before comparing GPVI/CLEC-2 double-depleted mice with Gp6-/-/CLEC-2 
depleted mice, it is important to note, that CLEC-2 deficient mice in a C57Bl6/J genetic 
background displayed a less severe defect in pathological thrombus formation compared to 
CLEC-2 deficient NMRI mice, evident in a small subpopulation of vessels where thrombi 
finally occurred which, albeit delayed, occluded the vessel. This was probably due to a 
different genetically determined thickness of the tissue surrounding the vessel or the vessel 
wall itself which influenced the diffusion of FeCl3 and thereby the severity of the injury 
(Hagedorn et al. unpublished).  
Similar to the aforementioned observations in GPVI/CLEC-2 depleted mice, small aggregate 
formation in Gp6-/-/CLEC-2 depleted mice was significantly delayed compared to wild-type 
mice (8.3 ± 1.8 min for Gp6-/-/CLEC-2 depleted mice and 6.4 ± 0.9 min for wild-type mice, 
p<0.01, Figure 17A,C) and consequent thrombus growth was severely reduced which 
resulted in no occlusion in 7 out of 11 vessels and significantly delayed occlusion times for 
the rest of the arterioles (mean time to occlusion 27.5 ± 4.6 min for Gp6-/-/CLEC-2 depleted 
mice and 16.2 ± 2.0 min for wild-type mice; p<0.05, Figure 17B,C). This defect also clearly 
exceeded the thrombus instability observed in the respective single-deficient mice (data not 
shown).  
Additionally, in the bleeding time assay, Gp6-/-/CLEC-2 depleted mice showed the same 
hemostatic defect as seen in the double-depleted mice (Bender, May et al., in revision). 
These data confirmed that the profound thrombotic defects in GPVI/CLEC-2 deficient mice 
were most probably exclusively related to the functional consequences of the receptor 
deficiencies and not to unspecific effects of the antibody treatment, although genetic double-
deficient mice would be necessary to completely exclude this possibility. 
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Figure 17. Arterial thrombus formation in INU1-treated Gp6-/- mice. Small mesenteric arterioles 
were injured by FeCl3 on day 5 after antibody injection and thrombus formation was analyzed using 
intravital fluorescence microscopy. A, Time to beginning of thrombus formation and B, time to stable 
vessel occlusion are shown. Horizontal lines indicate mean values. Each symbol represents one 
arteriole. C, Representative pictures at the indicated time points. Bar, 100 µm. Asterisk indicates 
occlusion of the vessel. 
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4.5 The small GTPase RhoA is a crucial mediator of platelet activation in 
hemostasis and thrombosis 
To investigate the specific function of RhoA in platelets, a conditional knockout approach was 
used. Mice carrying the RhoA gene flanked by loxP sites122 were crossed with transgenic 
mice expressing the Cre recombinase under the control of the megakaryocyte- and platelet-
specific platelet factor (PF) 4 promoter194. Gene deletion was intrinsically induced in RhoA 
(fl/fl, cre+, in the following referred to as RhoA-/-) mice upon induction of the PF4 promoter 
activity during megakaryopoiesis. Littermate RhoA (fl/fl, cre-, in the following referred to as 
wild-type) mice served as control animals.  
 
4.5.1 RhoA-/- mice display a marked thrombocytopenia 
The absence of RhoA protein in RhoA-/- platelets was confirmed by western blot analysis 
using GPIIIa protein expression as loading control (Figure 18A). Specific deletion of RhoA in 
megakaryocytes and platelets led to a pronounced macrothrombocytopenia apparent as an 
approximately 50% reduction of peripheral platelet counts (p<0.001; Figure 18B) and a 25% 
increased platelet volume when compared to wild-type mice (p<0.001; Figure 18C), 
suggesting a critical role of RhoA in megakaryocyte maturation and/or platelet production. 
The increased platelet size in RhoA-/- mice was also visualized by transmission electron 
microscopy (TEM; Figure 18D).  
 
 
Figure 18. RhoA-/- mice display a macrothrombocytopenia. A, Western blot analysis of platelet 
lysates from the indicated mice; α-GPIIIa antibody was used as control. B, Peripheral platelet counts 
and C, platelet volume of wt and RhoA-/- mice measured with a blood cell counter are depicted. Values 
are mean ± SD of 8 mice per group and representative of 3 individual measurements. 
D, Representative transmission electron microscopy (TEM) pictures of resting platelets from wt and 
RhoA-/- mice. Bar, 2 µm.***, p<0.001. 
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Resting RhoA-deficient platelets displayed a roundish shape in contrast to the normal 
discoid-shaped wild-type platelets. However, the overall ultrastructure of RhoA-/- platelets, as 
well as the numbers and distribution of granules appeared normal when compared to wild-
type platelets (Figure 18D). 
The abundance of major platelet surface receptors was unaltered in the mutant mice except 
for CLEC-2 and the integrins β1 and αIIbβ3 where expression levels were significantly 
increased compared to wild-type (Table 1). This can probably be ascribed to the increased 
size of RhoA-/- platelets 
 
 
4.5.2 RhoA-/- mice display a reduced platelet life span 
Continuous and rapid clearance of non-functional, structurally altered or hyperactive platelets 
by the reticulo-endothelial system can lead to a sustained thrombocytopenia. Hence, the 
platelet life span in RhoA-/- and wild-type mice was determined in vivo. To do so, circulating 
platelets were labeled with a fluorescent non-cytotoxic anti GPIX antibody derivative injected 
into mice and the labeled platelet population was monitored by flow cytometry over time. One 
hour after antibody treatment, >90% of circulating platelets were labeled in both wild-type 
and RhoA-/- mice and this platelet population constantly declined over 5 days in wild-type 
mice which is in accordance with the reported life span of mouse platelets (Figure 19). In 
contrast, the platelet life span was slightly reduced in RhoA-/- mice with a significant decrease 
of 30% on day 2 compared to wild-type mice and almost complete absence of labeled 
platelets on day 4 (3.8 ± 1.8% vs. 10.5 ± 1.7%; p<0.001; Figure 19). This finding 
demonstrated that RhoA-deficiency causes a moderately increased platelet turnover in vivo 
which may partially explain the observed thrombocytopenia in these mice. Consequently, the 
degree of the thrombocytopenia in RhoA-/- mice rather points to impaired platelet production 
from megakaryocytes.  
 
 
wild-type 
  RhoA-/-  significance 
Table 1. Platelet glycoprotein expression 
in wild-type and RhoA-/- mice. Expression 
of glycoproteins on the platelet surface was 
determined by flow cytometry. Diluted 
whole blood from the indicated mice was 
incubated with the respective FITC-labeled 
antibody at saturating conditions for 15 min 
at RT and platelets were analyzed directly. 
Results are expressed as mean 
fluorescence intensity ± SD for 4 mice per 
group. Values are representative of 3 
individual experiments. n.s.=not significant. 
*, p<0.05; ** p<0.01; ***, p<0.001. 
GPIb 
  353±22   349±14 n.s. 
GPV 
  302±8   329±25 n.s. 
GPIX 
  503±16   530±31 n.s. 
CD9 1433±42 1441±36 n.s. 
GPVI 
    48±5     56±5 n.s. 
α2 integrin     61±3     62±1 n.s. 
β1 integrin   163±4   183±3 *** 
αIIbβ3   457±10   590±39 ** 
CLEC-2 
  155±5   180±12 * 
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4.5.3 Reduced integrin activation and release of α granules in RhoA-/- platelets upon 
G13- and Gq-stimulation 
RhoA has been shown, albeit indirectly, to act downstream of G13 coupled receptors124,125 
and suggested to be involved in PAR-mediated platelet granule release and integrin 
activation136,195. To address the functional role of RhoA in these processes directly, integrin 
αIIbβ3 activation and exposure of P-selectin, a commonly used marker for α granule release, 
were analyzed upon agonist stimulation of wild-type and RhoA-/- platelets by flow cytometry. 
The use of a highly diluted platelet suspension in this experimental setting largely excludes 
the accumulation of released secondary mediators and thereby allows conclusions about the 
primary platelet signaling response. Interestingly, and contrary to the observations from 
Gα13-deficient mice, RhoA-/- platelets displayed significantly reduced integrin activation 
compared to wild-type platelets when stimulated with thrombin at high or intermediate 
concentrations (Figure 20A). This result was also confirmed by platelet stimulation with the 
PAR-4 activating peptide, activating the main thrombin receptor in mouse platelets (PAR4; 
data not shown). Responses to the weak agonists U46619 and ADP were similar in wild-type 
and RhoA-/- platelets, whereas the combination of both agonists resulted in profound integrin 
activation in wild-type but slightly reduced responses in RhoA-/- platelets. Interestingly, 
although RhoA-/- platelets reacted normally upon GPVI/ITAM-coupled receptor stimulation by 
CRP and convulxin, they showed decreased integrin activation levels in response to 
activation with rhodocytin (Figure 20A). RhoA-/- platelets also displayed specific defects in α 
granule release. U46619 alone is not able to mediate significant release of platelet α 
granules, unless costimulation with ADP occurs. Upon activation with both agonists, RhoA-/- 
platelets showed dramatically reduced P-selectin exposure as compared to wild-type 
platelets. Similarly, thrombin-induced degranulation was significantly reduced in RhoA-/- 
platelets at high agonist concentrations and this effect was even more pronounced at 
intermediate thrombin concentrations (Figure 20B). A remarkable reduction in P-selectin 
exposure of RhoA-/- platelets was also seen after stimulation with PAR-4 activating peptide 
 
Figure 19. RhoA-/- mice display a moderately 
reduced platelet life span. Wt and RhoA-/- mice 
were injected with a DyLight 488-conjugated 
anti-GPIX Ig derivate to label platelets in vivo. 
Percentage of fluorescently labeled platelets 
determined by flow cytometry at the indicated 
days after injection is illustrated. Values are 
mean ± SD of 5 mice per group. **, p<0.01; 
***, p<0.001. 
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(data not shown). Responses to all other tested agonists were indistinguishable between 
wild-type and RhoA-/- platelets. These data indicate that RhoA is involved in integrin αIIbβ3 
activation and critical for α granule release upon Gα13- and Gαq-mediated signaling in 
platelets. 
 
 
Figure 20. Reduced integrin activation and α granule release in RhoA-/- platelets upon Gα13- and 
Gαq-stimulation. A, Flow cytometric analysis of αIIbβ3 integrin activation (binding of JON/A-PE) and 
B, degranulation-dependent P-selectin exposure in response to the indicated agonists from wt and 
RhoA-/- mice. Results are mean fluorescence intensities (MFI) ± SD of 4 mice per group and 
representative of 4 individual measurements. Abbreviations: U46=U46619, CVX=convulxin, 
RC=rhodocytin. *, p<0.05; ** p<0.01; ***, p<0.001. 
 
Previous studies with inhibitors indicated a specific role for RhoA in dense granule release136. 
To assess whether dense granule release was also affected by RhoA deficiency, release of 
ATP, which is stored in dense granules, was measured upon agonist stimulation. At high and 
intermediate concentrations of U46619 and PAR-4 activating peptide, ATP release was 
clearly reduced in RhoA-/- platelets as compared to wild-type, whereas, interestingly, 
thrombin-induced ATP release was not significantly different between both groups. In line 
with data from α granule release, collagen stimulation lead to comparable ATP releases at 
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the tested concentrations in RhoA-/- and wild-type platelets (Figure 21). These observations 
demonstrated that RhoA-deficient platelets are principally able to release their granule 
content but rather display a defined defect in signaling via G13 and Gq. 
 
 
Figure 21. Decreased ATP release in RhoA-/- platelets after G13 and Gq-stimulation. Washed wt 
(black line) and RhoA-/- platelets (red line) were incubated with Luciferase-Luciferin reagent and ATP 
release was measured in a Chrono Log aggregometer after stimulation with the indicated agonists. 
Representative curves of 2 individual experiments of n=2 are shown. 
 
4.5.4 Defective shape change of RhoA-/- platelets after low agonist stimulation  
Previous studies have suggested that RhoA-mediated inhibition of the myosin light chain 
(MLC) phosphatase downstream of G13 activation is essential for stabilizing MLC 
phosphorylation and subsequently for platelet shape change105,130-134; however all these 
results were obtained in studies using isolated cell systems and/or pharmacological inhibitors 
of RhoA. To investigate the role of RhoA in platelet shape change in a more specific 
approach and to define the functional consequences of the reduced granule release and 
integrin αIIbβ3 activation in RhoA-/- platelets at the same time, aggregation studies were 
performed. At low concentrations of U46619, signaling is supposed to be dominantly 
mediated via G13. Under these conditions, shape change of RhoA-/- platelets was abolished. 
In line with this, shape change in response to low doses of thrombin was also affected in 
RhoA-/- platelets. The inability of RhoA-/- platelets to mediate platelet shape change at low 
U46619 concentrations could be clearly visualized by scanning electron microscopy (SEM; 
Figure 22A right). Whereas wild-type platelets showed a spherical shape and typically 
extended filopodia, RhoA-/- platelets maintained their roundish morphology and displayed 
only minimal protrusions. Notably, however, the shape change defect of RhoA-deficient 
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platelets was overcome when using higher concentrations of U46619 or thrombin, which 
involve also Gq-mediated signaling (Figure 22A).  
Remarkably, U46619-induced aggregation was significantly reduced in RhoA-/- platelets at 
intermediate concentrations, whereas it was completely restored at high agonist 
concentrations (Figure 22A left, C). Similar results were obtained when platelets were 
stimulated with PAR-4 activating peptide. A possible explanation for these findings may be 
that due to the high platelet concentration used in platelet aggregation measurements, 
released secondary mediators accumulate and influence the degree of maximal aggregation. 
Thus, the reduced granule release observed in RhoA-/- platelets upon U46619 and PAR-4 
activating peptide stimulation could account for the decreased aggregation response at 
threshold agonist concentrations. In contrast, thrombin induced similar aggregation in RhoA-/- 
and wild-type platelets irrespectively of the used concentration, suggesting that the reduced 
thrombin-dependent integrin activation and α degranulation, detected by flow cytometric 
analysis, did not translate into an altered aggregation response (Figure 22A,C). Stimulation 
with the weak agonist ADP, which signals via Gq and Gi proteins and does not trigger granule 
release by itself, caused normal aggregation, but interestingly failed to mediate shape 
change in RhoA-/- platelets at low concentrations, indicating that the GTPase may also be 
involved in Gαq-induced shape change (Figure 22B,C). Surprisingly, whereas the 
aggregation responses to high concentrations of the GPVI/ITAM agonists CRP and collagen 
were comparable between RhoA-/- and wild-type platelets, aggregation was clearly enhanced 
in RhoA-deficient platelets when stimulated with intermediate or low concentrations of the 
respective agonist (Figure 22B,C). Furthermore, shape change in response to CRP and 
collagen was also reduced in RhoA-/- platelets compared to wild-type platelets, irrespective of 
the used agonist concentration; particularly pronounced after activation with collagen. Taken 
together, these findings demonstrate that RhoA plays a central role for platelet shape change 
and is critical for platelet aggregation downstream of G13 and Gq protein-coupled receptor 
activation.  
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Figure 22. Defective shape change of RhoA-/- platelets after
 
agonist stimulation at low 
concentrations. Washed platelets were stimulated with the indicated agonists and light transmission 
was recorded on a Fibrintimer 4-channel aggregometer. ADP measurements were performed in prp. 
A,B Representative aggregation curves of wt (black line) and RhoA-/- platelets (grey line) of 3 individual 
measurements with n=2 are depicted. Representative scanning electron microscopy pictures of 
platelets after stimulation with 0.01 µM U46619 (right) are shown. Bar, 2 µm. C, Mean maximal 
% aggregation ± SD of each group. **,p<0.01; ***,p<0.001. Abbreviations: U46=U46619, thr=thrombin, 
PAR=PAR-4 peptide, coll=collagen. 
 
To analyze whether the observed platelet shape change defect was directly associated with  
decreased phosphorylation of MLC, the main effector molecule downstream of RhoA, (semi-) 
quantitative western blot analysis of MLC and phosphorylated MLC (MLC-P) upon agonist 
stimulation was performed (Figure 23). As expected, MLC-P was detectable after activation 
of wild-type platelets with all tested agonists. In contrast, RhoA-/- platelets showed virtually no 
MLC-P upon U46619, PAR-4 activating peptide and thrombin stimulation. Only MLC-P in 
response to CRP was similar to wild-type platelets. 
Results 
 
65 
 
 
Figure 23. Myosin light chain phosphorylation of wt and RhoA-/- platelets after activation. 
Western blot analysis of platelet lysates from wt and RhoA-/- platelets after stimulation with the 
indicated agonists. Expression levels of myosin light chain (MLC) and phosphorylated MLC (MLC-P) 
was assessed using appropriate antibodies. An α-GPIIIa antibody served as control. Data are 
representative of 2 individual experiments. Abbreviations: U46=U46619, thr=thrombin. 
 
4.5.5 RhoA is dispensable for agonist-induced Ca2+ mobilization in platelets 
Since RhoA-/- platelets displayed clearly reduced thrombin- and PAR-4 peptide-triggered 
integrin activation and α degranulation as well as impaired shape change response upon 
ADP stimulation, one may speculate that RhoA also signals downstream of Gq. To test 
whether RhoA is involved in the respective classical signaling cascade leading to PLCβ 
activation and subsequent Ca2+ mobilization, changes in intracellular calcium concentrations 
([Ca2+]i) in response to U466619 and thrombin were assessed (Figure 24). In addition, 
platelets were stimulated with CRP to determine whether an altered Ca2+ mobilization 
possibly accounts for the increased aggregation of RhoA-/- platelets in response to ITAM-
coupled agonists. However, notably, Ca2+ release from intracellular stores was similar 
between RhoA-/- and wild-type platelets for all tested agonists (Figure 24). 
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Figure 24. RhoA-/- platelets show normal Ca2+ responses upon activation. Fura-2-loaded wt and 
RhoA-/- platelets were stimulated with 3 µM U46619, 0.005 U/ml thrombin or 10 µg/ml CRP in the 
absence of Ca2+ and intracellular Ca2+ mobilization ([Ca2+]i) was monitored. A, Representative 
measurements of wt (black line) and RhoA-/- platelets (gray line) and B, maximal increase in 
intracellular Ca2+ concentration compared with baseline levels before stimulus (∆[Ca2+]i) ± SD of at 
least 10 mice per group are shown. 
 
4.5.6 RhoA-/- platelets spread normally on fibrinogen but exhibit abolished integrin-
dependent clot-retraction 
Platelet spreading requires integrin αIIbβ3 signaling-dependent cytoskeletal reorganizations 
leading to the development of F-actin bundles and focal adhesion-like structures, processes 
which have been ascribed to the function of RhoA106,112,196. However, previous studies 
suggested that RhoA is either not required140 or has to be inhibited139 for proper platelet 
spreading. To clarify this issue, wild-type and RhoA-/- platelets were allowed to spread on a 
fibrinogen-coated surface in the presence of thrombin (0.01 U/ml final concentration; Figure 
25A). Interestingly, RhoA-/- platelets were able to form filopodia and lamellipodia to the same 
extent and with similar kinetics as wild-type platelets, resulting in fully spread platelets after 
20 min in both groups. The overall morphological structure of spread RhoA-/- platelets 
seemed to be unchanged compared to wild-type platelets, however, the inner cell body 
appeared less condensed, indicating reduced granule centralization. A more detailed 
analysis of the morphology of both wild-type and RhoA-/- platelets by SEM studies confirmed 
these observations (Figure 25B).  
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Figure 25. RhoA-/- platelets normally spread on fibrinogen. Washed platelets of wt and RhoA-/- 
mice were allowed to spread on fibrinogen (100 µg/ml) after stimulation with 0.001 U/ml thrombin. A, 
Representative DIC images of 3 individual experiments were taken at the indicated time points (top) 
and statistical evaluation of the percentage of spread platelets at different spreading stages at the 
respective time point (bottom). Bar, 5 µm. B, Scanning electron microscopy (SEM) pictures of spread 
wt and RhoA-/- platelets. Bar, 2.5 µm. 
 
Furthermore, to assess whether the cytoskeletal ultrastructure was influenced by the RhoA 
deficiency although the spreading process of these platelets was entirely normal, the actin 
structures were visualized in more detail by Stimulated Emission Depletion (STED) 
microscopy in collaboration with Shuchi Gupta in our group (Figure 26A). Interestingly, 
spread wild-type platelets displayed a typical condensed F-actin ring structure and marked 
stress fiber formation, whereas in contrast, these structures were only partially formed and 
appeared more diffuse in fully spread RhoA-/- platelets. To determine whether RhoA-/- 
platelets generally have the capacity to assemble actin filaments, flow cytometric analyses 
were performed to measure F-actin assembly after agonist stimulation (Figure 26B). In these 
measurements, no differences in the F-actin content of resting platelets and thrombin-
induced F-actin assembly could be detected between the two groups. These data indicated 
that, although RhoA is suggested to be essential for F-actin bundling and stress fiber 
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formation in numerous cell types, RhoA-deficiency only moderately influenced actin 
cytoskeletal structures in activated platelets. 
 
 
Figure 26 RhoA-/- platelets show moderately altered actin cytoskeletal structures but unaltered 
F-actin assembly after activation. Washed wt and RhoA-/- platelets were allowed to spread on a 
fibrinogen-coated surface and analyzed with STED microscopy. A, Representative pictures taken after 
40 min of spreading are depicted. Bars, 5 µm. B, Resting and activated platelets of the indicated 
genotype were fixed, permeabilized, stained with phalloidin-FITC and directly analyzed using flow 
cytometry. Values are mean ± SD of at least 4 mice per group. Abbreviations: thr= thrombin. 
 
Moreover, additional detailed confocal microscopy studies were performed to visualize on the 
one hand tubulin structures and on the other hand the distribution of α granules in spread 
RhoA-/- platelets as the aforementioned DIC and SEM pictures indicated a less condensed 
cell body in these platelets. The microtubules formed a nearly two-ring structure with an outer 
and inner ring in wild-type platelets after spreading, whereas, in contrast the microtubule coil 
seemed rather disassembled and more branched in RhoA-/- platelets (Figure 27A). VWF–
staining of spread RhoA-/- platelets showed a broader distribution of granules by confocal 
microscopic analysis as compared to wild-type platelets, which confirmed the previous 
assumption that granules are less centralized in spread RhoA-/- platelets (Figure 27B). 
Together, these findings strongly suggest that RhoA deficiency affects to a certain extent the 
actin and tubulin cytoskeletal reorganization which, however, does not result in altered 
spreading of these platelets.  
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Figure 27. Moderately altered tubulin structures and less centralized α granules in spread 
RhoA-/- platelets. Washed wt and RhoA-/-  platelets were allowed to spread on a fibrinogen-coated 
surface and analyzed with confocal microscopy after A, staining for tubulin (green) and actin (red) and 
B, vWF (green) and actin (red; acquired with STED technique). Representative pictures taken after 
40 min of spreading are depicted. Bars, 5 µm.  
 
Upon ligand binding integrin αIIbβ3 can also mediate clot retraction which is highly 
dependent on the cytoskeletal contractility of platelets197. The role of RhoA in this signaling 
process is, however, controversially discussed139,140. Therefore, clot formation in prp of wild-
type and RhoA-/ mice was induced by high dose thrombin (5 U/ml) in the presence of high 
Ca2+ concentrations (20 mM) and clot retraction was monitored under non-stirring conditions 
over time (Figure 28). While, clot retraction started already 30 min after activation of wild-type 
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prp and proceeded to the maximum after 4 h, it was nearly abolished in RhoA-deficient prp 
showing only moderately retraction within the same time period.  
These data revealed that RhoA is essential for integrin-mediated clot retraction, but 
dispensable for spreading of activated platelets on fibrinogen.  
 
 
Figure 28. RhoA-/- platelets fail to support 
integrin-dependent clot retraction. Clot 
retraction of wt and RhoA-deficient prp upon 
activation with 5 U/ml thrombin and 20 mM CaCl2 
at the indicated time points is depicted. 
 
 
4.5.7 RhoA-/- platelets show slightly reduced aggregate formation on collagen and 
adhesion on vWF under high shear flow 
Thrombus formation at the wound site is initiated by platelet adhesion and activation on the 
extracellular matrix and promoted by the action of locally released secondary mediators 
which become, however, rapidly cleared in the flowing blood. Under these conditions, 
reduced platelet degranulation may limit thrombus formation, particularly at high shear rates. 
Therefore, the ability of RhoA-/- platelets to form platelet aggregates on a collagen-coated 
surface was analyzed in a whole blood perfusion system. To avoid differences in thrombus 
size due to the reduced platelet count in RhoA-/- mice, blood from RhoA-deficient mice was 
reconstituted with isolated RhoA-/- platelets to adjust the platelet count comparable to that of 
wild-type mice. At a shear rate of 1700 sec-1, mimicking flow conditions in arterioles, wild-
type and RhoA-/- platelets formed large three-dimensional aggregates which covered similar 
surface areas at the end of the perfusion time (52.3 ± 4.3% for RhoA-/- platelets and 53.7 ± 
6.0% for wild-type platelets; p=0.68; Figure 29A). The relative thrombus volume was also 
indistinguishable between wild-type and RhoA-/- platelets (data not shown). Remarkably, 
however, under higher shear rates (7700 sec-1), resembling flow conditions in small arterioles 
or stenosed arteries, aggregate formation of RhoA-/- platelets was moderately, but 
significantly reduced as compared to wild-type platelets (mean surface coverage 3.2 ± 0.9% 
for RhoA-/- platelets and 5.2 ± 1.8% for wild-type platelets, p<0.05; Figure 29A) indicating that 
RhoA is relevant for thrombus formation only under high shear conditions. These findings 
pointed to an impaired interaction between GPIb and collagen-bound vWF in the absence of 
RhoA.  
To directly test whether the reduced shear-dependent aggregate formation in RhoA-deficient 
blood was caused by an altered GPIb-vWF interaction, platelet adhesion to immobilized 
murine vWF was analyzed at a shear rate of 7700 sec-1 in the same flow chamber system. 
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Although the initial adhesion of RhoA-/- platelets and also the number of platelets adherent 
after 1 min of the washing period was comparable to wild-type platelets (Figure 29B), the 
distance which could be covered by rolling platelets within 1 min of the washing period on the 
vWF surface was significantly increased for RhoA-/- platelets in contrast to wild-type platelets 
(mean distance 26.4 ± 7.8 µm for RhoA-/- and 16.1 ± 2.3 µm for wild-type platelets; p<0.05; 
Figure 29B), suggesting a reduced ability of RhoA-deficient platelets to interact with vWF. 
 
 
Figure 29. Aggregate formation on collagen and adhesion on vWF of RhoA-/- platelets under 
flow conditions. Whole blood was perfused over a collagen-coated surface at the indicated shear 
rates. A, Representative phase contrast images at the end of the perfusion time are illustrated (top) 
and mean surface coverage ± SD of at least 5 mice is shown (bottom). Bar, 100 µm. B, Blood was 
perfused over immobilized murine vWF at a shear rate of 7700 sec-1 and representative pictures after 
1 min of the washing period are shown (top). The number of adherent platelets after 1 min of the 
washing period (bottom, left) and distance covered by wt and RhoA-/- platelets within 1 min under flow 
is depicted (bottom, right). *, p<0.05. 
 
4.5.8 RhoA is critical for thrombus stabilization in vivo 
To examine to which extent the observed in vitro defects of RhoA-/- platelets influence 
thrombus formation in vivo, intravital fluorescence microscopy after FeCl3-induced vascular 
injury of small mesenteric arterioles was performed. Although the kinetics of first thrombus 
formation were comparable between wild-type and RhoA-/- mice (data not shown), 
subsequent stable and occlusive thrombus formation was strongly impaired in RhoA-deficient 
mice as compared to wild-type. Whereas thrombi progressed to complete vessel occlusion in 
8 out of 9 wild-type arterioles (89%) (mean time to occlusion 16.9 ± 2.9 min; Figure 30A-C), 
only 21.5% of RhoA-/- vessels occluded irreversibly within the observation period of 40 min 
(p<0.01). In 57% arterioles of RhoA-/-mice no occlusion occurred at all and further 21.5% of 
the vessels were transiently occluded for <2 min but then completely recanalized (Figure 
30A-C). This defect was mainly based on embolization of thrombus fragments from the 
thrombus surface, after reaching a considerable size in the vessel whereby shear forces 
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probably passed a threshold at which the RhoA-dependent platelet activation defect became 
evident. 
 
 
Figure 30. RhoA-/- mice display unstable thrombus formation after FeCl3-induced vascular 
injury. Small mesenteric arterioles were injured by topical application of FeCl3 and thrombus formation 
of fluorescently labeled platelets was monitored using intravital microscopy. A, Time to stable vessel 
occlusion and B, amount of (1) non-occluded, (2) recanalized and (3) stably occluded vessels after 
injury of wt and RhoA-/- mice are shown. Each symbol represents one arteriole. C, Representative 
pictures at the indicated time point. Bar, 100 µm. Asterisk indicates stable occlusion of the vessel. 
 
In a second arterial thrombosis model, thrombus formation was induced by mechanical injury 
of the abdominal aorta and monitored by blood flow measurements using an ultrasonic flow 
probe. Although full and stable occlusion occurred in 9 out of 10 wild-type mice within 8 min 
(mean time to occlusion 384 ±79 sec; Figure 31A-C), blood flow only decelerated on average 
to 50% of the initial value after injury in RhoA-/- mice and remained rather constant with some 
fluctuations, indicating thrombus embolization, until the end of the observation period 
(p<0.001; Figure 31A-C). Consequently, none of the RhoA-/- mice displayed vessel occlusion. 
These results demonstrate that RhoA is required for final thrombus propagation and 
stabilization in small as well in large arteries. 
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Figure 31. Defective thrombus formation in RhoA-/- mice after mechanical injury. The abdominal 
aorta of wt and RhoA-/- mice was injured by tight compression with a forceps and blood flow was 
monitored for 30 min. A, Time to stable vessel occlusion and B, Representative blood flow curves are 
shown. Each symbol represents one individual. C, Representative cross sections of the abdominal 
aorta of wt and RhoA-/ mice 30 min after injury. Bar, 200 µm.- 
 
In line with the above described observations, RhoA-deficient mice also exhibited a profound 
hemostatic defect as assessed in a tail bleeding assay where mouse tails were immediately 
immerged into saline at 37°C after tail tip cut. Wh ereas bleeding stopped in 15 out of 16 
(94%) wild-type mice (mean bleeding time 179 ± 196 sec; Figure 32), bleeding was markedly 
increased in RhoA-/- mice with 13 out of 18 (72%) mice which bled for more than 20 min 
(p<0.001; Figure 32). Interestingly, in many of the RhoA-/- mice blood loss, determined by 
visual inspection, temporarily decreased or even transiently stopped for <1 min during the 
observation period, indicating that RhoA deficiency also destabilizes clots during normal 
hemostasis. 
 
 
Figure 32. Impaired hemostasis in RhoA-/- 
mice. Tail bleeding times determined in saline at 
37°C of wt and RhoA-/- mice. Each symbol 
represents one individual. 
 
 
4.5.9 RhoA-/- mice are protected from ischemic brain infarction 
Cerebral ischemia has been proposed to be a complex thrombo-inflammatory disease198 in 
which the microvascular integrity is disturbed199. However the signaling events leading to 
intravascular thrombus formation in the ischemic brain are only partially understood. To test 
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whether the observed thrombus instability of RhoA-/- mice in arterial thrombosis also affects 
the outcome in this setting, mice were challenged in a tMCAO model, performed in 
collaboration with Christoph Kleinschnitz, Department of Neurology, University Clinic, 
Würzburg, Germany. Therefore, a thread was advanced through the carotid artery into the 
middle cerebral artery to reduce cerebral blood flow and removed after 1 h to allow 
reperfusion. The extent of infarction was quantitatively assessed 24 h after reperfusion on 
2,3,5-triphenyltetrazolium chloride (TTC)-stained brain slices. In RhoA-/- mice, brain infarct 
volumes were reduced to ~50% of the infarct volumes in wild-type mice (43.7 ± 30.5 mm3 for 
RhoA-/- and 80.1 ± 28.8 mm3 for wild-type mice, p<0.01; Figure 33A). This reduction in 
ischemic lesions of RhoA-/- mice also resulted in significantly fewer neurological deficits 
compared to wild-type, determined as Bederson score assessing global neurological function 
(1.2 ± 1.3 vs. 2.9 ± 1.6, p<0.05; Figure 33B) and grip test which indicates motor function and 
coordination of the mice (3.7 ± 0.7 vs. 2.6 ± 1.0; p<0.01; Figure 33C). These data also 
established an important role for RhoA-dependent platelet signaling in the pathomechansim 
of ischemic stroke. 
 
 
Figure 33. RhoA-/- mice are protected from cerebral ischemia. Formation of cerebral brain 
infarction and consequential neurological defects were investigated in a murine stroke model. A, Brain 
infarct volumes in wt (n=24) and RhoA-/- mice (n=14) presented as mean ± SD; (left). Representative 
images of three corresponding coronal sections from wt and RhoA-/- mice stained with TTC 24 h after 
tMCAO. Infarct areas are marked with arrows (right). Bederson score B, and grip test C, determined 
24 h after tMCAO. *, p<0.05; **, p<0.01. 
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4.6 FXIIa inhibitor rHA-Infestin-4 abolishes occlusive arterial thrombus 
formation without affecting bleeding  
Previous studies with FXII deficient mice revealed that this coagulation factor is essential for 
arterial thrombus formation but dispensable for normal hemostasis169,170. Accordingly, FXII 
was proposed as a very promising target candidate for effective antithrombotic therapy that 
may not be accompanied by bleeding side effects. Based on this proposal, it was aspired to 
generate a new antithrombotic agent that targets FXII and concurrently exhibits clinically 
suitable pharmacokinetics. One possible approach for the identification of new inhibitors of 
the plasma coagulation system is the search for examples in nature and thus most promising 
anticoagulant proteins produced by blood-feeders. These animals have developed efficient 
mechanisms to overcome the host’s hemostatic barrier and to keep blood in a fluid state 
during acquisition and digestion. In 2002, Campos et al. isolated a specific thrombin inhibitor, 
named Infestin, from the midgut of the hematophagus insect Triatoma infestans200. Infestin 
belongs to the non-classical Kazal-type serine protease inhibitor family and is composed of 
two non-classical Kazal-type domains, although its gene encodes four domains, most 
probably due to unknown post-transcriptional mechanisms. Subsequent analysis of 
recombinant proteins expressing different non-classical Kazal-type domains of the Infestin 
gene revealed that domains 1-2 show strong thrombin inhibition whereas the fourth domain 
encodes a protein (Infestin-4) that exhibits a strong inhibitory potential against FXIIa201.  
According to these findings, CSL Behring (Marburg, Germany) generated a 73 kDa fusion 
protein consisting of recombinant human albumin (rHA) and Infestin-4 with the intention to 
develop a specific FXIIa inhibitor suitable for antithrombotic therapy. The protein was found 
to display a high recovery of ~92% and a half-life of 4.6 h after i. v. injection into mice202. The 
effect of rHA-Infestin-4 on the integrity of plasma coagulation in vitro was initially assessed 
by determining the clinical parameters activated partial thromboplastin time (aPTT) and 
prothrombin time (PT). rHA-Infestin-4 was shown to prolong aPTT in a dose-dependent 
manner without affecting PT in standard human plasma (SHP), in mouse as well as in rat 
plasma202. Similar results were obtained ex vivo when mice were treated with 200 mg/kg 
rHA-Infestin-4202. The following functional characterization of rHA-Infestin-4 was performed in 
collaboration with CSL Behring.  
 
4.6.1 rHA-Infestin-4 specifically inhibits the coagulation factor XIIa  
The initial analyses by CSL Behring indicated that rHA-Infestin-4 specifically inhibits the 
intrinsic coagulation pathway. To test this in more detail, the specificity of the protein for 
different human serine proteases of the intrinsic (αFXIIa, βFXIIa, FXIa and FIXa), the 
extrinsic (FVIIa) and the common (FXa and thrombin) pathway was analyzed using 
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chromogenic assays. After incubation of rHA-Infestin-4 with the respective protease in the 
presence of a specific chromogenic substrate, the remaining protease activity was 
determined based on absorption measurements at 405 nm. Interestingly, a 1:1 molar ratio of 
fully enzymatically active αFXIIa and rHA-Infestin-4 resulted in efficient FXIIa inhibition of 
>90%, equal to the inhibitory efficiency of rHA-Infestin-4 towards the small βFXIIa fragment, 
indicating that the inhibitor most probably interferes with the catalytic domain of FXIIa (Table 
2). In contrast, even a molar ratio of 1:90 of FXIa and rHA-Infestin-4 showed no effect on 
FXIa activity. To relate this inhibitory potential of rHA-Infestin-4 to the activity of the 
physiological inhibitor of contact activation, the plasmatic C1 inhibitor was used under the 
same conditions as control. Only a 16-fold molar excess of C1 inhibitor resulted in an 
approximate but not full inhibition of FXIIa, and a 1:90 molar ratio already inhibits 60% of 
FXIa activity. Since the used specific chromogenic substrates are small peptides which do 
not completely resemble the steric conditions during proteolysis present in vivo, a more 
physiologically structured macromolecule (Casein-Resorufin) was used by Stefan 
Schmidbauer (CSL Behring, Marburg, Germany) as chromogenic substrate for FXIIa and 
FXIa. Under these conditions, similar to results obtained with peptide substrates, a 1:1 ratio 
of FXIIa and rHA-Infestin-4 lead to a remarkable protease inhibition of ~85%, whereas it did 
not affect FXIa activity.  
 
Inhibitor Molar ratio Inhibition [%] 
rHA-Infestin-4 1:1, αFXIIa:inhibitor >90 
C1 inhibitor 1:16, αFXIIa:inhibitor 85 
rHA-Infestin-4 1:90, FXIa:inhibitor 0 
C1 inhibitor 1:90, FXIa:inhibitor 60 
rHA-Infestin-4 1:1, βFXIIa:inhibitor >90 
rHA-Infestin-4 1:100, FIXa:inhibitor 0 
rHA-Infestin-4 1:100, FXa:inhibitor 8 
rHA-Infestin-4 1:100, FVIIa:inhibitor 0 
rHA-Infestin-4 1:100, thrombin:inhibitor 0 
rHA-Infestin-4 1:100, kallikrein:inhibitor 7 
 
Table 2. Protease specificity of rHA-Infestin-4. Inhibition of the indicated proteases by 
rHA-Infestin-4 was assessed in a chromogenic assay. The inhibitor was incubated with the respective 
protease at the indicated molar ratio in presence of a specific protease substrate. The resulting 
protease activity was determined at 405 nm. The percentage of protease inhibition was calculated 
according to a standard curve. Results were obtained from 4 independent experiments. C1 inhibitor 
(plasmatic FXIIa inhibitor, CSL Behring) served as control inhibitor. (Hagedorn et al., Circulation, 
2010)202. 
 
Furthermore, rHA-Infestin-4 did not inhibit FIXa, FVIIa or thrombin activity and only mildly 
influenced (8% inhibition) FXa activity when tested in a 100-fold molar excess (Table 2). 
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Since FXIIa can also activate the kallikrein/kinin system, the direct effect of rHA-Infestin-4 on 
plasma kallikrein was determined, though, rHA-Infestin-4 only slightly inhibited (7% inhibition) 
the activity of the protease at a 1:100 molar ratio (Table 2). Taken together, these results 
clearly confirmed that rHA-Infestin-4 is a highly selective inhibitor of FXIIa. 
 
4.6.2 rHA-Infestin-4 displays a significant impact on fibrinolysis 
FXIIa has also been shown to be involved in the initiation of fibrinolytic processes151-153. 
Hence, to test a possible effect of rHA-Infestin-4 on fibrinolysis, pooled mouse plasma was 
incubated with either vehicle or different concentrations of rHA-Infestin-4 before clotting was 
triggered by thromboplastin (activation of the extrinsic pathway). The degree of subsequent 
clot lysis was determined as D-Dimer concentration assessed by an ELISA system 1 h after 
starting the reaction. A rHA-Infestin-4 concentration of 0.1 mg/ml had no influence on D-
Dimer concentration, whereas 1 mg/ml, which approximately mimics the inhibitor 
concentration used for the following in vivo experiments, moderately decreased D-Dimer 
concentration compared to control by 23% (158.8 ± 16.6 ng/ml for rHA-Infestin-4 and 205.5 ± 
21.0 ng/ml for control; p=0.04). However, this reduction never exceeded 38% even when a 
tenfold higher concentration of rHA-Infestin-4 (10 mg/ml) was used. These results showed 
that rHA-Infestin-4 exerts a moderate inhibitory effect on fibrinolysis.  
To determine whether this effect of rHA-Infestin-4 is indirectly mediated via FXIIa inhibition or 
directly by blockage of proteases of the fibrinolytic cascade, the potency of rHA-Infestin-4 to 
inhibit plasmin, tPA and uPA was analyzed using chromogenic assays. Interestingly, 
whereas rHA-Infestin-4 did not influence tPA and uPA activity, it efficiently inhibited 95% of 
the plasmin activity in a molar ratio of 1:0.8 (Table 3). These data suggested that rHA-
Infestin-4 affects fibrinolysis most probably by inhibiting plasmin. 
 
Inhibitor Molar ratio Inhibition [%] 
rHA-Infestin-4 1:0.8, plasmin 95 
rHA-Infestin-4 1:100, tPA 0 
rHA-Infestin-4 1:100, uPA 0 
 
Table 3. Inhibition of serine proteases of the fibrinolytic cascade by rHA-Infestin-4. Inhibition of 
the indicated proteases by rHA-Infestin-4 was assessed in a chromogenic assay. The inhibitor was 
incubated with the respective protease at the indicated molar ratio in presence of a specific protease 
substrate. The resulting protease activity was determined at 405 nm. The percentage of protease 
inhibition was calculated according to a standard curve. Results were obtained from 4 independent 
experiments. tPA=tissue plasminogen activator, uPA= urokinase plasminogen activator.  
 
4.6.3 Prevention of arterial thrombosis in rHA-Infestin-4 treated mice 
At sites of atherosclerotic plaque rupture, platelets and the plasma coagulation system 
become activated and lead to arterial thrombosis. Therefore, it was important to determine 
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the inhibitory effect of rHA-Infestin-4 on thrombus formation in vivo using a model of 
occlusive arterial thrombosis. The injury was induced on small mesenteric arterioles by 
topical application of 20% FeCl3. Based on results of previous dose-finding studies, one 
consistent and potent concentration of rHA-Infestin-4 was chosen for the in vivo experiments 
(200 mg/kg body weight). It is important to note that only approximately 10% of the molecular 
mass of rHA-Infestin-4 corresponds to the active inhibitor, Infestin-4 (~7 kDa), whereas 
albumin (~66 kDa) accounts for the rest. To additionally assess the time course of the effect 
of rHA-Infestin-4, arterioles of mice treated i.v. with the recombinant fusion protein or PBS as 
control were injured at different time points after the treatment and monitored by intravital 
fluorescence microscopy. In the first group of mice, vessels were subjected to injury 10 min 
after the injection of rHA-Infestin-4. In all animals, platelets rapidly adhered to the injured 
vessel wall, however, whereas in control mice formation of thrombi and finally full occlusion 
of the vessel occurred in all cases (mean time to occlusion 16.9 ± 2.2 min), only platelet 
adhesion was detectable in all (7/7) of the rHA-Infestin-4 injected mice throughout the 
observation period of 40 min (Figure 34A,C). A similar inhibitory potency of the fusion protein 
was detectable when injury was induced 60 min after injection (data not shown). When the 
lesion was induced in vessels ~105 min after the application of rHA-Infestin-4, small platelet 
aggregates formed but this was delayed in 71% of the arterioles (20.0 ± 3.7 min for rHA-
Infestin-4 treated mice and 6.3 ± 0.7 min for control; p<0.001; Figure 34B). Furthermore, all 
formed thrombi were unstable and in no case reached the size necessary for vessel 
occlusion. This was mainly due to the permanent detachment of single platelets from the 
surface of the thrombi. Similar findings were made when the mice were challenged in a 
second in vivo model, where the carotid artery was injured by 10% FeCl3 and blood flow was 
monitored by an ultrasonic flow probe to assess thrombus formation. In all control animals 
(10/10) irreversible vessel occlusion occurred within 14 min (mean time to occlusion 8.6 ± 2.2 
min) after injury, whereas in 90% of the rHA-Infestin-4 injected (189 mg/kg body weight) mice 
blood flow remained unaltered throughout the observation period of 60 min (Figure 34D).  
In addition, to exclude that the observed inhibitory potency of rHA-Infestin-4 was only 
restricted to mice, CSL Behring (Marburg, Germany) also analyzed the effect of the inhibitor 
on arterial thrombosis in rats. Injection of rHA-Infestin-4 (100 mg/kg body weight) efficiently 
prolonged aPTT in these animals as compared to controls without affecting PT and as a 
consequence profoundly protected rats from occlusive thrombus formation in a FeCl3-
induced injury model of the carotid artery202.  
Together, these results demonstrated that rHA-Infestin-4 is a strong inhibitor of arterial 
thrombus formation in mice as well as in rats. 
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Figure 34. rHA-Infestin-4 blocks arterial thrombus formation in mice. Thrombus formation after 
FeCl3-induced injury of mesenteric arterioles was monitored using intravital fluorescence microscopy. 
Beginning of first thrombus formation >10 µm and time to full vessel occlusion after injury, A, 10 min 
and B, 105 min, prior to i.v. injection of rHA-Infestin-4 (n=7) and PBS (n=7), respectively, are 
illustrated. Each symbol represents one arteriole. C, Representative images taken at the indicated 
time points. Bar, 100 µm. The asterisk indicates complete vessel occlusion. D Time to occlusion after 
FeCl3-induced thrombosis in the carotid artery is depicted (n=10). Each symbol represents one 
individual. Ctrl = control and Inf-4 = recombinant human albumin-Infestin-4 fusion protein. (Hagedorn 
et al., Circulation, 2010)202. 
 
During the operations to gain access to the respective vessels, small lesions of the 
circumjacent tissue could not be avoided. However, similar to the observations in FXII-
deficient mice169, rHA-Infestin-4 injected animals showed no alterations in surgery-caused 
bleeding compared to controls. To corroborate this observation, the effect of rHA-Infestin-4 
on hemostasis was studied in a tail bleeding model (Figure 35). All rHA-Infestin-4 treated 
mice (10/10) were able to arrest bleeding within the same time frame as the control animals, 
even when injected with an extremely high dose (400 mg/kg of body weight), (114 ± 77 sec 
for rHA-Infestin-4 treated mice, 190 mg/kg; p=0.38; 115 ± 35 sec for rHA-Infestin-4 treated 
mice, 400 mg/kg; p=0.34; 153 ± 146 sec for control). In line with this, also the blood loss 
during the period of bleeding was comparable between rHA-Infestin-4 treated and control 
mice (data not shown). Similarly, also rHA-Infestin-4 treated rats displayed normal bleeding 
times as assessed in a tail bleeding assay by CSL Behring (Marburg, Germany)202. These 
results indicate that rHA-Infestin-4 treatment does not interfere with normal hemostasis. 
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Figure 35. Tail bleeding assay of control and 
rHA-Infestin-4 treated mice. Tail tip was 
removed 10 min after i.v. injection of PBS (n=15) 
or rHA-Infestin-4 (n=10). Each symbol represents 
one individual. Ctrl = control and Inf-4 = 
recombinant human albumin-Infestin-4 
fusion protein. (Hagedorn et al., Circulation, 
2010)202. 
 
 
4.6.4 rHA-Infestin-4 does not reduce residual thrombus formation in F12-/- mice 
Previous studies on FXII-deficient mice revealed that they are markedly protected from 
arterial thrombosis, but the formation of microaggregates and unstable thrombi was still 
observed after endothelial damage in those animals169. In contrast, FXIIa inhibition in wild-
type mice by rHA-Infestin-4 resulted in completely abolished thrombus formation raising the 
question whether the inhibitor, in addition to FXIIa, interfered with other components of the 
coagulation system. To test this directly, we compared thrombus formation in the mesenteric 
arteriole thrombosis model between wild-type and F12-/- mice, in each case untreated or 
treated with 200 mg/kg of rHA-Infestin-4 (Figure 36A,B). In all control animals (6/6) FeCl3-
induced injury lead to initial thrombus formation within 7.3 ± 0.9 min resulting in complete 
vessel occlusion during the 40 min observation period (mean time to occlusion 17.7 ± 
3.0 min). As previously reported169, beginning of thrombus formation in F12-/- mice was 
delayed (18.4 ± 9.3 min; p=0.02) compared to control mice and all formed thrombi were 
consistently unstable, degraded and frequently detached from the vessel wall and, 
consequently, never occluded the vessel. Remarkably, virtually the same result was obtained 
when F12-/- mice had been treated with rHA-Infestin-4 10 min prior to injury. In these animals, 
platelets rapidly adhered to the vessel wall and also formed little thrombi within a time frame 
similar to untreated F12-/- mice (18.1 ± 3.0 min; p=0.95). These thrombi were similarly 
unstable as those observed in untreated F12-/- mice and never reached vessel occlusion 
(Figure 36A,B). Importantly, in wild-type mice injected with rHA-Infestin-4 no aggregates 
formed and the vessel did not occlude during the observation period (data not shown). These 
observations demonstrated that rHA-Infestin-4 had no detectable effect on thrombus 
formation in FXII-deficient mice. 
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Figure 36. Arterial thrombosis in F12-/- mice injected with rHA-Infestin-4. F12-/- mice received 
rHA-Infestin-4 10 min before FeCl3-induced endothelial injury. A, Time to first thrombus formation and 
B, time to complete vessel occlusion are shown. Each symbol represents one arteriole (n=6 for control 
and rHA-Infestin-4 inj. F12-/- mice, n=7 for F12-/- mice). C, Representative images acquired at the 
indicated time points/interval. Ctrl = control and Inf-4 = recombinant human albumin-Infestin-4 fusion 
protein. (Hagedorn et al., Circulation, 2010)202. 
 
4.6.5 rHA-Infestin-4 protects mice from ischemic brain infarction 
Ischemic brain infarction is a thromboembolic disease that is frequently associated with 
death and severe disability. As recently shown on knockout mice, FXII is an important player 
in the development of experimental ischemic stroke making it a promising target for effective 
and safe therapy170,203. To test this hypothesis directly, the protective potency of 
rHA-Infestin-4 was assessed in a murine model of ischemic stroke together with Christoph 
Kleinschnitz, Department of Neurology, University Hospital, Würzburg, Germany. To initiate 
transient cerebral ischemia, a thread was advanced through the carotid artery into the middle 
cerebral artery (MCA) and allowed to remain for 1 h (transient MCA occlusion - tMCAO), 
reducing regional cerebral flow by >90%204. In rHA-Infestin-4 treated animals, infarct volumes 
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24 h after reperfusion, as assessed by 2,3,5-triphenyltetrazolium chloride (TTC) staining, 
were reduced to less than 17% of the infarct volumes in untreated animals (69.5 ± 33.7 mm3 
vs. 11.2 ± 5.3 mm3; p<0.001; Figure 37A). Importantly, the observed protective effect of rHA-
Infestin-4 was functionally relevant, as the Bederson score assessing global neurological 
function (1.2 ± 0.9 vs. 3.7 ± 0.7; p<0.001; Figure 37B) and the grip test, which specifically 
measures motor function and coordination (3.8 ± 0.8 vs. 1.9 ± 1.4; p=0.003; Figure 37C) 
were both significantly better in rHA-Infestin-4 treated mice as compared to control. These 
findings strongly indicate that inhibition of FXIIa by rHA-Infestin-4 could be a promising 
strategy to prevent ischemic brain infarction. 
 
 
Figure 37. rHA-Infestin-4 injected mice are protected from ischemic stroke. Formation of cerebral 
ischemia and consequential neurological defects were investigated in a murine stroke model. A, Brain 
infarct volumes in controls (n=13) and rHA-Infestin-4 treated mice (n=10) presented as mean ± SD 
(left). Representative images of three corresponding coronal sections from control and rHA-Infestin-4-
treated mice stained with TTC 24 h after tMCAO. Infarct areas are marked with arrows (right). 
Bederson score B, and grip test C, determined 24 h after tMCAO of control (n=9) and rHA-Infestin-4 
treated mice (n=10); horizontal bar indicates the median. The experiment was started 10 min after i.v. 
injection of PBS and rHA-Infestin-4, respectively; **, p<0.01; ***, p<0.001. Ctrl = control and Inf-4 = 
recombinant human albumin-Infestin-4 fusion protein. (Hagedorn et al., Circulation, 2010)202. 
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5 DISCUSSION 
Platelet activation and aggregation together with the initiation of the coagulation system are 
critical steps during thrombus formation to limit post-traumatic blood loss at sites of vascular 
injury. However, under pathological conditions, these processes may also lead to full vessel 
occlusion causing myocardial infarction or stroke. Therefore, antiplatelet agents such as 
aspirin, clopidogrel and integrin αIIbβ3 antagonists that act by the inhibition of platelet 
function have been beneficial in the prophylaxis and treatment of cardio-and cerebrovascular 
diseases205. Similarly, anticoagulation with vitamin K antagonists, heparins and direct 
inhibitors of thrombin and FXa has provided an efficient therapeutic option against 
thromboembolic events206. However, reduced pathological thrombus formation by the 
application of the currently available antithrombotic agents is often associated with an 
increase in bleeding complications, which can possibly either aggravate the clinical outcome 
of the thrombotic disease or even be life-threatening. Hence, the detailed analysis of platelet 
activation and the respective signaling pathways as well as activation mechanisms of plasma 
coagulation factors has become an important and developing field in cardiovascular research 
during the last decades.  
Thrombus formation is a multistep process that involves a complex but well defined interplay 
of multiple platelet adhesion/activation receptors, intracellular signaling molecules and 
coagulation factors. The major players and mechanisms in these processes are, however, 
only partially known and characterized. In the current thesis, several mechanisms underlying 
thrombus formation in hemostasis and thrombosis were assessed using different approaches 
such as specific protein blockage, immunodepletion or genetic deficiency in mice. In 
particular, the role of the GPIbα-vWF interaction, the platelet activating receptors GPVI and 
CLEC-2 as well as the intracellular signaling proteins PLD1 and RhoA for platelet function 
and in vivo thrombus formation were investigated. The presented results revealed that these 
proteins are critical for thrombus formation but differently regulate thrombus initiation, 
propagation and stabilization. Additionally, the data provided further evidence for the recently 
raised possibility that pathological thrombus formation and hemostasis may involve partially 
distinct mechanisms. Moreover, the functional characterization of the newly generated FXIIa 
inhibitor rHA-Infestin-4, presented in the last part of this study revealed that this inhibitor may 
serve as a promising pharmacological agent that abolishes occlusive thrombus formation 
without affecting hemostasis.  
Consequently, although data gained from studies using murine thrombosis models cannot 
directly be transferred to the human situation, the new findings presented here may serve as 
the basis for the development of a novel generation of antithrombotic agents and strategies 
for effective therapy of thromboembolic diseases with a good safety profile. 
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5.1 Studies on the functional role of the GPIbα-vWF interaction and 
downstream signaling in shear-dependent thrombus formation 
5.1.1 The GPIbα-vWF interaction is essential for in vivo thrombus stabilization at 
high shear 
Under conditions of arteriolar shear, the initial tethering of flowing platelets to the exposed 
ECM at sites of vascular injury is mediated by the interaction of the platelet receptor GPIbα 
with vWF immobilized on collagen. This commonly accepted knowledge has been gained 
during the last decades from numerous in vitro studies using flow chamber assays but also 
from intensive in vivo analyses of arterial thrombus formation in mice deficient in functional 
GPIbα43,44,189. Since mice lacking GPIbα27 or GPIbβ28 displayed a severe bleeding diathesis 
accompanied by a marked macrothrombocytopenia phenotypically resembling the symptoms 
of human BSS, these mice were not suitable for investigating the role of GPIb in thrombosis. 
This limitation was, however, overcome by the generation of transgenic mice expressing a 
mutated form of GPIbα in which the extracellular domain was replaced by the α-subunit of 
the human IL-4 receptor207. As a consequence, these mice revealed dysfunctional GPIbα but 
nearly normal platelet counts207. Bergmeier et al. demonstrated that these mice were 
profoundly protected from FeCl3-induced arterial thrombus formation in mesenteric arterioles 
as platelets virtually failed to adhere to the injured vessel wall43. Furthermore, they showed 
that platelets with mutated GPIbα were unable to incorporate into a growing thrombus of 
wild-type platelets in the same injury model43. These data provided the first in vivo evidence 
that GPIbα is essential for platelet adhesion and thrombus propagation at sites of vascular 
lesions. This could also be confirmed in another vascular bed by Konstantinides et al. 
challenging the same mice in a FeCl3-induced carotid injury model44. Similarly, Jain et al. 
reported defective thrombus formation after FeCl3-dependent injury of carotid arteries in mice 
carrying a genetically modified C-terminus of GPIbα, a mutation that disabled binding of the 
downstream signaling molecule 14-3-3ξ189. The observed phenotype of these mice was not 
as pronounced as in mutant mice lacking the functional extracellular domain of GPIbα43, 
which indicated that GPIbα signaling through 14-3-3ξ is less important for arterial thrombus 
formation than binding of GPIbα to its ligand(s). However, previous thrombosis studies in 
vWF-deficient mice by Denis et al.172 and Ni et al.174, using the same experimental 
conditions, demonstrated that the main GPIbα ligand is less important for arterial thrombus 
formation than the receptor itself. In both studies, initial aggregate formation was indeed 
delayed but not absent in vWF-deficient mice, and also further thrombus progression 
occurred. This suggests that GPIbα binding to other ligand(s) in addition to vWF might 
mediate platelet adhesion and consequent thrombus formation in the applied injury models. 
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According to the impressive in vivo data of GPIbα mutant mice, the receptor has been 
proposed as a promising target for powerful antithrombotic therapy43. 
To test, whether this proposal first of all holds true for mice, GPIbα was targeted in vivo and 
the effect on pathological thrombus formation was assessed in a FeCl3-induced injury model 
which was comparable to that used in the above mentioned studies. To do so, GPIbα was 
functionally inhibited in mice by treatment with non-cytotoxic Fab fragments of the 
monoclonal antibody p0p/B that specifically block the vWF-binding site on the extracellular 
domain of GPIbα183. These Fab fragments had previously been tested in another murine 
thrombosis model of ligation-induced endothelial damage in the carotid artery where 
completely inhibited platelet adhesion to the injured vessel wall was observed42. In the 
current thesis, anti-GPIbα Fab fragment treatment significantly delayed initial aggregate 
formation but, in line with data obtained in vWF-/- mice175, did not abrogate subsequent 
thrombus growth in FeCl3-injured mesenteric arterioles (Figure 5A,B). These data further 
supported the notion that vWF-binding to GPIbα contributes to, but is not essential for the 
initial adhesion of platelets to the exposed ECM at the wound site. However, an alternative 
ligand(s) of GPIbα, which may dominantly mediate this process, has not yet been 
determined. It also remains unclear whether the previously proposed binding partners of 
GPIbα, thrombospondin-1 and P-selectin, which have been shown to be involved in 
thrombosis208,209, may represent likely candidates. 
Moreover, in the present study, the GPIbα-vWF interaction rather appeared to be critical for 
stable platelet-platelet connections in a growing thrombus at very high shear rates as 
revealed by the continuous release of individual platelets from the thrombus surface when it 
reached a size that nearly occluded the artery (Figure 5B,C). Consequently, thrombus 
formation arrested at this stage, allowing blood to pass through a small open channel and 
thus preventing vessel occlusion in 89% of the p0p/B Fab fragment-treated mice. The 
thromboprotective effect observed in these animals partially exceeded that reported for 
vWF-/- mice as only 50% of these animals were protected from stable vessel occlusion175. 
However, the overall characteristics of thrombus formation were quite similar between both 
groups of mice. These findings strongly indicate that the FeCl3-injury model in our hands 
provides reliable results that are well comparable to those obtained by other groups and 
hence confirmed the suitability of this thrombosis model as a valid method in the laboratory 
for further analysis of thrombus formation in mice. The minimal discrepancies between the 
two studies might be due to slightly different injury procedures which may cause variable 
severities of the vascular lesion and subsequently different degrees of platelet activation. 
Furthermore, the data in the present study provided direct proof that vWF-mediated cross-
linking of platelets via GPIbα represents the main mechanism for platelet recruitment to a 
growing thrombus at very high shear rates22,43. The interaction of vWF bound to GPIbα on a 
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circulating platelet with activated integrin αIIbβ3 on the thrombus surface may also account 
for that process. However, the latter possibility seems rather unlikely as there is increasing 
evidence that under conditions of extremely high shear, thrombus propagation requires 
GPIbα and vWF but occurs independently of platelet activation and thereby also of activated 
integrin αIIbβ321-23. Whether vWF binding to GPIbα is sufficient to mediate stable platelet-
platelet cohesion in a growing thrombus or, according to its high “off-rate”, is only crucial for 
the initial tethering of new platelets from the circulation to the thrombus surface, remains still 
to be determined. The interaction of GPIbα with other ligands might also be responsible for 
the final step of firm platelet adhesion, such as plasma fibronectin which has previously been 
shown to be involved in platelet recruitment into a developing thrombus210,211.  
Nevertheless, the results of the p0p/B Fab fragment-treated mice analyzed in a mechanical 
injury model of the abdominal aorta also supported the importance of the GPIbα-vWF 
interaction for stable thrombus expansion. Similar to the data of the FeCl3-induced injury, 
initial thrombus formation was unaltered in animals challenged in this model, but subsequent 
thrombus progression was virtually abolished when it reached a size that occluded up to 50% 
of the vessel (as estimated from to the blood flow measurements, Figure 6A,B). Accordingly, 
one may assume that also under these experimental conditions platelets failed to 
incooperate into the growing thrombus when the GPIbα-vWF interaction was blocked. These 
findings are in line with previous studies reporting that maximal thrombus size in a model of 
laser-induced thrombosis was decreased in mice lacking vWF212 and that maintenance of 
open channels after vascular injury prevented vessel occlusion in pigs suffering from von 
Willebrand’s disease213.  
Taken together, the GPIbα-vWF interaction appears to be essential for thrombus progression 
independently of the applied injury model. Thus, the respective binding site might serve as a 
novel target for effective antithrombotic therapy (Figure 40). This approach may, however, be 
accompanied by unwanted bleeding complications as p0p/B Fab fragment treatment 
severely prolonged tail bleeding times in mice (Figure 6C). However, the hemostatic defect 
was clearly less pronounced as compared to mice treated with integrin αIIbβ3 blocking 
Fab fragments45. Similarly prolonged bleeding times have previously been observed in our 
group by Kleinschnitz et al. using the same p0p/B Fab fragments45 and by Denis et al. who 
studied hemostasis in vWF-/- mice173. Although bleeding time experiments in mice do not 
directly correlate with possible clinically relevant hemorrhages214, one may assume that 
therapeutic targeting of GPIbα might be associated with an increased bleeding tendency. It 
remains, however, questionable to which extent these anticipated complications would occur 
in humans. Two independent studies, for example, showed that GPIbα blockage by Fab 
fragments of monoclonal antibodies, similar to that used in the present study, efficiently 
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prevented arterial thrombosis in baboons, but at the same time only mildly prolonged skin 
bleeding times215,216. 
The proposal that GPIbα blockage of the vWF-binding site may represent an attractive 
antithrombotic concept is also supported by the finding of Kleinschnitz et al. that treatment 
with p0p/B Fab fragments dramatically protected mice from ischemic brain infarction45. 
Importantly, both prophylactic and therapeutic administration of the Fab fragments equally 
prevented lesion progression and ameliorated the neurological outcome after experimentally 
induced stroke in the animals. GPIbα targeting was, notably, not associated with an increase 
in intracranial hemorrhage45. In line with these findings, similar data were obtained with 
vWF-/- mice46. 
In summary, the results of the present study show that vWF binding to GPIbα is an essential 
mechanism for the incorporation of flowing platelets into a growing thrombus after FeCl3- and 
mechanically induced vascular injury in mice. Furthermore, the data provide clear evidence 
that blocking of the GPIbα-vWF interaction by Fab fragments virtually mirrors the 
antithrombotic phenotype of mice lacking vWF. Based on these findings and those discussed 
above, targeting of the vWF interaction site of GPIbα might be an attractive therapeutic 
strategy whereas Fab fragments of an anti-GPIbα antibody may serve as a potential 
therapeutic agent for the prophylaxis and treatment of acute cardio- and cerebrovascular 
diseases.  
 
5.1.2 PLD1 mediates αIIbβ3 integrin activation under high shear and is critical for 
pathological thrombus formation but dispensable for hemostasis  
As discussed above, GPIbα was suggested as an attractive pharmacological target for 
antithrombotic therapy. This proposal may, however, similarly be applied to downstream 
signaling effectors of GPIbα, particularly as mice lacking the GPIbα-binding site for 
14-3-3ξ189 have also been described to display clearly decreased in vivo thrombus formation. 
According to the data presented here, the intracellular signaling protein PLD1 may represent 
one potential candidate molecule. It could be shown that PLD1 is required for efficient αIIbβ3 
integrin activation in a GPIbα-dependent manner under high shear flow conditions and 
consequently important for stable thrombus formation in vitro and in vivo. The finding that 
genetic PLD1 deficiency in mice resulted in impaired thrombus stabilization in models of 
arterial thrombosis and protection from ischemic brain infarction for the first time identified 
this enzyme as a fundamental player in pathological thrombus formation. 
Studies with inhibitor indirectly blocking PLD activity in human platelets have previously 
suggested a role of this enzyme for platelet activation and degranulation191 This was 
particularly proposed upon PAR1 stimulation63, a process which has later also been 
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supposed to trigger PLD-dependent Rap1 activation64. However, all these studies made use 
of a partially insufficient approach by repressing the production of PA, the major downstream 
messenger of PLD. Due to the lack of alternative methods at that time, the primary alcohol 
butanol-1 was used to divert PLD activity towards the generation of phosphatidylbutanol 
instead of the physiologically active PA. Subsequently drawn conclusions about PLD- and 
PA-dependent functions may have been influenced by the fact that butanol-1 only 
incompletely prevents PA generation and that it has in addition to phosphatidylbutanol 
several off-target effects on cell activity217. This rather limited the reliability of the respective 
data. Moreover, this method did not allow discriminations between possibly different roles of 
the individual PLD isoforms in platelet function.  
In the present study, using a knockout approach, these limitations were circumvented. It was 
demonstrated for the first time that PLD1 and PA are involved in integrin αIIbβ3 inside-out 
activation after stimulation of G protein- as well as ITAM-coupled receptors, whereas the 
proposed191 contribution of PLD1 in the process of α or dense granule release could not be 
confirmed190. Furthermore, the enzyme was identified to be critical for GPIbα-mediated stable 
platelet adhesion under high shear conditions. The exact mechanism how PLD1 becomes 
activated in platelets and facilitates integrin αIIbβ3 activation is not clear at present. A 
previous report by Powner et al., described related signaling events in neutrophils where 
PLD- activity is required for talin-binding to the integrin MAC-1 and thereby essential for 
mediating cell adhesion and migration218. It appears possible that similar mechanisms may 
also be relevant for integrin activation in platelets. Accordingly, one may hypothesize that 
PLD1 might activate a signaling cascade that is responsible for proper talin-1 binding to the 
integrin β subunit, which is the final step of integrin activation and essential for platelet 
adhesion and aggregation. However, further analyses are required to test this assumption 
and to clarify the interplay of PLD1 with other signaling proteins.  
Furthermore, this study demonstrated that thrombus stabilization was severely diminished in 
Pld1-/- mice under high shear flow conditions in vitro and also in vivo. Interestingly, PLD1 was 
dispensable for the initial adhesion of platelets to the collagen surface and also for the 
following process of aggregate and thrombus formation (Figure 7A). However, the enzyme 
appeared to be critical for sustained platelet-platelet interactions in the growing thrombus 
under high shear rates as revealed by the release of platelets from the thrombus surface and 
finally complete disintegration of formed thrombi after a few minutes of perfusion (Figure 7A). 
The recruitment and attachment of platelets to the thrombogenic matrix is known to be driven 
by GPIb, GPVI and the integrins α2β1 and αIIbβ3. Interestingly, the presented data indicated 
that the first layer of Pld1-/- platelets is sufficiently activated under the experimental 
conditions, most probably due to the GPVI-collagen interaction. This mechanism appears to 
be independent of PLD1-driven integrin activation, allowing the platelets to firmly adhere on 
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the collagen surface and to initiate aggregate formation. In contrast, activation and stable 
incorporation of platelets in the upper layers of the thrombus was impaired. This process is 
known to be mediated by the action of released soluble mediators, namely ADP and TxA2 as 
well as by the GPIbα-vWF interaction and the subsequent signaling20. In the light of the data 
in this thesis showing that Pld1-/- platelets failed to firmly adhere on a vWF surface at high 
shear rates (Figure 7B), one may suggest that PLD1 plays an important role in the platelet 
activation process during thrombus growth particularly under high shear conditions because 
it mediates signaling events downstream of GPIbα that lead to integrin αIIbβ3 activation. 
This process also appeared to be relevant for thrombus formation in vivo, as Pld1-/- mice 
displayed severely defective thrombus stabilization in arterial thrombosis models. In line with 
the results of the in vitro flow adhesion assays, the initial thrombus formation after 
mechanically as well as chemically induced vascular injury was unaltered in Pld1-/- mice 
when compared to wild-type mice (Figure 8A-C) and even subsequent thrombus propagation 
was nearly comparable between both groups of animals. However, the final step in thrombus 
growth to fully occlude the vessel or the irreversible stabilization of occlusive thrombi, 
respectively was completely abolished in Pld1-/- mice (Figure 8A-C). As a consequence and 
irrespective of the applied injury model, almost all vessels of these animals remained open at 
the end of the observation period, indicating that at very high shear rates, such as those 
occurring in stenosed arterial vessels, the lack of PLD1 becomes evident. This observation 
further supports the assumption that the enzyme plays a critical role in GPIbα-mediated 
αIIbβ3 integrin activation. Moreover, this function may also account for the reduced 
phosphatidylserine exposure of Pld-/- platelets when activated and aggregated on a collagen 
surface under high shear flow conditions190, because it has previously been shown that the 
platelet procoagulant activity is dependent on GPIbα and αIIbβ3 integrin activation219. The 
decreased ability of Pld1-/- platelets to stimulate the coagulation process may at least partially 
contribute to the defective thrombus stabilization seen in these mice. 
Very interestingly, although PLD1 deficiency prevented stable vessel occlusion in 
pathological thrombosis models, it had no effect on normal hemostasis, as bleeding times of 
Pld1-/- mice were unaltered (Figure 8D). This indicated that PLD1 may represent a novel 
target molecule for potent antithrombotic therapy without causing bleeding complications. 
This would especially be advantageous for the treatment of acute ischemic stroke, where the 
risk of intracranial hemorrhage (ICH) is the major limitation of current antithrombotic 
treatments220-222. In the previous part of the presented study (5.1), it was described that 
blockage of the GPIbα-vWF interaction dramatically diminished lesion progression after 
experimentally induced ischemic stroke, and that this treatment did not induce ICH, although 
increasing bleeding times in those mice45. In accordance with the assumption that PLD1 acts 
as a signal transducing enzyme downstream of GPIbα, also Pld1-/- mice displayed markedly 
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reduced infarct volumes and a better neurological outcome, which was, similarly to GPIbα 
inhibition, not accompanied by an increase in intracerebral bleeding190. Since in addition 
PLD1 deficiency did not affected normal hemostasis, the data clearly emphasize that this 
enzyme or even downstream effectors might be a preferable target for effective and safe 
prevention or treatment of thromboembolic events. It is Important to note that, despite the 
proposed contribution of PLD1 to several cellular functions including degranulation, 
cytoskeletal reorganization, proliferation and migration49,223, Pld-/- mice are viable, healthy and 
fertile190. These findings have meanwhile also been confirmed by others224 and might be 
explained by a potential compensatory capacity of the second PLD isoform, PLD2, or 
additional enzymes that function similarly to PLD1. Nevertheless, according to these 
observations, a good general safety profile of an anti-PLD1 therapy may be anticipated. 
 
5.2 Studies on the functional role of the (hem)ITAM-coupled receptors GPVI 
and CLEC-2 in hemostasis and thrombosis 
5.2.1 GPVI is a critical mediator of arterial thrombosis upon FeCl3- and mechanically 
induced vascular injury 
During the last years, GPVI has been established as the major platelet activation receptor for 
collagen and proposed as an attractive antithrombotic target (Figure 40). This is particularly 
due to the observation that injection of anti-GPVI antibodies (JAQ1-3) into mice induces 
specific downregulation of the receptor from the surface of circulating platelets, resulting in a 
long-term antithrombotic protection but rather no or only a minimal hemostatic 
defect42,77,82,83,225. However, contradictory results have been reported about the functional 
significance of GPVI for pathological thrombus formation in different experimental thrombosis 
models. For example, previous studies yielded either no role78,212 or only a minor role79,85 for 
GPVI in laser-induced thrombus formation and only one report showed a significant 
contribution of the receptor to thrombus formation in this model226. These observations are 
likely explained by the fact that platelet activation and aggregation upon laser-injury is largely 
dependent on thrombin generation. Variations in the severity of the induced lesions may 
determine to which extent other signaling pathways contribute to thrombus formation under 
these experimental conditions79,85,178. Many controversies also exist about the relative 
importance of GPVI-mediated platelet adhesion and activation for arterial thrombosis after 
FeCl3-induced vascular injury. This type of injury model is a widely used and accepted 
method in the field of thrombosis research as it relatively easy to perform and to standardize. 
Moreover, it allows variable levels of injury in different vascular beds and it has been 
reported to trigger the formation of thrombi that are similar in their composition to those 
appearing in humans174. Previous studies provided evidence for a critical role of GPVI in 
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FeCl3-induced thrombus formation in mice. Massberg et al. were the first to show that GPVI-
immunodepletion protected mice from FeCl3-induced occlusive thrombus formation in the 
carotid artery42. This was later confirmed by Dubois et al. assessing thrombus formation in 
mesenteric arterioles of FcRγ-chain-deficient mice (which lack GPVI on the platelet 
surface227) after FeCl3 application78. In a third report, also Konstantinides et al. described that 
the majority of tested Gp6-/- mice revealed abnormal thrombus formation in a model of FeCl3-
induced vascular lesions in carotid arteries44. However, these data stand in contrast to the 
observation recently made by Eckly et al.86, who reported that GPVI-immunodepleted mice 
are not protected from vessel occlusion after FeCl3-induced injury of mesenteric arterioles as 
well as carotid arteries. In the study presented here, for the first time a comprehensive 
analysis of the thrombotic response of genetically as well as immunodepleted GPVI-deficient 
mice upon FeCl3-induced vascular injury in mesenteric arterioles and carotid arteries was 
performed. It could be clearly demonstrated that the initial thrombus formation in injured 
mesenteric arterioles was not altered in mice lacking GPVI compared to wild-type mice, 
whereas thrombus propagation was impaired due to permanent embolization that strongly 
delayed or abolished vessel occlusion in these mice (Figure 9A,B). Furthermore, this 
significant contribution of GPVI-mediated signaling in FeCl3-induced thrombosis was also 
shown to be independent of the targeted vascular bed as similar observations were made in 
both groups of GPVI-deficient mice after injury of the carotid artery (Figure 9C). These 
findings are in line with the above discussed data from earlier studies reported by other 
groups42,44,78, but are contradictory to the data obtained by Eckly et al.86. These discrepancies 
are difficult to explain at present, but they are most likely related to different experimental 
conditions. The severity of the vascular injury may vary due to the used FeCl3 concentration, 
the application method via filter paper or liquid drop and accordingly the exposure time of the 
vessel to the applied chemical. Consequently, the different experimental conditions may 
cause variable exposure of different thrombogenic proteins and factors to the flowing blood 
which differently influence platelet activation and aggregation. To at least partially test this 
assumption in the present study, another FeCl3 concentration and also a different exposure 
time was used to achieve a more severe vascular injury in the carotid artery. As a result, 
thrombus formation was indeed less affected but notably still impaired in GPVI-deficient mice 
when the injury was induced by 15% instead of 10% FeCl3 or by 3 min instead of 1.5 min 
application time of the saturated filter paper (data not shown). This indicates that GPVI-
mediated platelet adhesion and activation is less important for arterial thrombus formation 
upon severe chemically induced vascular damage, which is in line with previous reports by 
others suggesting a pivotal role for TF-mediated thrombin generation in the process of 
thrombus formation under these conditions228-230. However, it remains questionable whether 
such an extreme vascular injury, probably triggering massive platelet activation in a way that 
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loss of one critical signaling pathway may be compensated by others, mimics the conditions 
under which thrombotic events are triggered in human disease.  
Eckly et al. explained their results by providing a new mechanisms underlying thrombus 
formation after FeCl3-induced injury86. In contrast to the hitherto existing assumption that 
FeCl3 induces strong denudation of endothelial cells and exposure of subendothelial 
proteins172,231, the authors showed that in their hands, FeCl3 indeed severely injures the 
endothelium but without damaging the internal elastic lamina (IEL)86. As a consequence, 
Eckly et al. hypothesized that only components of the basement membrane are exposed to 
the blood flow whereas adhesive proteins which activate GPVI, such as collagen type I, are 
not present at the injury site and thereby do not contribute to thrombus formation in this 
model. Furthermore, they demonstrated that FeCl3 application also led to the formation of 
ferric ion-filled spherical bodies sprouting out of the endothelium into the vessel lumen86. 
According to the finding that on the surface of these bud-like structures high amounts of TF 
were exposed, they suggested that subsequently generated thrombin is the driving force for 
thrombus formation after FeCl3-induced injury. Consequently, the authors state that this 
model may not be suitable to assess the role of subendothelial adhesive proteins and their 
respective platelet receptors in arterial thrombus formation86. The results of the present 
study, however, strongly suggest that FeCl3 induces a type of vascular injury that causes the 
exposure of subendothelial collagens and other ECM components to the flowing blood and 
that these significantly contribute to platelet activation and thrombus formation. This is also 
supported by previous data from Dubois et al., who visualized considerable exposure of 
collagen type I to the vessel lumen in vivo and on sections of cremaster muscles after injury 
with FeCl378. Moreover, one has to consider that also proteins of the basement membrane 
such as collagen type IV, despite its known function as a weak affinity ligand for GPVI, and 
laminin may also be importantly involved in the initiation of thrombus formation. The role of 
laminin in vivo has still to be determined, but it has been described to mediate platelet 
spreading through integrin α6β1-dependent activation of GPVI72. Recently, it was 
hypothesized that proteins from the tunica media, involving also collagen type I, may still be 
exposed232 even if the IEL is not damaged as it has been shown to be fenestrated233. 
Together, this indicates that further investigations are required to determine the exact 
mechanisms underlying platelet adhesion and activation at sites of vascular injury after 
application of FeCl3.  
In a second set of thrombosis experiments, Gp6-/- and GPVI-immunodepleted mice were 
analyzed in a model of mechanical injury of the abdominal aorta. Under these conditions, 
GPVI deficiency resulted in virtually abrogated thrombus formation and efficiently protected 
mice from vessel occlusion (Figure 10). These results confirm previous findings from our 
group by Grüner et al. demonstrating that GPVI-immunodepletion in mice inhibited thrombus 
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formation in that model. Thereby, these studies strongly suggest that platelet adhesion and 
activation after mechanical vascular injury is largely mediated by exposed collagens and 
possibly other ECM proteins which interact with their respective platelet receptors in a GPVI-
dependent manner. Notably, the observed protection of GPVI-deficient mice from arterial 
thrombosis after injury of the abdominal aorta (Figure 10) exceeds the effect seen in mice 
with blocked vWF-GPIbα interaction (Figure 6 A,B). Whereas GPVI-deficient mice only 
showed minimal reduction of the blood flow after vessel injury, p0p/B-treated mice revealed 
an initial decline of the blood flow within the first minutes similar to that of wild-type mice, 
which indicates initially unaltered thrombus formation. This suggests a dominant role of GPVI 
instead of vWF-GPIbα for platelet adhesion and activation at sites of vascular lesions under 
these experimental conditions. The proposed important role of GPVI for mechanically 
induced thrombus formation is, however, not supported by Mangin et al., who challenged 
FcRg-/- mice in a Folts-like stenosis-injury model79. The discrepancies may to a great extent 
be explained by the different experimental procedures used in the studies. In contrast to the 
thrombosis model performed in the present study where the abdominal aorta was injured by 
a single firm compression for 15 sec with a forceps, the model by Mangin et al. comprised an 
induced vessel stenosis of the carotid artery with a suture followed by one or even repetitive 
sets of 5 crushes with a forceps. Consequently, as indicated above for a severe FeCl3-
induced vascular injury, one may speculate that such a massive vascular injury induces 
extensive activation of different platelet signaling pathways, which are able to promote 
thrombus formation independently of each other. 
Taken together, this study demonstrates that GPVI-mediated platelet adhesion and activation 
mechanisms are essential for thrombus formation following FeCl3-induced and mechanically 
induced vascular injury in mice. These findings confirm that the FeCl3 injury model is well 
suited to study the involvement of ECM components and their respective platelet receptors in 
thrombus formation. Furthermore, the data provide direct evidence that GPVI-
immunodepletion results in a comparable thromboprotective effect as genetic GPVI 
deficiency in different thrombosis models, which strongly suggests that GPVI targeting by 
antibodies in vivo does not produce significant undesired side effects on platelet function. 
These findings are particularly important for the potential development of anti-GPVI based 
antithrombotic agents. Similar to the observation that injection of JAQ1-3 into mice caused 
specific immunodepletion of GPVI from the platelet surface77,225, also two patients have been 
described who suffer from an autoimmune disease where endogenously developed anti-
GPVI antibodies lead to the downregulation of this platelet receptor87,88. As a consequence, 
both mice and patients lacking GPVI display abolished platelet responses to collagen and 
CRP but only a mild bleeding tendency. Based on this correlation between humans and mice 
and in the light of the presented data, one may speculate that also a “therapeutically” 
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induced downregulation of GPVI in human platelets by antibody treatment might be 
successful and may represent a valuable strategy for the therapy of thromboembolic 
diseases. This concept is currently under investigation in monkeys using human GPVI-
specific mouse monoclonal antibodies to downregulate GPVI from the platelet surface234. 
First success has already been achieved in these studies, as a single subcutaneous injection 
of one of the analyzed antibodies led to a long-term antiplatelet effect due GPVI-
immunodepletion without, notably, significant thrombocytopenia234, a known “side-effect” of 
anti-GPVI antibody injection into mice77.  
 
5.2.2 CLEC-2 is important for thrombus stabilization in hemostasis and thrombosis 
CLEC-2 has recently been identified as a prominent transmembrane receptor on the platelet 
surface that exhibits a remarkable activatory potential9,235. However, its physiological role in 
platelet function has been largely unknown. This study provided the first evidence that 
CLEC-2 is an essential player in thrombus formation during hemostasis and thrombosis. 
Anti-CLEC-2 antibody injection into mice led to the irreversible downregulation of the 
receptor from the surface of circulating platelets and resulted in severely impaired thrombus 
formation at arteriolar shear in vitro and also in vivo. Notably, the initial adhesion of CLEC-2 
deficient platelets on collagen under high shear flow conditions was unaltered (Figure 12A), 
which was, however, not surprising as this process is well established to be mediated by the 
action of GPIb, GPVI and also α2β1 and αIIbβ3 integrins7,236. CLEC-2 dependent signaling 
rather appears to be important for the stabilization of direct platelet-platelet contacts in the 
growing thrombus under flow conditions, as indicated by the fact that newly recruited 
platelets failed to firmly adhere on the surface of collagen-adherent platelets and were 
permanently released. As a consequence, aggregates of CLEC-2 deficient platelets formed 
on collagen at high shear covered less surface area and were strongly diminished in their 
volume compared to aggregates of control platelets (Figure 12B). Comparable to these data, 
the process also seemed to be relevant for stable thrombus formation in a FeCl3-induced 
injury model as single platelets were constantly released and also small aggregate fragments 
frequently embolized from the surface of the growing thrombus in CLEC-2 deficient mice. 
Consequently, these animals were profoundly protected from arterial vessel occlusion 
(Figure 13), suggesting that CLEC-2 may represent an interesting target for effective 
antithrombotic therapy (Figure 40). Contrary to these data, the overall thrombotic response in 
CLEC-2 deficient mice after mechanical injury of the abdominal aorta was comparable to 
control mice (Figure 14). Only a tendency towards delayed vessel occlusion was detectable, 
indicating a rather minor contribution of CLEC-2 mediated signaling in thrombus formation 
under these experimental conditions. These observations are not easily explainable but the 
severity of the mechanical injury may be the reason because it results in massive endothelial 
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denudation followed by rapid thrombus formation within a few minutes in contrast to the 
characteristics of the FeCl3-induced vascular injury. One may assume that under such 
conditions, the profound activation of different platelet activation mechanisms, critical for 
thrombus growth may overcome the defect in CLEC-2 activity. Ideally, to exclude that 
CLEC-2 function is only relevant for thrombus stabilization in a FeCl3-injury model, CLEC-2 
deficient mice should be analyzed in additional thrombosis models such as the FeCl3-injury 
model on carotid arteries or the laser-injury model.  
Interestingly, however, the importance of CLEC-2 for thrombus stabilization in vitro and in 
vivo has meanwhile been supported by Suzuki-Inoue et al. who used a genetic knockout 
approach9. As a constitutive CLEC-2 knockout is lethal in mice due to impaired organization 
and separation of lymphatic and blood vessels during embryonic development99,100, the group 
generated CLEC-2 deficient chimeric mice by transplanting fetal liver cells from Clec-2-/- 
embryos into irradiated wild-type mice9. In line with data of the present study, the authors 
reported normal adhesion but a significantly reduced thrombus propagation of CLEC-2 
deficient platelets on a collagen surface under high shear flow conditions9. Furthermore, 
these CLEC-2 deficient mice displayed virtually abolished aggregate and thrombus formation 
in a model of laser-induced injury of mesenteric arterioles9. The defect was apparent by the 
frequent release of only loosely attached platelets from the vessel wall or from platelet 
aggregates which finally prevented vessel occlusion. These findings also emphasize CLEC-2 
as a potential antithrombotic target and concurrently reveal that CLEC-2 immunodepletion 
perfectly reflect the thrombotic phenotype of genetically CLEC-2 deficient mice. However, a 
recent report by Hughes et al. described contradictory results concerning the role of CLEC-2 
for thrombus formation in vitro237. The authors also used chimeric mice lacking functional 
CLEC-2 and analyzed the ability of the platelets to from aggregates/thrombi on collagen 
under arteriolar shear rates. Surprisingly, they found no differences between CLEC-2 
deficient and wild-type platelets237. The reason for these discrepancies between the different 
studies are not clear at present, particularly because the used experimental conditions 
(anticoagulants and shear rate) were largely comparable. One possible explanation could be 
that due to differences in blood sampling, handling or slightly insufficient anticoagulation in 
the study by Hughes et al. the amount of present soluble mediators such as ADP, TxA2 and 
thrombin may have been elevated in their samples. This may consequently affect in vitro 
thrombus formation by compensating the CLEC-2 signaling defect. In the present study, it 
could be shown that under non-anticoagulated conditions or co-infusion of ADP and U46619, 
CLEC-2 deficient platelets displayed stable thrombi on collagen in the flow chamber system 
indistinguishable from controls (Figure 12C). However, it remains questionable whether 
slightly increased levels of soluble platelet agonists may cause such effects. Due to bleeding 
complications in the CLEC-2 chimeric mice, Hughes et al. were unfortunately not able to 
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challenge these mice in an arterial thrombosis model237. Such an analysis would possibly 
have been helpful to clarify the controversial results about the role of CLEC-2 in thrombus 
formation at arteriolar shear. 
Nevertheless, the present thesis, demonstrated that antibody-induced CLEC-2 deficiency 
results in defective thrombus growth and stabilization under flow conditions in vitro and in 
vivo (Figure 12 and Figure 13). The mechanism underlying CLEC-2 activation and function 
remains elusive as the only known physiological ligand of the receptor, podoplanin, is mainly 
expressed on tumor and lymphatic endothelial cells but not found in the vasculature96,97. 
According to the here presented data, one may speculate that the potential ligand(s) of 
CLEC-2 should circulate in the plasma or may be expressed/immobilized on the surface of 
activated platelets. It may also be released by platelets or even become exposed to the 
blood flow at the wound site. In agreement with these assumptions, Suzuki-Inoue et al. 
recently proposed an interesting mechanism for thrombus stabilization involving CLEC-2 
itself as a ligand candidate, as they could demonstrate in different in vitro analyses that 
CLEC-2 molecules are able to undergo direct homophilic associations100. However, the 
relative significance of this interaction for thrombus growth and also the mechanisms that 
regulate a possible switch between different homophilic binding affinities of CLEC-2 on 
resting and activated platelets remain to be determined. 
The described findings that thrombus stabilization and growth of CLEC-2 deficient platelets is 
profoundly reduced under flow conditions in vitro and in vivo may explain the thrombus 
formation defects observed in other mice lacking different intracellular signaling proteins that 
act in the CLEC-2-induced activation pathway. The thrombus defect observed in CLEC-2 
deficient mice was characterized by a continuous release of single platelets and embolization 
of small thrombus fragments from the surface of the thrombus during its expansion phase. A 
similar phenotype of defective thrombus formation in vitro as well as in vivo has been 
described for mice lacking stromal interaction molecule 1 (STIM1), a critical regulator of 
SOCE in platelets238. Platelets of STIM1-deficient mice displayed a selective signaling defect 
in hem(ITAM)-dependent pathways, indicating that this activation axis is not only involved in 
platelet adhesion/activation on the ECM via GPVI but also to a certain extent in thrombus 
progression. Based on the presented data one may assume that the latter process is 
impaired in STIM1-deficient mice, possibly due to defective CLEC-2 signaling. Similarly, the 
thrombus instability observed in mice lacking essential molecules of the hem(ITAM)-signaling 
cascade, such as LAT239 and PLCγ2178 as well as the reduced thrombus growth of Filamin A-
null platelets determined under flow conditions in vitro240 might also be caused by impaired 
CLEC-2 mediated signal transduction. Accordingly, the massive thrombus formation under 
flow conditions in vitro of platelets from mice carrying a gain-of-function mutation in the Plcg2 
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gene and also the prothrombotic phenotype of these mice in vivo is certainly explainable by 
the enhanced PLCγ2 activity downstream of CLEC-2241. 
Furthermore, in the present study it was shown that CLEC-2 can be specifically targeted and 
functionally inactivated by the antibody INU1 in vivo. Remarkably, CLEC-2 inhibition was not 
caused by an INU1-dependent blockade of the receptor but rather based on an antibody-
induced irreversible downregulation of CLEC-2 from the surface of circulating platelets. This 
process of in vivo receptor depletion has previously been described for GPVI in mice and in 
humans77,88. The complete loss of CLEC-2 from the platelet surface within a few hours after 
INU1 injection was confirmed by flow cytometric measurements (Figure 11B) and also by 
immunoprecipitation182. Upon injection of 200 µg INU1 per mouse, the receptor was absent 
for up to 6 days and as a consequence the platelets were completely unresponsive to 
rhodocytin during this time, whereas all other activation pathways were virtually unaffected 
(Figure 11C,D). The mechanism underlying this specific CLEC-2 downregulation has not 
been identified, particularly because this process is not inducible by antibodies in vitro and 
thereby difficult to assess. For GPVI, it has previously been shown that the receptor is 
downregulated by antibodies mainly through ectodomain shedding but also through 
internalization/degradation and that these processes are initiated by GPVI downstream 
signaling events77,242,243. Further experiments are required to determine which process 
accounts for CLEC-2 downregulation; however, as Fab fragments of INU1 cause a 
comparable effect to the full IgG, the involvement of the Fc part or the dimeric form of the 
antibody for this action can be excluded182. 
Irrespective of the exact underlying mechanism, INU1 injection caused a specific CLEC-2 
deficiency in platelets that profoundly protected the treated mice from occlusive arterial 
thrombus formation. At the same time, loss of CLEC-2 was associated with variably but 
overall significantly prolonged bleeding times (Figure 15). The extent of the bleeding was, 
however, rather mild when compared to the hemostatic defects accompanied with 
integrin αIIbβ3 45 or GPIbα (Figure 6C) blockade, as only one third of CLEC-2 deficient mice 
displayed prolonged bleeding times or could not arrest bleeding within the observation 
period, respectively. The high variability of the bleeding times also indicates that CLEC-2 
deficiency caused a moderate hemostatic defect most likely due to thrombus instability at the 
wound site on the tail. Based on this assumption, one may speculate that the lack of CLEC-2 
activity may be, at least partially, compensated by the action of other platelet agonists, such 
as ADP, TxA2 and thrombin which may vary site between individual mice in their levels 
present at the wound, possibly due to differences in the tail injury. Similar observations in the 
variability of the tail bleeding times have previously been reported for mice deficient in other 
activatory receptors, namely P2Y1244
 
or the α2A adrenergic receptor245, indicating that the 
mentioned soluble mediators are critical for normal hemostasis. Although bleeding times are 
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not a valid parameter that allows reliable predictions of a potential bleeding risk214, it is 
tempting to speculate that an anti-CLEC-2 therapy might be associated with a relatively low 
risk of hemorrhagic complications. Interestingly, the finding of the present study that 
antibody-induced CLEC-2 deficiency translates into a slight hemostatic defect contrasts with 
data from genetically engineered CLEC-2 deficient mice. Suzuki-Inoue et al. reported only a 
mild bleeding tendency for CLEC-2 deficient chimeras which was, however, not statistically 
significant100 and Hughes et al. described no alterations in the bleeding times of CLEC-2 
deficient chimeras237. These discrepancies between the studies may be related to different 
modes of tail tip removal which may, as indicated above, lead to a variable compensation of 
the CLEC-2 signaling defect by other platelet activation mechanisms. An additional and more 
likely explanation for the controversial results of the tail bleeding assay could be the different 
experimental procedures. Whereas the filter paper method was used in the present study, 
where hemostasis takes place at room temperature and in the presence of air, Suzuki-Inoue 
et al. and Hughes et al. determined the bleeding time of the mice in prewarmed saline at 
37°C 100,237. These different external factors appear to strongly influence the process of 
hemostasis and thereby determine to which extent the lack of CLEC-2 activity becomes 
evident. In line with this assumption, also preliminary results showed that INU1-induced 
CLEC-2 depletion in mice did not result in a significant hemostatic defect when bleeding 
times were determined in saline (Bender, May et al. in revision). These results also argue 
against INU1 treatment-caused unspecific effects that may, in addition to CLEC-2 depletion, 
further impair platelet function. 
In summary, the present study suggested that CLEC-2 is an essential platelet surface 
receptor for thrombus stabilization in vitro and in vivo that can be specifically targeted and 
functionally inactivated in vivo. Thus, CLEC-2 can be proposed as a promising target for 
effective antithrombotic therapy. However, this prediction is at present rather speculative. It 
has previously been reported that GPVI can be irreversibly immunodepleted from the surface 
of murine as well as human platelets in vivo77,87,88,225. Therefore, one may anticipate that, 
similar to the observations in mice, also anti-CLEC-2 antibody treatment of humans may 
result in a specific loss of the receptor from circulating platelets. However, patients with an 
acquired CLEC-2 deficiency due to autoantibody-induced downregulation of the receptor 
have not been described yet. The identification of such patients might help to clarify whether 
CLEC-2 receptor clearance can also be initiated in humans and thereby be considered as a 
potential therapeutic strategy for antithrombotic treatment. Moreover, INU1 injection into mice 
has been shown to be associated with a transient but marked thrombocytopenia that 
persisted for approximately 3 days after antibody treatment182. Although it has been 
experimentally proven that a dramatic drop of platelet count does not per se cause 
spontaneous bleeding complications246, this may certainly increase the bleeding tendency 
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after injuries and thereby limit the therapeutic use of anti-CLEC-2 antibodies. The relevance 
of this concern, however, remains to be determined, as the mechanisms of the transient 
thrombocytopenia and a possible mechanistic link to the receptor depletion are completely 
unclear at present. Additionally, there is no evidence so far that therapeutically induced 
CLEC-2 clearance is also combined with a pronounced reduction of the platelet count in 
humans as it has been described for mice. Furthermore, the recently described observation 
that CLEC-2 plays an essential role in blood and lymphatic vessel separation by binding to 
podoplanin exposed on lymphatic endothelial cells during embryonic development99,100 may 
also question its suitability as an adequate antithrombotic target. Nevertheless, according to 
the current state of knowledge, the findings of the present study may serve as the basis for 
the development of novel antithrombotic agents for the prophylaxis and treatment of ischemic 
cardiovascular diseases.  
 
5.2.3 Functionally redundancy of GPVI and CLEC-2 during in vivo thrombus 
formation 
As described above the (hem)ITAM-bearing receptors GPVI and CLEC-2 play essential roles 
in arterial thrombus formation but at the same time do not significantly or only moderately 
affect normal hemostasis, respectively. As a consequence, these findings, together with the 
observation that the receptors can be functionally inactivated in vivo by specific antibodies, 
suggested that both receptors might be promising antithrombotic targets. 
Therefore, it was assessed whether GPVI and CLEC-2 can be simultaneously 
downregulated in circulation platelets. Furthermore, since these receptors utilize a similar 
signaling cascade, including the downstream effectors LAT, SLP76 and PLCγ273, it was of 
high interest to analyze a putative redundant function of GPVI and CLEC-2 in the process of 
in vivo thrombus formation. 
This issue was addressed by combined treatment of mice with JAQ1 and INU1. Platelets 
from these animals showed a specific loss of GPVI and CLEC-2 and were concomitantly 
refractory to the stimulation with CRP and rhodocytin whereas the expression levels of other 
prominent surface receptors and the activation response to other platelet agonists was 
largely unaffected (Bender, May et al. in revision). These data provided the first evidence that 
(hem)ITAM-coupled receptors can simultaneously be targeted in vivo without provoking 
additional effects on platelet function.  
The induced double-deficiency of GPVI and CLEC-2 had, however, a remarkable effect on 
arterial thrombus formation after FeCl3-induced vascular injury that clearly exceeded the 
defects seen in the respective single-deficient mice (Figure 16). The onset of aggregate 
formation was significantly delayed and subsequent thrombus propagation was severely 
diminished as the developing thrombus was more fragile and less in size when compared to 
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thrombi formed in GPVI- and CLEC-2 single-deficient mice. As a consequence, blood flow 
maintained in all tested double-deficient mice. These findings strongly suggest that GPVI and 
CLEC-2 exhibit partially redundant functions in both the initiation of aggregate and thrombus 
formation, a process that has so far been ascribed to the function of GPIb, GPVI, α2β1 and 
αIIbβ3 integrins7,236, and the stabilization of arterial thrombi. Accordingly, it is tempting to 
speculate that a combined antithrombotic therapy targeting both platelet activation receptors 
might be more beneficial in the prevention or treatment of thromboembolic diseases than the 
use of a single mode of platelet inhibition. However, in view of the virtually abolished 
hemostatic function in GPVI/CLEC-2 double-depleted mice (Bender, May et al. in revision), 
and although there is no direct correlation between bleeding time and bleeding risk214, the 
clinical use of such a therapeutic approach would likely be limited by the side-effect of 
hemorrhagic complications.  
The hemostatic defect observed in GPVI/CLEC-2 double-depleted mice clearly exceeded the 
effects seen in mice treated with Fab fragments of the GPIbα blocking antibody p0p/B 
(Figure 6C) but was less pronounced as compared to mice in which the integrin αIIbβ3 was 
inhibited by Fab fragments of the JON/A antibody45. In line with these findings, it has 
previously been described that concomitant deficiency of GPVI and integrin α2β1 resulted in 
severely prolonged bleeding times in contrast to the respective single-deficiency83. Similar 
observations have been made with aspirin-treated GPVI-deficient mice83, suggesting that 
simultaneous inhibition of two platelet adhesion/activation receptors or signaling pathways, 
respectively, can largely impair the hemostatic function of platelets.  
The data of the present study may also be relevant for predicting possible complications of 
an antithrombotic therapy targeting only one (hem)ITAM-coupled receptor. Based on the 
severe bleeding defect in GPVI/CLEC-2 double-depleted mice, it can be suggested that the 
therapeutic deletion of one receptor may severely increase the bleeding tendency in patients 
suffering from genetic or acquired deficiency or bearing a low expression level of the 
respective other receptor. Although CLEC-2 deficient patient have not been described yet, 
most probably because CLEC-2 is critically involved in lymphatic vascular development 
during embryogenesis99,100, it can be assumed that patients with an acquired loss of CLEC-2, 
caused by an autoimmune disease, exist. However, as GPVI-deficient patients have already 
been described, the scenario of massive bleeding complications upon an anti-CLEC-2 
therapy in these individuals appears to be the more relevant problem. These hypotheses 
could also be supported by a murine model where Gp6-/- mice were injected with INU1. 
Pathological thrombus formation after FeCl3-induced vascular injury (Figure 17) as well as 
normal hemostasis (Bender, May et al. in revision) was severely affected in these mice 
similar to the defects observed in JAQ1 + INU1-treated mice. In accordance with results of 
the previous sections, these findings also suggested, albeit only partially, that antibody-
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induced irreversible depletion of the (hem)ITAM-coupled receptors from the platelet surface 
phenotypically mirrors the defects in thrombus formation associated with genetic receptor 
deficiency. Hence, this further supports the assumption that anti-GPVI antibody-treatment 
does not cause any obvious side-effects on platelet function. 
In summary, this part of the study demonstrated that simultaneous in vivo targeting of the 
(hem)ITAM-bearing receptors GPVI and CLEC-2 results in specific receptor downregulation 
without influencing other signaling pathways. Furthermore, this double receptor-deficiency in 
mice has been shown to virtually abolish in vivo thrombus formation. These observations 
may have important implications for the development and application of anti-GPVI and/or 
anti-CLEC-2 antithrombotic agents.  
 
5.3 RhoA is involved in G13-and Gq-mediated platelet activation and essential 
for in vivo thrombus formation  
The functional role of RhoA in platelets has previously been addressed in numerous studies 
using pharmacological inhibitors, however, this study used for the first time a genetic 
knockout approach (PF-4 Cre/lox P system) to specifically investigate the impact of RhoA 
deficiency on platelet function in vitro and in vivo. It was shown that platelet- and 
megakaryocyte-specific deletion of RhoA resulted in a marked macrothrombocytopenia, a 
reduced platelet life span and, as expected, abolished platelet shape change and impaired α 
and dense granule release in response to G13 but notably also to Gq stimulation. The 
presented data in addition demonstrated that RhoA is required for integrin αIIbβ3-dependent 
clot retraction but is dispensable for cytoskeletal rearrangements during platelet spreading. 
Importantly, this study is the first to identify an essential role for the GTPase in hemostasis 
and thrombosis.  
The pronounced thrombocytopenia in RhoA-/- mice was accompanied by an increased 
platelet size but largely unaltered platelet morphology (Figure 18B-D). Surprisingly, the 
platelet life span was only slightly reduced (Figure 19), indicating that an increased platelet 
turnover did not account for the reduced platelet counts in these animals. Rather, the findings 
point to a critical involvement of RhoA in megakaryocyte differentiation and/or platelet 
formation which would stand in contrast to reports by other groups using inhibitors of the 
RhoA/ROCK pathway in cultured human megakaryocytes142,247. Further experiments are 
required to clarify this aspect.  
Multiple studies using pharmacological inhibitors of RhoA or downstream effectors previously 
suggested RhoA as a central platelet signaling protein that mediates MLC phosphorylation 
and consequently platelet shape change upon G13-coupled receptor stimulation105,131-134. The 
results of the present thesis clearly confirmed this view as low concentrations of U46619, 
thrombin or PAR-4 activating peptide failed to trigger platelet shape change in RhoA-/- 
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platelets (Figure 22A). These findings are also completely in line with data from a previous 
report by Moers et al., showing that platelets lacking Gα13 displayed abolished RhoA 
activation and shape change under similar experimental conditions125. The shape change 
defect observed in both studies was also associated with impaired phosphorylation of the 
RhoA effector MLC (Figure 23 and 125), establishing RhoA-mediated MLC phosphorylation as 
the primary signaling pathway for platelet shape change downstream of G13. Interestingly, 
higher doses of U46619, thrombin and PAR-4 activating peptide, which involved signaling via 
Gq, largely but not fully re-established the capacity of RhoA-/- platelets to undergo shape 
change (Figure 22A). Together with the finding that low concentrations of ADP, a platelet 
agonist that exclusively binds to Gq- and Gi-coupled receptors, did not induce shape change 
in RhoA-deficient platelets (Figure 22B), the data indicated that RhoA may also act 
downstream of Gq. This has previously also been suggested by others analyzing receptor-
dependent regulation of RhoA activation in different cell lines. Chikumi et al. demonstrated 
that activated Gαq proteins were able to stimulate endogenous RhoA in HEK-293T cells248 
and Vogt et al. reported that RhoA activation occurred in mouse embryonic fibroblasts by 
receptor agonists via G12/13 stimulation but also, albeit with a lower potency, via Gq/11-
mediated signaling249. Consistent with this, Moers et al. detected some level of RhoA 
activation and MLC phosphorylation in response to high concentrations of U46619 in 
platelets lacking Gα13 and also in wild-type platelets after activation with ADP126. Together, 
this strongly suggests that RhoA activity may also be regulated by Gαq-coupled receptors, 
however the underlying molecular mechanism is entirely unclear so far. The herein 
presented data at least indicated that the additionally proposed way of RhoA activation 
occurs independently of the classical Gq-induced signaling cascade via PLCβ stimulation and 
intracellular Ca2+ mobilization (Figure 24). This was also supported by Vogt et al. in a cell line 
study249, which at the same time proposed the RhoGEF protein LARG as a potential 
mediator for Gαq-dependent RhoA activation. However, whether LARG or other members of 
the same RhoGEF family, such as p115RhoGEF or PDZ-RhoGEF, as indicated by Chikumi 
et al.248, provide this signaling link also in platelets remains still to be determined. 
The present study further demonstrated that shape change of RhoA-/- platelets was abolished 
in response to low concentrations of CRP and collagen and was still defective at intermediate 
and high agonist concentrations, particularly for collagen (Figure 22B). These findings are, 
however, not surprising as previous reports demonstrated that collagen-induced shape 
change strongly depends on the release/secretion of soluble mediators such as ADP and 
mainly TxA2 that act via G13- and Gq- and Gi-coupled receptors and thereby also via RhoA 
signaling126,250. In contrast, marked MLC phosphorylation was detectable in the mutant 
platelets upon stimulation with high CRP concentrations (Figure 23), indicating that under 
these experimental conditions GPVI-induced MLC phosphorylation is dominantly regulated 
Discussion 
 
103 
 
via Ca2+/calmodulin-dependent MLCK activation and independently of RhoA, as previously 
supposed for human platelets136. This signaling pathway appears, however, not to be 
sufficient to trigger GPVI activation-dependent shape change under the conditions of 
aggregometry. 
Moreover, the data showed that RhoA plays a critical role in α and dense granule release 
upon G13-mediated signaling but, interestingly, also partially downstream of Gq (Figure 20B 
and Figure 21), which directly translated into a reduced aggregation response of RhoA-/- 
platelets at intermediate concentrations of U46619 and PAR-4 activating peptide (Figure 
22A,C). These findings confirmed previous indications from inhibition studies136,249 as well as 
from reports by Moers et al., analyzing Gα13-deficient and Gα13/Gαq double-deficient 
platelets125,126. Notably, in line with observations from the latter studies, thrombin-induced 
dense granule release and subsequent aggregation was not affected in RhoA-/- platelets 
(Figure 21 and Figure 22A,C), whereas P-selectin exposure, determined by flow cytometry, 
was strongly reduced after thrombin activation (Figure 20). This suggested that thrombin 
induces additional, PAR-independent signaling that may compensate for the lack of RhoA 
under conditions present in highly dense platelet suspension for aggregation measurements 
but not under conditions of a strongly diluted platelet sample for flow cytometry. However, as 
indicated by studies in Gα13-deficient platelets, thrombin-mediated aggregation processes via 
GPIbα most probably are not involved125. Surprisingly, and in contrast to the finding that 
secretion after stimulation of the hem(ITAM) receptors GPVI and CLEC-2 was unaltered in 
RhoA-/- platelets (Figure 20B and Figure 21), low and intermediate concentrations of CRP 
and collagen induced an increased aggregation response in these platelets (Figure 22B,C). It 
is difficult to explain this phenomenon at present, but as GPVI signaling seemed to be 
unaffected by the absence of RhoA (Figure 24), rather signaling-independent processes 
might be altered. Accordingly, the increased size of RhoA-deficient platelets and possibly an 
associated elevated amount of granules might be involved. This may then lead to an 
increased degranulation response upon the primary GPVI activation signal in comparison to 
wild-type platelets. However, further analyses, e.g. concerning the number of granules per 
RhoA-/- platelet are indispensable to assess this vague hypothesis. The data of the present 
study clearly demonstrated that RhoA is essential for the induction of granule release 
downstream of G13- and Gq-coupled receptors, however the exact underlying mechanism is 
unclear at present. The process of RhoA-dependent exocytosis has previously been 
investigated in different cell types and although a direct association of the GTPase with the 
membrane of secretory granules has been described, the studies indicated that RhoA rather 
is involved in actin remodeling to negatively instead of positively regulate exocytosis251. Thus, 
it remains to be determined how RhoA induces degranulation in platelets. 
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Besides granule release, RhoA has also been implicated in integrin αIIbβ3 inside-out 
activation124,125,135,195 as well as in outside-in signaling-dependent cytoskeletal 
reorganizations139,140. In the current study, it was found that RhoA-/- deficiency resulted in 
slightly reduced integrin αIIbβ3 activation in response to U46619 co-stimulated with ADP as 
well as to thrombin and rhodocytin (Figure 20A). Interestingly, these defects clearly 
exceeded those observed in platelets lacking Gα13, particularly for thrombin (data not shown 
and 125), which further supported the notion that RhoA is required for signal transduction 
downstream of G13, but also to a certain extent of Gq. However, additional investigations are 
necessary to determine whether RhoA directly regulates integrin αIIbβ3 activation or whether 
the reduced level of activated integrin detectable on the platelets surface is a consequence 
of defective RhoA-dependent degranulation and subsequently reduced integrin exposure 
from intracellular compartments during platelet activation. 
In a recent study, Gong et al. proposed a new model for ligand-induced integrin αIIbβ3 
outside-in signaling involving a tight and temporally defined regulation of RhoA activity139. 
They suggested that the GTPase is transiently inhibited by c-Src bound to the β3-tail of the 
integrin during the early phase of platelet spreading whereas in the following it becomes 
reactivated and allows clot retraction due to calpain-dependent cleavage of the c-Src-integrin 
interaction139. Although the underlying mechanism was not proven in the herein presented 
study, the results provided clear evidence that RhoA is dispensable for spreading of 
activated platelets on fibrinogen but essential for clot retraction (Figure 25 and Figure 28). 
These findings, however, stand in contrast to observations by Leng et al., using C3 
exoenzyme to inactivate RhoA140, which may be explained by a potential limited specificity 
and efficiency of the inhibitor.  
Interestingly, although RhoA is known to be a critical mediator of cytoskeletal reorganizations 
and consequently contributes to F-actin bundling and stress fiber formation in numerous cell 
types106,112,196, the current thesis indicated that RhoA is not required for F-actin assembly in 
activated platelets and only partially involved in stress fiber formation and proper granule 
centralization spread platelets (Figure 26 and Figure 27B). These observations reflect 
findings of an inhibition study with human platelets140 and are in line with a recent report by 
Jackson et al., describing that RhoA-deficient keratinocytes were perfectly able to form stress 
fibers and focal adhesions122. Likewise, RhoA was dispensable for actomyosin regulation in 
primary mouse embryonic fibroblasts252 which may be due to a functional compensation of 
RhoA-deficiency by RhoB and RhoC. Since RhoA is the only known Rho isoform expressed 
in platelets, this kind of redundancy appears not to be a likely explanation for the only 
moderately altered F-actin structures in RhoA-/- platelets253. However, one may assume that 
functional redundancies with other members of the Rho GTPase family may be present in 
platelets, as RhoA, Cdc42, Rac1 and also RhoF mediate cytoskeletal rearrangements 
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partially via the common downstream effector mDia254,255. Further studies, using e.g. double-
deficient mouse strains, are required to elaborate this aspect. 
In addition, the data of the current study revealed a role of RhoA in the organization of 
microtubule structures in spread platelets (Figure 27A). However, the underlying mechanism 
how RhoA may regulate the tubulin cytoskeleton and whether this is a direct signaling effect 
or indirectly caused by altered actin structures has not yet been identified. A previous study 
suggested that microtubule coils may be regulated via the Rho/ROCK pathway during 
platelet shape change256, but a contribution of RhoA-dependent activation of mDia, as shown 
for other cell types257, should also be considered.  
Interestingly, the specific signaling defects of RhoA-/- platelets detected in vitro did not result 
in impaired thrombus formation on collagen under high shear flow conditions (Figure 29A). 
This indicated that RhoA-deficient platelets are sufficiently activated via GPVI to allow 
adhesion to the matrix, a process that functions independently of soluble mediators126, but 
also formation of stable thrombi despite the impaired G13/Gq-signaling pathways. These 
findings are surprising, particularly as Gα13-/- platelets have been shown to display defective 
thrombus formation in a similar perfusion assay125. The discrepancies are difficult to explain 
but slight differences in the methodology of the experiment and/or possible side effects on 
platelet function by injection of polyinosinic-polycytidylic acid into mice to induce gene 
deletion (Mx Cre/lox P system) may be involved. However, RhoA deficiency appeared to 
moderately but significantly impair platelet adhesion to the surface of an expanding 
aggregate at very high shear rates (Figure 29A). This defect might probably be ascribed to a 
reduced GPIbα-vWF-dependent platelet-platelet interaction under high shear conditions in 
the absence of RhoA, as RhoA-/- platelets displayed, despite normal adhesion to vWF, a 
significantly higher rolling velocity on a the matrix as compared to wild-type platelets (Figure 
29B). Consistent with these observations, also human platelets have previously been 
described to exhibit reduced stationary adhesion contacts with vWF under flow when 
inhibiting the RhoA/ROCK signaling pathway138. 
Importantly, however, RhoA deficiency resulted in clearly impaired thrombus formation in 
vivo and protected mice from irreversible vessel occlusion. Initial thrombus formation was 
unaltered in RhoA-/- mice, whereas thrombus progression in increasingly stenosed vessels or 
stabilization of occlusive thrombi was strongly diminished in FeCl3-injured mesenteric 
arterioles due to permanent release of platelets from the thrombus surface and embolization 
of thrombus fragments (Figure 30). Similar results were obtained in the model of 
mechanically induced vascular damage of the abdominal aorta (Figure 31). The observed 
defect in thrombus stabilization was certainly caused by defective platelet incorporate into an 
expanding thrombus at high shear but mainly due to impaired degranulation-dependent 
release of soluble mediators. The latter process is known to be of central importance for 
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thrombus formation under in vivo conditions244,258,259. It is important to note that the defective 
thrombus formation in RhoA-/- mice was not caused by the decreased platelet counts in these 
mice, as e.g. conditional knockout mice (PF-4 Cre/lox P system) deficient in Cdc42 even 
displayed significantly accelerated thrombus formation in the same FeCl3-injury model due to 
enhanced granule secretion but despite reduced platelet counts of only 50-80% compared to 
control107. Additionally, thrombocytopenic mice that had a reduced platelet count ranging 
between 30-50% of normal levels showed slightly delayed but, notably, irreversible vessel 
occlusion after mechanically induced vascular injury of the abdominal aorta (Figure 38). 
Thrombocytopenia in these mice was experimentally induced by i.v. injection of 2.5 µg of the 
anti-GPIbα antibody p0p/B 24 h prior to the experiment183. Taken together, this strongly 
suggested that RhoA plays a fundamental role in occlusive thrombus stabilization. 
 
 
Figure 38. Thrombocytopenic mice display 
largely unaltered thrombus formation in a 
mechanical injury model. Mice received either 
vehicle or 2.5 µg p0p/B antibody 24 h prior to 
injury to reduce platelet counts to 30-50% of 
normal levels. The abdominal aorta was injured 
by tight compression with a forceps and blood 
flow was monitored using an ultrasonic flow 
probe. Time to stable vessel occlusion is 
depicted. One symbol represents one individual.  
 
Furthermore, RhoA deficiency was also associated with a severe increase in bleeding times, 
indicating that RhoA is also required for thrombus formation during hemostasis (Figure 32). 
Importantly, RhoA-/- mice were profoundly protected from ischemic brain infarction and 
displayed a better neurological outcome in a model of experimental stroke (Figure 33). 
Although the bleeding times in these mice were affected, no indications for an increase in 
ICH, which represents the main complication of current antithrombotic therapy during acute 
stroke, were detectable. This finding is in line with the previous observation that an increase 
in bleeding times does not necessarily correlate with an increase in bleeding risk214. 
According to these data, it is tempting to speculate that RhoA may represent a potential 
target molecule for effective therapy of thromboembolic diseases. However, serious 
problems of such a therapy may arise from the ubiquitous expression of RhoA and its central 
role in many cellular functions such as cell contraction, adhesion, migration and 
cytokinesis109. Additionally, the fact that RhoA is located within the cell would further 
complicate targeting of this GTPase. 
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In summary, the presented study revealed selective, yet important roles for RhoA in platelet 
function in vitro and in vivo. It was shown that RhoA is critical for platelet shape change and 
efficient α and dense granule release downstream of G13 and Gq. In addition, RhoA appeared 
to be essential for integrin-mediated clot retraction, but not for actomyosin rearrangements 
and spreading of activated platelets. Furthermore, this study identified RhoA as a crucial 
mediator of stable thrombus formation during hemostasis and thrombosis. 
 
5.4 The FXIIa inhibitor rHA-Infestin-4 is a potent antithrombotic agent without 
causing bleeding side effects 
In the present study, the suitability of FXII/FXIIa as a novel potential target for antithrombotic 
therapy (Figure 40) was assessed by characterizing the newly developed FXIIa inhibitor 
rHA-Infestin-4 and testing its antithrombotic potential in animal models of thrombosis and 
ischemic stroke. Generation, production and initial characterization of rHA-Infestin-4 were 
performed by CSL Behring (Marburg, Germany) and served as the basis for this part of the 
thesis. Our collaboration partners at CSL Behring cloned the above described 7 kDa FXIIa 
inhibitor Infestin-4 from the hematophagus insect Triatoma infestans, extended by an (His)6-
tag and determined the pharmacokinetic characteristics of the resulting (His)6-Infestin-4 after 
i.v. application of 20 mg/kg body weight (2.7 µmol/kg) of the protein into mice. Unfortunately, 
these measurements revealed that (His)6-Infestin-4 lead to a very low recovery of only 8% of 
the protein in mice and a short half-life of 0.3 h (Figure 39A) which excluded the application 
of (His)6-Infestin-4 for further studies employing a reasonable efficient treatment schedule. To 
circumvent this limitation, CSL Behring generated the rHA-Infestin-4 fusion protein to 
enhance the bioavailability. SDS-PAGE analysis confirmed the successful generation of the 
protein with the expected molecular weight of 73 kDa and a purity of approximately 95% 
(Figure 39B). Pharmacokinetic analysis of rHA-Infestin-4 demonstrated a high recovery of 
92% and a half-life of 4.6 h after i. v. injection (2.7 µmol/kg) (Figure 39A).  
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Figure 39. Pharmacokinetic analysis and in vitro coagulation. A, Infestin-4 plasma levels in mice 
at different time points after either rHA-Infestin-4 or (His)6-Infestin-4 injection. Representative 
measurements from at least 10 individuals are shown. B, SDS-PAGE of purified rHA-Infestin-4 and 
rHA. C,D, Activated partial thromboplastin time (aPTT) and prothrombin time (PT) of standard human 
plasma after 2 min incubation with rHA-Infestin-4 at the indicated concentrations. Representative data 
of 4 independent measurements are illustrated. rHA=recombinant human albumin. (Hagedorn et al., 
Circulation, 2010)202. 
 
The initial in vitro characterization of rHA-Infestin-4 by CSL Behring revealed that the protein 
specifically inhibited the intrinsic coagulation pathway while leaving the extrinsic pathway 
completely unaffected as rHA-Infestin-4 prolonged aPTT in a dose-dependent manner in 
SHP without influencing PT (Figure 39C,D). Similar observations were made with mouse and 
rat plasma202.  
These data together with the results of the herein presented study clearly showed that rHA-
Infestin-4 specifically inhibited FXIIa in vitro and in vivo irrespectively of the analyzed species 
and induces potent protection of mice and rats from thrombotic events without any detectable 
effects on hemostasis. Immediately after injection, rHA-Infestin-4 abolished platelet 
aggregation and thrombus formation at sites of vascular injury (Figure 34A,C), demonstrating 
rapid and highly efficient inhibition of FXIIa. This strong inhibitory effect was reversible and 
gradually declined probably when rHA-Infestin-4 was metabolized and cleared from the 
circulation, as small but unstable thrombi (diameter: ~10 µm) were formed upon vessel injury 
when rHA-Infestin-4 was administered ~100 min prior to injury. This effect of rHA-Infestin-4 
on arterial thrombus formation was confirmed in two different arterial beds, small mesenteric 
arterioles as well as the carotid artery (Figure 34A-D) and found to be similar in mice and 
Discussion 
 
109 
 
rats. This indicates that the inhibitor might be effective in different species, including humans, 
as it very potently inhibits human α/βFXIIa in vitro (Table 2). The antithrombotic activity of 
rHA-Infestin-4 was also evident in a transient cerebral ischemia model where mice displayed 
profound protection from neurological damage (Figure 37A-C). Furthermore, rHA-Infestin-4 
moderately inhibited fibrinolysis as indicated by a reduced D-Dimer concentration in clotted 
rHA-Infestin-4 spiked plasma. The underlying mechanism is not clear at present, but 
inhibition of plasmin, as determined in a chromogenic assay (Table 3), may at least partially 
account for this effect. However, this inhibition does certainly not explain the effective 
antithrombotic potency of the inhibitor. Whether the antifibrinolytic effect of the inhibitor has 
any relevance in vivo has yet to be determined. Together, these results indicate that rHA-
Infestin-4 might be effective in the prophylaxis and treatment of thromboembolic diseases. 
Unexpectedly, the marked protection of rHA-Infestin-4 treated mice from arterial thrombosis 
and ischemic stroke exceeded the effects previously found in FXII-deficient mice169,170. 
Notably, it could be shown that rHA-Infestin-4 did not abrogate the residual thrombotic 
activity in FXII-deficient mice which excludes an additional albeit subordinated influence of 
rHA-Infestin-4 on other proteins relevant in thrombus formation. Based on these findings, one 
may rather hypothesize that the genetic loss of FXII in the mutant mice leads to 
compensatory upregulation of alternative mechanisms that account for the residual 
thrombotic activity (Figure 36). Remarkably, the temporary and efficient inhibition of FXIIa in 
vivo was not associated with excessive bleeding (Figure 35), even under conditions of major 
surgery, in accordance with observations in FXII-deficient mice and humans169,260. These 
findings support the intriguing hypothesis that hemostasis and thrombosis are two 
mechanistically different processes169,203 and establish rHA-Infestin-4 as a promising 
candidate molecule for highly effective and safe antithrombotic therapy. Such a safe therapy 
might be particularly advantageous in the treatment of acute stroke, as the conventional 
therapy to prevent lesion progression and recurrent thromboembolism with platelet 
aggregation inhibitors and anticoagulants like coumarins and heparins is inheritably 
associated with an increased risk of ICH220-222. Moreover, transient blockade of FXIIa activity 
may help to bridge the risk of vessel reocclusion after thrombolytic therapy. Lack of a 
sufficiently effective therapy of acute ischemic stroke makes it one of the leading causes of 
death and disability worldwide261,262. 
The potential use of rHA-Infestin-4 as an antithrombotic agent in clinical practice may to a 
great extent be influenced by its relatively short in vivo half-life (Figure 39A), its 
corresponding time-dependent antithrombotic effect (Figure 34A,B) as well as its protein size 
and partially heterologous origin. These properties suggest that rHA-Infestin-4 might be a 
potent drug for short-term therapy of patients at high risk of thromboembolism in acute 
clinical settings such as vascular and heart surgery263. In addition, rHA-Infestin-4 might be 
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effective in the prevention of secondary infarctions and subsequent stroke progression, 
which often occurs shortly after transient ischemic attacks or ischemic stroke even after 
previously successful recanalization264.  
Furthermore, a recent study on hyperglycemia-induced cerebral hematoma expansion in 
rodents with ICH suggested another, very specialized therapeutic area for FXIIa inhibitors265. 
Primary ICH is an acutely life-threatening disease state often caused by hypertension and 
represents besides cerebral ischemia the second leading cause of all stroke cases266. This is 
particularly due to the absence of effective treatment options for acute ICH to date. Diabetes 
or acute hyperglycemia are additional risk factors which can negatively influence the clinical 
outcome of ICH. Liu et al.265 now described that plasma kallikrein (PK) inhibits platelet 
aggregation at sites of tissue trauma under high blood glucose concentrations, thereby 
enhancing hematoma expansion of ICH in diabetic or acute hyperglycemic rats and mice. 
Accordingly, a PK inhibitor prevented the extension of the hemorrhagic area in the brain after 
induced ICH in diabetic rats265. Assuming that these pathophysiological mechanisms are also 
valid in humans, specific inhibition of FXIIa by rHA-Infestin-4 and thus subsequent blockage 
of PK production might be clinically useful to lower the risk of severe ICH in patients with 
acute hyperglycemia at hospital admission. 
However, to directly transfer the here presented results for the development of a suitable 
therapeutic concept for humans, a set of further studies is still required, especially because 
the relationship between FXII and pathological clotting in humans is so far not as clear as in 
rodents. Various studies reported conflicting results about the impact of FXII deficiency on 
thrombotic events which may lead to different conclusions about the potential safety profile of 
an anti-FXIIa therapy. While FXII deficiency was once found to be even a risk factor for 
thromboembolic diseases267,268, studies on Swiss and Dutch patients did not confirm this 
correlation269,270. Moreover, reduced plasma FXII levels were identified to afford protection 
from acute coronary syndrome and lower thrombosis risk271,272, which would match the 
situation in mice. In contrast, the Study of Myocardial Infarction-Leiden (SMILE) project 
demonstrated an inverse association between FXII levels and risk of myocardial infarction273. 
The study by Endler et al.274 described similar observations, whereas, the mortality for a 
small subpopulation of patients with only 1-10% of normal FXII levels was comparable to the 
mortality for the population median, indicating a clear difference in thrombosis between 
moderate and severe FXII deficiency. This, however, raised the possibility that nearly 
abolished FXIIa activity, which can probably be induced by effective and specific FXIIa 
inhibition, is different from the conditions of hereditarily reduced FXII levels in humans. To 
make more reliable predictions about the functional relevance of FXIIa-induced thrombotic 
activity in humans, inhibition studies in higher developed mammalians than rodents will be 
important. Remarkably, a recent publication already showed that antibody-mediated 
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inhibition of FXI activation by FXIIa potently reduced platelet-rich thrombus formation in 
collagen-coated grafts inserted into an arteriovenous shunt in baboons275. Thus, the 
FXIIa/FXI activation axis appears to play a significant role in pathological thrombus growth 
across a wide range of species, also emphasizing direct FXII/FXIIa inhibition as a very 
promising therapeutic option for the treatment of thromboembolic diseases in humans.  
Besides rHA-Infestin-4 also other FXIIa inhibitors have been described during the last years 
which confirmed that FXIIa can be well targeted in vivo. However, these inhibitors were either 
not specific, which might cause several undesirable side effects when therapeutically used, 
and/or they were clearly less effective as compared to rHA-Infestin-4. The recombinant 
protein Ir-CPI expressed by the tick Ixodes ricinus e.g. interacts with different contact phase 
factors (FXIIa, FXIa, PK) as well as plasmin276 and the synthetic FXIIa inhibitor D-Pro-Phe-
Arg chloromethyl ketone (PCK) has been described to also block the amidolytic activity of 
PK, plasmin, FXa, and thrombin in vitro277. PCK has been shown to protect mice from 
ischemic stroke in a tMCAO model170 but displayed a prothrombotic effect in a Rose Bengal 
murine thrombosis model278. Recently, also 3-carboxamide-coumarins have been described 
as a new class of non-peptidic specific FXIIa inhibitors in vitro, however, the member 
COU254 failed to protect mice from acute ischemic stroke279. 
In summary, the study demonstrated that the newly developed selective FXIIa inhibitor 
rHA-Infestin-4 is highly active in human plasma and profoundly protects mice and rats from 
pathological thrombus formation while not affecting hemostasis. This indicates that 
rHA-Infestin-4 might be a powerful, yet safe, agent for prevention and treatment of acute 
ischemic cardio- and cerebrovascular events. 
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Figure 40. Simplified scheme of platelet receptors and activation pathways required for 
thrombus formation. Proteins that were analyzed in this study and proposed/tested as promising 
targets for an effective antithrombotic therapy are highlighted in color. Receptor stimulation leads to 
the activation of different intracellular signaling molecules and cascades subsequently resulting in the 
functional upregulation of integrins. PLD1 is activated downstream of different receptors most notably 
GPIb-V-IX complex and regulates integrin activation, however the defined signaling mechanism 
remains elusive. Coagulation factor XII contributes to platelet activation via generation of thrombin. 
(Modified from: Hagedorn et al., Haemostasiologie, 2010)280. 
 
5.5 Concluding remarks and future plans 
The presented thesis provides new insights into the complex mechanisms underlying 
thrombus formation during arterial thrombosis and hemostasis with a special emphasis on 
the functional roles of the platelet adhesion receptor GPIbα, the (hem)ITAM receptors GPVI 
and CLEC-2 as well as of the intracellular signaling proteins PLD1 and the Rho GTPase 
RhoA. 
The high incidence of ischemic cardio- and cerebrovascular diseases in industrialized 
countries together with the limited use of current antithrombotic agents due to bleeding side 
effects strongly requires alternative therapeutic options. Importantly, some of the data 
discussed here support the recently raised hypothesis that pathological thrombosis and 
primary hemostasis may be two mechanistically distinct processes. If this also holds true for 
humans, it will be possible to target proteins/processes that drive pathological thrombus 
formation without affecting hemostasis, which would open up new avenues for the 
development of a novel generation of powerful, yet safe antithrombotic agents.  
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Additionally, the data point out that genetically engineered mice combined with arterial 
thrombosis models represent a practical and also a very valuable tool to improve the 
understanding of in vivo thrombus formation and to identify novel targets for therapeutic 
interventions. This is especially based on the studies of F12-/- mice and the consequent 
generation and functional characterization of rHA-Infestin-4. Furthermore, the development 
of humanized antibodies and Fab fragments to specifically downregulate or block surface 
proteins in platelets, respectively, appears to be an attractive pharmacological option for 
future antithrombotic therapies. 
 
Further experiments are planned in our laboratory to study the role of the second PLD 
isoform, PLD2, for platelet function and thrombus formation as well as PLD1/PLD2 double-
deficient mice to assess potential redundant functions of these enzymes. Moreover, the 
effects of genetic CLEC-2 deficiency and also of combined GPVI and CLEC-2 deficiency on 
thrombus formation in pathological thrombosis and hemostasis will be assessed using 
conditional CLEC-2 knockout mice (a collaboration with S. Watson, University of 
Birmingham, UK). These investigations will shed new light on the importance of PLD 
isoforms and (hem)ITAM receptors for platelet function. 
In another set of experiments, the impact of RhoA on megakaryocyte maturation and/or 
platelet formation will be analyzed in detail to clarify the reason for the marked 
macrothrombocytopenia in RhoA-deficient mice. Further studies will address potential 
redundancies in platelet and megakaryocyte function of RhoA with the other prominent Rho 
GTPases, Rac1 and Cdc42, using cell-specific double knockout mice. 
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7 APPENDIX 
Abbreviations 
µ      micro 
AC      adenylate cyclase 
ADAP adhesion and degranulation promoting adaptor 
protein 
ADP      adenosine diphosphate 
aPTT      thromboplastin time  
ATP      adenosine trisphosphate 
BK      bradikinin 
BSA      bovine serum albumin  
BSS      Bernard-Soulier syndrome 
°C      Degree Celsius 
C1 inhibitor     C1 esterase inhibitor  
[Ca2+]i      intracellular calcium concentration 
CLEC-2     C-type lectin-like receptor 2 
CRP      collagen-related peptide 
CVX      convulxin 
DAG      diacylglycerol 
ddH2O      double-distilled water 
DIC      differential interference contrast 
ECM      extracellular matrix 
ELISA      enzyme-linked immuno absorbance assay 
et al.      et alteri 
F(VII)a activated coagulation factor (VII) 
F(XII)      coagulation factor (XII) 
F-actin      filamentous actin 
Fc      Fragment crystallisable 
FcR      Fc receptor 
FeCl3      Ferric(III)chloride 
Fg      fibrinogen 
FITC      fluorescein isothiocyanate 
g      gram 
GAP      GTPase-activating protein 
GDI Guanine nucleotide-dissociation inhibitor  
GDP      guanosine diphosphate 
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GEF      guanine nucleotide exchange factor 
GP      glycoprotein 
GPCR      G protein-coupled receptor 
GTP      guanosine trisphosphate 
h      hour(s) 
H2O      water 
HIV-1 human immunodeficiency virus type I 
HK      high molecular weight kininogen 
HRG      Histidine-rich glycoprotein 
ICH      intracranial hemorrhage  
IEL      internal elastic lamina 
IFI      integrated fluorescence intensity 
Ig      immunoglobulin 
IL      interleukin 
IP3      inositol 1,4,5-triphosphate 
ITAM      immunoreceptor tyrosine-based activation motif 
kb      kilo base pair 
kDa      kilo Dalton 
l      liter 
LAT      linker for activation of T-cells 
M      molar 
mDia1 first identified mammalian homologue of 
Drosophila diaphanous 
MFI      mean fluorescence intensity 
min      minute(s) 
MK      megakaryocyte 
ml      milliliter 
MLC      myosin light chain 
MLCK myosin light chain kinase  
MLCP myosin light chain phosphatase 
mm²      square millimeter 
NaCl      sodium chloride 
o/n      overnight 
PA      phosphatidic acid  
PAI-1      plasminogen activator inhibitor-I 
PAR protease-activated receptor 
PBS      phosphate buffered saline 
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PC       phosphatidylcholine  
PCK      D-Pro-Phe-Arg chloromethyl ketone 
PCR      polymerase chain reaction 
PE      phycoerythrin 
PF4      platelet factor 4 
PI3K      phosphoinositide-3-kinase 
PI4P5 kinase phosphatidylinositol-4-phosphate 5-kinase  
PIP2      phosphatidyinositol-4,5-bisphosphate 
PIP3 phosphatidylinositol-3,4,5-triphosphate  
PK      prekallikrein  
PKC      proteinkinase C 
PL (C)      phospholipase (C) 
P-MLC      phosphorylated MLC 
ppp      platelet poor plasma 
prp      platelet rich plasma 
PS      phosphatidylserine 
PT      prothrombin time 
RC      rhodocytin 
ROCK  RhoA-kinase  
rpm      rounds per minute 
RT      room temperature 
SD      standard deviation 
SDS      Sodium dodecyl sulfate  
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
sec      second(s) 
SEM      scanning electron microscopy 
SLP-76  Src-homology 2 domain-containing leukocyte-
specific phospho-protein of 76 kDa 
SOCE       store-operated Ca2+ entry 
TAE      TRIS acetate EDTA buffer 
TE      TRIS EDTA buffer 
TEM      transmission electron microscopy 
TF      tissue factor 
TFPI      tissue factor pathway inhibitor 
tMCAO transient middle cerebral occlusion  
tPA      tissue plasminogen activator 
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TRIS      trishydroxymethylaminomethane 
TxA2       thromboxane A2 
U      units 
uPA      urokinase plasminogen activator 
vWF      von Willebrand factor 
wt      wild-type 
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